Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO2015176640) COMPOSÉS TRICYCLIQUES ANTIDIABÉTIQUES
Document

说明书

发明名称 0001   0002   0003   0004   0005   0006   0007   0008   0009   0010   0011   0012   0013   0014   0015   0016   0017   0018   0019   0020   0021   0022   0023   0024   0025   0026   0027   0028   0029   0030   0031   0032   0033   0034   0035   0036   0037   0038   0039   0040   0041   0042   0043   0044   0045   0046   0047   0048   0049   0050   0051   0052   0053   0054   0055   0056   0057   0058   0059   0060   0061   0062   0063   0064   0065   0066   0067   0068   0069   0070   0071   0072   0073   0074   0075   0076   0077   0078   0079   0080   0081   0082   0083   0084   0085   0086   0087   0088   0089   0090   0091   0092   0093   0094   0095   0096   0097   0098   0099   0100   0101   0102   0103   0104   0105   0106   0107   0108   0109   0110   0111   0112   0113   0114   0115   0116   0117   0118   0119   0120   0121   0122   0123   0124   0125   0126   0127   0128   0129   0130   0131   0132   0133   0134   0135   0136   0137   0138   0139   0140   0141   0142   0143   0144   0145   0146   0147   0148   0149   0150   0151   0152   0153   0154   0155   0156   0157   0158   0159   0160   0161   0162   0163   0164   0165   0166   0167   0168   0169   0170   0171   0172   0173   0174   0175   0176   0177   0178   0179   0180   0181   0182   0183   0184   0185   0186   0187   0188   0189   0190   0191   0192   0193   0194   0195   0196   0197   0198   0199   0200   0201   0202   0203   0204   0205   0206   0207   0208   0209   0210   0211   0212   0213   0214   0215   0216   0217   0218   0219   0220   0221   0222   0223   0224   0225   0226   0227   0228   0229   0230   0231   0232   0233   0234   0235   0236   0237   0238   0239   0240   0241   0242   0243   0244   0245   0246   0247   0248   0249   0250   0251   0252   0253   0254   0255   0256   0257   0258   0259   0260   0261   0262   0263   0264   0265   0266   0267   0268   0269   0270   0271   0272   0273   0274   0275   0276   0277   0278   0279   0280   0281   0282   0283   0284   0285   0286   0287   0288   0289   0290   0291   0292   0293   0294   0295   0296   0297   0298   0299   0300   0301   0302   0303   0304   0305   0306   0307   0308   0309   0310   0311   0312   0313   0314   0315   0316   0317   0318   0319   0320   0321   0322   0323   0324   0325   0326   0327   0328   0329   0330   0331   0332   0333   0334   0335   0336   0337   0338   0339   0340   0341   0342   0343   0344   0345   0346   0347   0348   0349   0350   0351   0352   0353   0354   0355   0356   0357   0358   0359   0360   0361   0362   0363   0364   0365   0366   0367   0368   0369   0370   0371   0372   0373   0374   0375   0376   0377   0378   0379   0380   0381   0382   0383   0384   0385   0386   0387   0388   0389   0390   0391   0392   0393   0394   0395   0396   0397   0398   0399   0400   0401   0402   0403   0404   0405   0406   0407   0408   0409   0410   0411   0412   0413   0414   0415   0416   0417   0418   0419   0420   0421   0422   0423   0424   0425   0426   0427   0428   0429   0430   0431   0432   0433   0434   0435   0436   0437   0438   0439   0440   0441   0442   0443   0444   0445   0446   0447   0448   0449   0450   0451   0452   0453   0454   0455   0456   0457   0458   0459   0460   0461   0462   0463   0464   0465   0466   0467   0468   0469   0470   0471   0472   0473   0474   0475   0476   0477   0478   0479   0480   0481   0482   0483   0484   0485   0486   0487   0488   0489   0490   0491   0492   0493   0494   0495   0496   0497   0498   0499   0500   0501   0502   0503   0504   0505   0506   0507   0508   0509   0510   0511   0512   0513   0514   0515   0516   0517   0518   0519   0520   0521   0522   0523   0524   0525   0526   0527   0528   0529   0530   0531   0532   0533   0534   0535   0536   0537   0538   0539   0540   0541   0542   0543   0544   0545   0546   0547   0548   0549   0550   0551   0552   0553   0554   0555   0556   0557   0558   0559   0560   0561   0562   0563   0564   0565   0566   0567   0568   0569   0570   0571   0572   0573   0574   0575   0576   0577   0578   0579   0580   0581   0582   0583   0584   0585   0586   0587   0588   0589   0590   0591   0592   0593   0594   0595   0596   0597   0598   0599   0600   0601   0602   0603   0604   0605   0606   0607   0608   0609   0610   0611   0612   0613   0614   0615   0616   0617   0618   0619   0620   0621   0622   0623   0624   0625   0626   0627   0628   0629   0630   0631   0632   0633   0634   0635   0636   0637   0638   0639   0640   0641   0642   0643   0644   0645   0646   0647   0648   0649   0650   0651   0652   0653   0654   0655   0656   0657   0658   0659   0660   0661   0662   0663   0664   0665   0666   0667   0668   0669   0670   0671   0672   0673   0674   0675   0676   0677   0678   0679   0680   0681   0682   0683   0684   0685   0686   0687   0688   0689   0690   0691   0692   0693   0694   0695   0696   0697   0698   0699   0700   0701   0702   0703   0704   0705   0706   0707   0708   0709   0710   0711   0712   0713   0714   0715   0716   0717   0718   0719   0720   0721   0722   0723   0724   0725   0726   0727   0728   0729   0730   0731   0732   0733   0734   0735   0736   0737   0738   0739   0740   0741   0742   0743   0744   0745   0746   0747   0748   0749   0750   0751   0752   0753   0754   0755   0756   0757   0758   0759   0760   0761   0762   0763   0764   0765   0766   0767   0768   0769   0770   0771   0772   0773   0774   0775   0776   0777   0778   0779   0780   0781   0782   0783   0784   0785   0786   0787   0788   0789   0790   0791   0792   0793   0794   0795   0796   0797   0798   0799   0800   0801   0802   0803   0804   0805   0806   0807   0808   0809   0810   0811   0812   0813   0814   0815   0816   0817   0818   0819   0820   0821   0822   0823   0824   0825   0826   0827   0828   0829   0830   0831   0832   0833   0834   0835   0836   0837   0838   0839   0840   0841   0842   0843   0844   0845   0846   0847   0848   0849   0850   0851   0852   0853   0854   0855   0856   0857   0858   0859   0860   0861   0862   0863   0864   0865   0866   0867   0868   0869   0870   0871   0872   0873   0874   0875   0876   0877   0878   0879   0880   0881   0882   0883   0884   0885   0886   0887   0888   0889   0890   0891   0892   0893   0894   0895   0896   0897   0898   0899   0900   0901   0902   0903   0904   0905   0906   0907   0908   0909   0910   0911   0912   0913   0914   0915   0916   0917   0918   0919   0920   0921   0922   0923   0924   0925   0926   0927   0928   0929   0930   0931   0932   0933   0934   0935   0936   0937   0938   0939   0940   0941   0942   0943   0944   0945   0946   0947   0948   0949   0950   0951   0952   0953   0954   0955   0956   0957   0958   0959   0960   0961   0962   0963   0964   0965   0966   0967   0968   0969   0970   0971   0972   0973   0974   0975   0976   0977   0978   0979   0980   0981   0982   0983   0984   0985   0986   0987   0988   0989   0990   0991   0992   0993   0994   0995   0996   0997   0998   0999   1000   1001   1002   1003   1004   1005   1006   1007   1008   1009   1010   1011   1012   1013   1014   1015   1016   1017   1018   1019   1020   1021   1022   1023   1024   1025   1026   1027   1028   1029   1030   1031   1032   1033   1034   1035   1036   1037   1038   1039   1040   1041   1042   1043   1044   1045   1046   1047   1048   1049   1050   1051   1052   1053   1054   1055   1056   1057   1058   1059   1060   1061   1062   1063   1064   1065   1066   1067   1068   1069   1070   1071   1072   1073   1074   1075   1076   1077   1078   1079   1080   1081   1082   1083   1084   1085   1086   1087   1088   1089   1090   1091   1092   1093   1094   1095   1096   1097   1098   1099   1100   1101   1102   1103   1104   1105   1106   1107   1108   1109   1110   1111   1112   1113   1114   1115   1116   1117   1118   1119   1120   1121   1122   1123   1124   1125   1126   1127   1128   1129   1130   1131   1132   1133   1134   1135   1136   1137   1138   1139   1140   1141   1142   1143   1144   1145   1146   1147   1148   1149   1150   1151   1152   1153   1154   1155   1156   1157   1158   1159   1160   1161   1162   1163   1164   1165   1166   1167   1168   1169   1170   1171   1172   1173   1174   1175   1176   1177   1178   1179   1180   1181   1182   1183   1184   1185   1186   1187   1188   1189   1190   1191   1192   1193   1194   1195   1196   1197   1198   1199   1200   1201   1202   1203   1204   1205   1206   1207   1208   1209   1210   1211   1212   1213   1214   1215   1216   1217   1218   1219   1220   1221   1222   1223   1224   1225   1226   1227   1228   1229   1230   1231   1232   1233   1234   1235   1236   1237   1238   1239   1240   1241   1242   1243   1244   1245   1246   1247   1248   1249   1250   1251   1252   1253   1254   1255   1256   1257   1258   1259   1260   1261   1262   1263   1264   1265   1266   1267   1268   1269   1270   1271   1272   1273   1274   1275   1276   1277   1278   1279   1280   1281   1282   1283   1284   1285   1286   1287   1288   1289   1290   1291   1292   1293   1294   1295   1296   1297   1298   1299   1300   1301   1302   1303   1304   1305   1306   1307   1308   1309   1310   1311   1312   1313   1314   1315   1316   1317   1318   1319   1320   1321   1322   1323   1324   1325   1326   1327   1328   1329   1330   1331   1332   1333   1334   1335   1336   1337   1338   1339   1340   1341   1342   1343   1344   1345   1346   1347   1348   1349   1350   1351   1352   1353   1354   1355   1356   1357   1358   1359   1360   1361   1362   1363   1364   1365   1366   1367   1368   1369   1370   1371   1372   1373   1374   1375   1376   1377   1378   1379   1380   1381   1382   1383   1384   1385   1386   1387   1388   1389   1390   1391   1392   1393   1394   1395   1396   1397   1398   1399   1400   1401   1402   1403   1404   1405   1406   1407   1408   1409   1410   1411   1412   1413   1414   1415   1416   1417   1418   1419   1420   1421   1422   1423   1424   1425   1426   1427   1428   1429   1430   1431   1432   1433   1434   1435   1436   1437   1438   1439   1440   1441   1442   1443   1444   1445   1446   1447   1448   1449   1450   1451   1452   1453   1454   1455   1456   1457   1458   1459   1460   1461   1462   1463   1464   1465   1466   1467   1468   1469   1470   1471   1472   1473   1474   1475   1476   1477   1478   1479   1480   1481   1482   1483   1484   1485   1486   1487   1488   1489   1490   1491   1492   1493   1494   1495   1496   1497   1498   1499   1500   1501   1502   1503   1504   1505   1506   1507   1508   1509   1510   1511   1512   1513   1514   1515   1516   1517   1518   1519   1520   1521   1522   1523   1524   1525   1526   1527   1528   1529   1530   1531   1532   1533   1534   1535   1536   1537   1538   1539   1540   1541   1542   1543   1544   1545   1546   1547   1548   1549   1550   1551   1552   1553   1554   1555   1556   1557   1558   1559   1560   1561   1562   1563   1564   1565   1566   1567   1568   1569   1570   1571   1572   1573   1574   1575   1576   1577   1578   1579   1580   1581   1582   1583   1584   1585   1586   1587   1588   1589   1590   1591   1592   1593   1594   1595   1596   1597   1598   1599   1600   1601   1602   1603   1604   1605   1606   1607   1608   1609   1610   1611   1612   1613   1614   1615   1616   1617   1618   1619   1620   1621   1622   1623   1624   1625  

权利要求书

1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34  

说明书

发明名称 : ANTIDIABETIC TRICYCLIC COMPOUNDS

BACKGROUND OF THE INVENTION

[0001]
Diabetes mellitus is a disease derived from multiple causative factors and characterized by elevated levels of plasma glucose (hyperglycemia) in the fasting state or after administration of glucose during an oral glucose tolerance test. There are two generally recognized forms of diabetes. In Type 1 diabetes, or insulin-dependent diabetes mellitus (IDDM) , patients produce little or no insulin, the hormone which regulates glucose utilization. In Type 2 diabetes, or noninsulin-dependent diabetes mellitus (NIDDM) , insulin is still produced in the body, however patients have a resistance to the effects of insulin in stimulating glucose and lipid metabolism in the insulin-sensitive muscle, liver and adipose tissues. Type 2 diabetes patients often have normal levels of insulin, and may have hyperinsulinemia (elevated plasma insulin levels) , as they compensate for the reduced effectiveness of insulin by secreting increased amounts of insulin. This lack of responsiveness to insulin results in insufficient insulin-mediated activation of uptake, oxidation and storage of glucose in muscle, and inadequate insulin-mediated repression of lipolysis in adipose tissue and of glucose production and secretion in the liver.
[0002]
Persistent or uncontrolled hyperglycemia is associated with increased and premature morbidity and mortality. Abnormal glucose homeostasis is associated both directly and indirectly with obesity, hypertension, and alterations of the lipid, lipoprotein and apolipoprotein metabolism, as well as other metabolic and hemodynamic disease. Patients with Type 2 diabetes mellitus have a significantly increased risk of macrovascular and microvascular complications, including atherosclerosis, coronary heart disease, stroke, peripheral vascular disease, hypertension, nephropathy, neuropathy, and retinopathy. Therefore, therapeutic control of glucose homeostasis, lipid metabolism, obesity, and hypertension are critically important in the clinical management and treatment of diabetes mellitus.
[0003]
Patients who have insulin resistance often have Metabolic Syndrome (as defined in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III) , National Institutes of Health, 2001, NIH Publication No. 01-3670) . Patients with Metabolic Syndrome have an increased risk of developing the macrovascular and microvascular complications that occur with Type 2 diabetes, such as atherosclerosis and coronary heart disease.
[0004]
There are several available treatments for Type 2 diabetes. Physical exercise and a reduction in dietary intake of calories are the recommended first-line treatment of Type 2 diabetes and of pre-diabetic conditions associated with insulin resistance, however compliance is generally poor. Pharmacologic treatments for diabetes have largely focused on three areas of pathophysiology: (1) hepatic glucose production (biguanides, such as phenformin and metformin) , (2) insulin resistance (PPAR agonists, such as rosiglitazone, troglitazone, engliazone, balaglitazone, and pioglitazone) , (3) insulin secretion (sulfonylureas, such as tolbutamide, glipizide and glimipiride) ; (4) incretin hormone mimetics (GLP-1 derivatives and analogs, such as exenatide, liraglutide, dulaglutide, semaglutide, lixisenatide, albiglutide and taspoglutide) ; and (5) inhibitors of incretin hormone degradation (DPP-4 inhibitors, such as sitagliptin, alogliptin, vildagliptin, linagliptin, denagliptin and saxagliptin) .
[0005]
The two best known biguanides, phenformin and metformin, cause some correction of hyperglycemia, but can also induce lactic acidosis and nausea/diarrhea. PPAR gamma agonists, such as rosiglitazone and pioglitazone, are modestly effective in reducing plasma glucose and Hemoglobin A1C. However, the currently marketed glitazones do not greatly improve lipid metabolism and may negatively effect on the lipid profile. The administration of insulin secretagogues, such as the sulfonylureas (e.g. tolbutamide, glipizide, and glimepiride) can result in hypoglycemia; their administration must therefore be carefully controlled.
[0006]
There has been a renewed focus on pancreatic islet-based insulin secretion that is controlled by glucose-dependent insulin secretion. This approach has the potential for stabilization and restoration of β-cell function. Several orphan G-protein coupled receptors (GPCR's) have been identified that are preferentially expressed in the β-cell and that are implicated in glucose stimulated insulin secretion (GSIS) . GPR40 is a cell-surface GPCR that is highly expressed in human (and rodent) islets as well as in insulin-secreting cell lines. Several naturally-occurring medium to long-chain fatty acids (FA's) as well as synthetic compounds, including several members of the thiazolidinedione class of PPARγ agonists, have recently been identified as ligands for GPR40 [Itoh, Y.et al., Nature, 422: 173 (2003) ; Briscoe, C.P. et al., J.Biol.Chem., 278: 11303 (2003) ; Kotarsky, K.et al., Biochem. Biophys. Res. Comm., 301: 406 (2003) ] . Under hyperglycemic conditions, GPR40 agonists are capable of augmenting the release of insulin from islet cells. The specificity of this response is suggested by results showing that the inhibition of GPR40 activity by siRNA attenuates FA-induced amplification of GSIS. These findings indicate that, in addition to the intracellular generation of lipid-derivatives of FA’s that are thought to promote insulin release, FA’s (and other synthetic GPR40 agonists) may also act as extracellular ligands that bind to GPR40 in mediating FA-induced insulin secretion. There are several potential advantages of GPR40 as a target for the treatment of Type 2 diabetes. First, since GPR40-mediated insulin secretion is glucose dependent, there is little or no risk of hypoglycemia. Second, the limited tissue distribution of GPR40 (mainly in islets) suggests that there would be less chance for side effects associated with GPR40 activity in other tissues. Third, GPR40 agonists that are active in the islets may have the potential to restore or preserve islet function. This would be advantageous, because long term diabetes therapy often leads to the gradual diminution of islet activity; after extended periods of treatment, it is often necessary to treat Type 2 diabetic patients with daily insulin injections. By restoring or preserving islet function, GPR40 agonists may delay or prevent the diminution and loss of islet function in a Type 2 diabetic patient.
[0007]
Compounds that are agonists of G-protein-coupled receptor 40 (GPR40) may be useful to treat type 2 diabetes mellitus, obesity, hypertension, dyslipidemia, cancer, and metabolic syndrome, as well as cardiovascular diseases, such as myocardial infarction and stroke, by improving glucose and lipid metabolism and by reducing body weight. There is a need for potent GPR40 agonists that have pharmacokinetic and pharmacodynamic properties suitable for use as human pharmaceuticals.
[0008]
G-protein-coupled receptor 40 (GPR40) agonists are disclosed in WO 2007/136572, WO 2007/136573, WO 2009/058237, WO 2006/083612, WO 2006/083781, WO 2010/085522, WO 2010/085525, WO 2010/085528, WO 2010/091176, WO 2004/041266, EP 2004/1630152, WO 2004/022551, WO 2005/051890, WO 2005/051373, EP 2004/1698624, WO 2005/086661, WO 2007/213364, WO 2005/063729, WO 2005/087710, WO 2006/127503, WO 2007/1013689, WO 2006/038738, WO 2007/033002, WO 2007/106469, WO 2007/123225, WO 2008/001931, WO 2008/030520, WO 2008/030618, WO 2008/054674, WO 2008/054675, WO 2008/066097, WO 2008/130514, WO 2009/048527, WO 2009/058237, WO 2009/111056, WO 2010/004347, WO y2010/045258, WO 2010/085522, WO 2010/085525, WO 2010/085528, WO 2010/091176, WO 2010/143733, WO 2012/0004187, WO 2012/072691, WO 2013/122028, WO2013/122029, WO2014/022528, and GB 2498976.
[0009]
GPR40 agonists are also disclosed in Walsh et al., Bioorganic &Medicinal Chemistry Letters (2011) , 21 (11) , 3390-3394; Zhou et al., Bioorganic &Medicinal Chemistry Letters (2010) , 20(3) , 1298-1301; Tan et al., Diabetes (2008) , 57 (8) , 2211-2219; Houze et al., Bioorganic &Medicinal Chemistry Letters (2012) , 22 (2) , 1267-1270; Brown et al., ACS Medicinal Chemistry Letters (2012) , 3 (9) , 726-730; Lin et al., PloS One (2011) , 6 (11) , e27270; Lou et al., PloS One (2012) , 7 (10) , e46300; Lin et al., Molecular Pharmacology (2012) , 82 (5) , 843-859; Yang, Lihu, Abstracts of Papers, 239th ACS Meeting, San Francisco, CA, USA March 21-25, 2010 MEDI-313; and Houze et al., Abstracts of Papers, 243rd ACS National Meeting &Exposition, San Diego, CA, USA March 25-29, 2012, MEDI-265.
[0010]
SUMMARY OF THE INVENTION
[0011]
The present invention relates to novel substituted compounds of structural formula I:
[0012]


[0013]
and pharmaceutically acceptable salts thereof. The compounds of structural formula I, and embodiments thereof, are agonists of G-protein-coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases, disorders and conditions mediated by agonism of the G-protein-coupled receptor 40, such as Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Metabolic Syndrome and atherosclerosis.
[0014]
The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention and a pharmaceutically acceptable carrier. The present invention also relates to methods for the treatment, control or prevention of disorders, diseases, and conditions that may be responsive to agonism of the G-protein-coupled receptor 40 in a subject in need thereof by administering the compounds and pharmaceutical compositions of the present invention. The present invention also relates to the use of compounds of the present invention for manufacture of a medicament useful in treating diseases, disorders and conditions that may be responsive to the agonism of the G-protein-coupled receptor 40. The present invention is also concerned with treatment of these diseases, disorders and conditions by administering the compounds of the present invention in combination with a therapeutically effective amount of another agent that may be useful to treat the disease, disorder and condition. The invention is further concerned with processes for preparing the compounds of this invention.

DETAILED DESCRIPTION OF THE INVENTION

[0015]
The present invention is concerned with novel compounds of structural Formula II:
[0016]


[0017]
or a pharmaceutically acceptable salt thereof; wherein
[0018]
X is selected from the group consisting of:
[0019]
(1) oxygen, and
[0020]
(2) NR 7
[0021]
T is selected from the group consisting of: CH, N and N-oxide;
[0022]
U is selected from the group consisting of: CH, N and N-oxide;
[0023]
V is selected from the group consisting of: CH, N and N-oxide;
[0024]
W is selected from the group consisting of: CH, N and N-oxide,
[0025]
provided that no more than two of T, U, V and W are N or N-oxide;
[0026]
A is selected from the group consisting of:
[0027]
(1) bicyclic aryl ring, and
[0028]
(2) bicyclic heteroaryl ring,
[0029]
wherein each bicyclic aryl ring and bicyclic heteroaryl ring is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring, or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH;
[0030]
B is selected from the group consisting of:
[0031]
(1) C 1-6alkyl,
[0032]
(2) aryl,
[0033]
(3) aryl-O-,
[0034]
(4) C 3-6cycloalkyl-,
[0035]
(5) C 3-6cycloalkyl-C 1-10alkyl-,
[0036]
(6) C 3-6cycloalkyl-C 1-10alkyl-O-,
[0037]
(7) C 2-5cycloheteroalkyl-,
[0038]
(8) C 3-6cycloheteroalkyl-C 1-10alkyl-,
[0039]
(9) C 3-6cycloheteroalkyl-C 1-10alkyl-O-,
[0040]
(10) heteroaryl,
[0041]
(11) heteroaryl-O-,
[0042]
(12) aryl-C 1-10 alkyl-, and
[0043]
(13) heteroaryl-C 1-10 alkyl-;
[0044]
wherein B is unsubstituted or substituted with one to six substituents selected from R b
[0045]
each R 1 is independently selected from the group consisting of:
[0046]
(1) hydrogen,
[0047]
(2) halogen,
[0048]
(3) –OR e,
[0049]
(4) –CN,
[0050]
(5) -C 1-6alkyl, and
[0051]
(6) -C 3-6cycloalkyl,
[0052]
wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to three substituents selected from R i
[0053]
R 2 is selected from the group consisting of:
[0054]
(1) hydrogen,
[0055]
(2) -C 1-6alkyl, and
[0056]
(3) -C 3-6cycloalkyl,
[0057]
wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to three substituents selected from R j
[0058]
each R 3 is independently selected from the group consisting of:
[0059]
(1) hydrogen,
[0060]
(2) halogen,
[0061]
(3) -OR e,
[0062]
(4) -C 1-6alkyl,
[0063]
(5) -C 2-6alkenyl,
[0064]
(6) -C 2-6alkynyl,
[0065]
(7) -C 3-6cycloalkyl, and
[0066]
(8) -C 2-6cycloheteroalkyl,
[0067]
wherein each alkyl, alkenyl, alkynyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to three substituents selected from R L
[0068]
each R 4 is independently selected from the group consisting of:
[0069]
(1) hydrogen,
[0070]
(2) halogen,
[0071]
(3) -OR e,
[0072]
(4) -C 1-6alkyl,
[0073]
(5) -C 2-6alkenyl,
[0074]
(6) -C 2-6alkynyl,
[0075]
(7) -C 3-6cycloalkyl, and
[0076]
(8) -C 2-6cycloheteroalkyl,
[0077]
wherein each alkyl, alkenyl, alkynyl, and cycloalkyl is unsubstituted or substituted with one to three substituents selected from R L
[0078]
R 5 is selected from the group consisting of:
[0079]
(1) hydrogen,
[0080]
(2) -C 1-3alkyl, and
[0081]
(3) halogen;
[0082]
R 6 is selected from the group consisting of:
[0083]
(1) hydrogen,
[0084]
(2) -C 1-3alkyl, and
[0085]
(3) halogen, or
[0086]
R 5 and R 6 can together form oxo;
[0087]
R 7 is selected from the group consisting of:
[0088]
(1) hydrogen,
[0089]
(2) -C (O) R e, and
[0090]
(3) -C 1-10alkyl,
[0091]
wherein -C 1-10alkyl is unsubstituted or substituted with one to five fluorines;
[0092]
each R 8 is selected from the group consisting of:
[0093]
(1) hydrogen,
[0094]
(2) -C (O) R e, and
[0095]
(3) -C 1-10alkyl,
[0096]
wherein -C 1-10alkyl is unsubstituted or substituted with one to five fluorines;
[0097]
each R 9 is selected from the group consisting of:
[0098]
(1) hydrogen, and
[0099]
(2) -C 1-6alkyl,
[0100]
wherein -C 1-6alkyl is unsubstituted or substituted with one to five fluorines;
[0101]
each R a is independently selected from the group consisting of:
[0102]
(1) -C 1-6alkyl,
[0103]
(2) -O-C 1-6alkyl,
[0104]
(3) halogen,
[0105]
(4) oxo,
[0106]
(5) -OR e,
[0107]
(6) –N (R c) S (O) mR e,
[0108]
(7) -S (O) mR e,
[0109]
(8) -S (O) mNR cR d,
[0110]
(9) -NR cR d,
[0111]
(10) -C (O) R e,
[0112]
(11) -OC (O) R e,
[0113]
(12) -CO 2R e,
[0114]
(13) -CN,
[0115]
(14) -C (O) NR cR d,
[0116]
(15) -N (R c) C (O) R e,
[0117]
(16) -N (R c) C (O) OR e,
[0118]
(17) -N (R c) C (O) NR cR d,
[0119]
(18) -CF 3,
[0120]
(19) -OCF 3,
[0121]
(20) -OCHF 2,
[0122]
(21) - (CH 2) p-C 3-6cycloalkyl,
[0123]
(22) - (CH 2) p-C 2-10cycloheteroalkyl,
[0124]
(23) - (CH 2) p-aryl, and
[0125]
(24) - (CH 2) p-heteroaryl,
[0126]
wherein R a is unsubstituted or substituted with one to three substituents selected from R m
[0127]
each R b is independently selected from the group consisting of:
[0128]
(1) -C 1-10 alkyl,
[0129]
(2) -O-C 1-10alkyl,
[0130]
(3) -C 2-10 alkenyl,
[0131]
(4) halogen,
[0132]
(5) -OH,
[0133]
(6) -OC 2-10 alkenyl,
[0134]
(7) -O (CH 2) pOC 1-10alkyl,
[0135]
(8) -O (CH 2) pC 3-6cycloalkyl,
[0136]
(9) -O (CH 2) pC 2-10cycloheteroalkyl,
[0137]
(10) -O (CH 2) p-aryl,
[0138]
(11) -O (CH 2) p-heteroaryl,
[0139]
(12) -N (R c) S (O) mR e,
[0140]
(13) -S (O) mR e,
[0141]
(14) -O (CH 2) p-S (O) mR e,
[0142]
(15) -S (O) mNR cR d,
[0143]
(16) -NR cR d,
[0144]
(17) -C (O) R e,
[0145]
(18) -OC (O) R e,
[0146]
(19) -CO 2R e,
[0147]
(20) -CN,
[0148]
(21) -C (O) NR cR d,
[0149]
(22) -N (R c) C (O) R e,
[0150]
(23) -N (R c) C (O) OR e,
[0151]
(24) -N (R c) C (O) NR cR d,
[0152]
(25) -O (CH 2) pO-C 3-6cycloalkyl,
[0153]
(26) -O (CH 2) pO-C 2-10cycloheteroalkyl,
[0154]
(27) -CF 3,
[0155]
(28) -OCF 3,
[0156]
(29) -OCHF 2,
[0157]
(30) - (CH 2) p-C 3-6cycloalkyl,
[0158]
(31) - (CH 2) p-C 2-10cycloheteroalkyl,
[0159]
(32) - (CH 2) p-aryl, and
[0160]
(33) - (CH 2) p-heteroaryl,
[0161]
wherein each R b is unsubstituted or substituted with one to five substituents selected from R k
[0162]
each R c and R d is independently selected from the group consisting of:
[0163]
(1) hydrogen,
[0164]
(2) -C 1-10alkyl,
[0165]
(3) -C 2-10alkenyl,
[0166]
(4) -C 3-6cycloalkyl,
[0167]
(5) C 3-6 cycloalkyl-C 1-10alkyl-,
[0168]
(6) -C 2-6cycloheteroalkyl,
[0169]
(7) C 2-6cycloheteroalkyl-C 1-10alkyl-,
[0170]
(8) aryl,
[0171]
(9) heteroaryl,
[0172]
(10) aryl-C 1-10alkyl-, and
[0173]
(11) heteroaryl-C 1-10alkyl-, or
[0174]
R c and R d together with the atom (s) to which they are attached form a cycloheteroalkyl ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R g, and wherein each R c and R d is unsubstituted or substituted with one to three substituents independently selected from R f
[0175]
each R e is independently selected from the group consisting of:
[0176]
(1) hydrogen,
[0177]
(2) -C 1-10alkyl,
[0178]
(3) -C 2-10 alkenyl,
[0179]
(4) -C 3-6 cycloalkyl,
[0180]
(5) -C 3-6 cycloalkyl-C 1-10alkyl-,
[0181]
(6) -C 2-5cycloheteroalkyl,
[0182]
(7) -C 2-5cycloheteroalkyl-C 1-10alkyl-,
[0183]
(8) aryl,
[0184]
(9) heteroaryl,
[0185]
(10) aryl-C 1-10alkyl-, and
[0186]
(11) heteroaryl-C 1-10alkyl-,
[0187]
wherein each R e is unsubstituted or substituted with one to three substituents selected from R h
[0188]
each R f is selected from the group consisting of:
[0189]
(1) halogen,
[0190]
(2) -C 1-10alkyl,
[0191]
(3) -OH,
[0192]
(4) -OC 1-6alkyl,
[0193]
(5) -S (O) m-C 1-4alkyl,
[0194]
(6) -CN,
[0195]
(7) -CF 3,
[0196]
(8) -OCHF 2, and
[0197]
(9) -OCF 3,
[0198]
wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S (O) 2CH 3
[0199]
each R g is selected from the group consisting of:
[0200]
(1) hydrogen,
[0201]
(2) -C (O) R e, and
[0202]
(3) -C 1-10alkyl,
[0203]
wherein alkyl is unsubstituted or substituted with one to five fluorines;
[0204]
each R h is selected from the group consisting of:
[0205]
(1) halogen,
[0206]
(2) -C 1-10alkyl,
[0207]
(3) -OH,
[0208]
(4) -O-C 1-4alkyl,
[0209]
(5) -S (O) m-C 1-4alkyl,
[0210]
(6) -CN,
[0211]
(7) -CF 3,
[0212]
(8) -OCHF 2, and
[0213]
(9) -OCF 3,
[0214]
wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and –S (O) 2CH 3
[0215]
R i is independently selected from the group consisting of:
[0216]
(1) -C 1-6alkyl,
[0217]
(2) -OR e,
[0218]
(3) -N (R c) S (O) mR e,
[0219]
(4) halogen,
[0220]
(5) -S (O) mR e,
[0221]
(6) -S (O) mNR cR d,
[0222]
(7) -NR cR d,
[0223]
(8) -C (O) R e,
[0224]
(9) -OC (O) R e,
[0225]
(10) -CO 2R e,
[0226]
(11) -CN,
[0227]
(12) -C (O) NR cR d,
[0228]
(13) -N (R c) C (O) R e,
[0229]
(14) -N (R c) C (O) OR e,
[0230]
(15) -N (R c) C (O) NR cR d,
[0231]
(16) -CF 3,
[0232]
(17) -OCF 3,
[0233]
(18) -OCHF 2,
[0234]
(19) -C 3-6cycloalkyl, and
[0235]
(20) -C 2-5cycloheteroalkyl;
[0236]
R j is independently selected from the group consisting of:
[0237]
(1) -C 1-6alkyl,
[0238]
(2) -OR e,
[0239]
(3) -N (R c) S (O) mR e,
[0240]
(4) halogen,
[0241]
(5) -S (O) mR e,
[0242]
(6) -S (O) mNR cR d,
[0243]
(7) -NR cR d,
[0244]
(8) -C (O) R e,
[0245]
(9) -OC (O) R e,
[0246]
(10) -CO 2R e,
[0247]
(11) -CN,
[0248]
(12) -C (O) NR cR d,
[0249]
(13) -N (R c) C (O) R e,
[0250]
(14) -N (R c) C (O) OR e,
[0251]
(15) -N (R c) C (O) NR cR d,
[0252]
(16) -CF 3,
[0253]
(17) -OCF 3,
[0254]
(18) -OCHF 2,
[0255]
(19) -C 3-6cycloalkyl, and
[0256]
(20) -C 2-5cycloheteroalkyl;
[0257]
each R k is independently selected from the group consisting of:
[0258]
(1) halogen,
[0259]
(2) -C 1-6alkyl,
[0260]
(3) -OH,
[0261]
(4) oxo,
[0262]
(5) -OC 1-6alkyl,
[0263]
(6) -SO 2-C 1-6 alkyl,
[0264]
(7) -C 1-6alkyl-SO 2C 1-6alkyl,
[0265]
(8) -CN,
[0266]
(9) -CF 3,
[0267]
(10) -OCHF 2,
[0268]
(11) -OCF 3,
[0269]
(12) -NH 2,
[0270]
(13) -NHSO 2C 1-6alkyl,
[0271]
(14) –NHC (O) C 1-6alkyl,
[0272]
(15) =N (OCH 3) ,
[0273]
(16) -P (O) (OH) 2, and
[0274]
(17) -P (O) (OC 1-6alkyl) 2,
[0275]
wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl;
[0276]
R L is selected from the group consisting of:
[0277]
(1) –C 1-6alkyl,
[0278]
(2) halogen,
[0279]
(3) -OR e,
[0280]
(4) -N (R c) S (O) mR e,
[0281]
(5) -S (O) mR e,
[0282]
(6) -S (O) mNR cR d,
[0283]
(7) -NR cR d,
[0284]
(8) -C (O) R e,
[0285]
(9) -OC (O) R e,
[0286]
(10) -CO 2R e,
[0287]
(11) -CN,
[0288]
(12) -C (O) NR cR d,
[0289]
(13) -N (R c) C (O) R e,
[0290]
(14) -N (R c) C (O) OR e,
[0291]
(15) -N (R c) C (O) NR cR d,
[0292]
(16) -CF 3,
[0293]
(17) -OCF 3,
[0294]
(18) -OCHF 2,
[0295]
(19) -C 3-6cycloalkyl, and
[0296]
(20) -C 2-5cycloheteroalkyl;
[0297]
each R m is independently selected from the group consisting of:
[0298]
(1) halogen,
[0299]
(2) -C 1-6 alkyl,
[0300]
(3) -OH,
[0301]
(4) oxo,
[0302]
(5) -OC 1-6alkyl,
[0303]
(6) -SO 2-C 1-6 alkyl,
[0304]
(7) -C 1-6alkyl-SO 2C 1-6alkyl,
[0305]
(8) -CN,
[0306]
(9) -CF 3,
[0307]
(10) -OCHF 2,
[0308]
(11) -OCF 3,
[0309]
(12) -NH 2,
[0310]
(13) -NHSO 2C 1-6alkyl,
[0311]
(14) –NHC (O) C 1-6alkyl,
[0312]
(15) =N (OCH 3) ,
[0313]
(16) -P (O) (OH) 2, and
[0314]
(17) -P (O) (OC 1-6alkyl) 2,
[0315]
wherein each C 1-10 alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl;
[0316]
n is independently 0, 1, 2 or 3;
[0317]
each m is independently 0, 1 or 2;
[0318]
each p is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and
[0319]
q is independently selected from: 1, 2 or 3.
[0320]
In another embodiment, the present invention is concerned with novel compounds of structural Formula I:
[0321]


[0322]
or a pharmaceutically acceptable salt thereof; wherein
[0323]
X is selected from the group consisting of:
[0324]
(1) oxygen, and
[0325]
(2) NR 7
[0326]
T is selected from the group consisting of: CH, N and N-oxide;
[0327]
U is selected from the group consisting of: CH, N and N-oxide;
[0328]
V is selected from the group consisting of: CH, N and N-oxide;
[0329]
W is selected from the group consisting of: CH, N and N-oxide,
[0330]
provided that no more than two of T, U, V and W are N or N-oxide;
[0331]
A is selected from the group consisting of:
[0332]
(1) bicyclic aryl ring, and
[0333]
(2) bicyclic heteroaryl ring,
[0334]
wherein each bicyclic aryl ring and bicyclic heteroaryl ring is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring, or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH;
[0335]
B is selected from the group consisting of:
[0336]
(1) aryl,
[0337]
(2) aryl-O-,
[0338]
(3) C 3-6cycloalkyl-,
[0339]
(4) C 3-6cycloalkyl-C 1-10alkyl-,
[0340]
(5) C 3-6cycloalkyl-C 1-10alkyl-O-,
[0341]
(6) C 2-5cycloheteroalkyl-,
[0342]
(7) C 3-6cycloheteroalkyl-C 1-10alkyl-,
[0343]
(8) C 3-6cycloheteroalkyl-C 1-10alkyl-O-,
[0344]
(9) heteroaryl,
[0345]
(10) heteroaryl-O-,
[0346]
(11) aryl-C 1-10 alkyl-, and
[0347]
(12) heteroaryl-C 1-10 alkyl-;
[0348]
wherein B is unsubstituted or substituted with one to six substituents selected from R b
[0349]
each R 1 is independently selected from the group consisting of:
[0350]
(1) hydrogen,
[0351]
(2) halogen,
[0352]
(1) –OR e,
[0353]
(2) –CN,
[0354]
(3) -C 1-6alkyl, and
[0355]
(4) -C 3-6cycloalkyl,
[0356]
wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to three substituents selected from R i
[0357]
R 2 is selected from the group consisting of:
[0358]
(1) hydrogen,
[0359]
(2) -C 1-6alkyl, and
[0360]
(3) -C 3-6cycloalkyl,
[0361]
wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to three substituents selected from R j
[0362]
each R 3 is independently selected from the group consisting of:
[0363]
(1) hydrogen,
[0364]
(2) halogen,
[0365]
(3) -OR e,
[0366]
(4) -C 1-6alkyl,
[0367]
(5) -C 2-6alkenyl,
[0368]
(6) -C 2-6alkynyl,
[0369]
(7) -C 3-6cycloalkyl, and
[0370]
(8) -C 2-6cycloheteroalkyl,
[0371]
wherein each alkyl, alkenyl, alkynyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to three substituents selected from R L
[0372]
each R 4 is independently selected from the group consisting of:
[0373]
(1) hydrogen,
[0374]
(2) halogen,
[0375]
(3) -OR e,
[0376]
(4) -C 1-6alkyl,
[0377]
(5) -C 2-6alkenyl,
[0378]
(6) -C 2-6alkynyl,
[0379]
(7) -C 3-6cycloalkyl, and
[0380]
(8) -C 2-6cycloheteroalkyl,
[0381]
wherein each alkyl, alkenyl, alkynyl, and cycloalkyl is unsubstituted or substituted with one to three substituents selected from R L
[0382]
R 5 is selected from the group consisting of:
[0383]
(1) hydrogen,
[0384]
(2) -C 1-3alkyl, and
[0385]
(3) halogen;
[0386]
R 6 is selected from the group consisting of:
[0387]
(1) hydrogen,
[0388]
(2) -C 1-3alkyl, and
[0389]
(3) halogen, or
[0390]
R 5 and R 6 can together form oxo;
[0391]
R 7 is selected from the group consisting of:
[0392]
(1) hydrogen,
[0393]
(2) -C (O) R e, and
[0394]
(3) -C 1-10alkyl,
[0395]
wherein -C 1-10alkyl is unsubstituted or substituted with one to five fluorines;
[0396]
each R 8 is selected from the group consisting of:
[0397]
(1) hydrogen,
[0398]
(2) -C (O) R e, and
[0399]
(3) -C 1-10alkyl,
[0400]
wherein -C 1-10alkyl is unsubstituted or substituted with one to five fluorines;
[0401]
each R a is independently selected from the group consisting of:
[0402]
(1) -C 1-6alkyl,
[0403]
(2) -O-C 1-6alkyl,
[0404]
(3) halogen,
[0405]
(4) oxo,
[0406]
(5) -OR e,
[0407]
(6) –N (R c) S (O) mR e,
[0408]
(7) -S (O) mR e,
[0409]
(8) -S (O) mNR cR d,
[0410]
(9) -NR cR d,
[0411]
(10) -C (O) R e,
[0412]
(11) -OC (O) R e,
[0413]
(12) -CO 2R e,
[0414]
(13) -CN,
[0415]
(14) -C (O) NR cR d,
[0416]
(15) -N (R c) C (O) R e,
[0417]
(16) -N (R c) C (O) OR e,
[0418]
(17) -N (R c) C (O) NR cR d,
[0419]
(18) -CF 3,
[0420]
(19) -OCF 3,
[0421]
(20) -OCHF 2,
[0422]
(21) - (CH 2) p-C 3-6cycloalkyl,
[0423]
(22) - (CH 2) p-C 2-10cycloheteroalkyl,
[0424]
(23) - (CH 2) p-aryl, and
[0425]
(24) - (CH 2) p-heteroaryl,
[0426]
wherein R a is unsubstituted or substituted with one to three substituents selected from R m
[0427]
each R b is independently selected from the group consisting of:
[0428]
(1) -C 1-10 alkyl,
[0429]
(2) -O-C 1-10alkyl,
[0430]
(3) -C 2-10 alkenyl,
[0431]
(4) halogen,
[0432]
(5) -OH,
[0433]
(6) -OC 2-10 alkenyl,
[0434]
(7) -O (CH 2) pOC 1-10alkyl,
[0435]
(8) -O (CH 2) pC 3-6cycloalkyl,
[0436]
(9) -O (CH 2) pC 2-10cycloheteroalkyl,
[0437]
(10) -O (CH 2) p-aryl,
[0438]
(11) -O (CH 2) p-heteroaryl,
[0439]
(12) -N (R c) S (O) mR e,
[0440]
(13) -S (O) mR e,
[0441]
(14) -O (CH 2) p-S (O) mR e,
[0442]
(15) -S (O) mNR cR d,
[0443]
(16) -NR cR d,
[0444]
(17) -C (O) R e,
[0445]
(18) -OC (O) R e,
[0446]
(19) -CO 2R e,
[0447]
(20) -CN,
[0448]
(21) -C (O) NR cR d,
[0449]
(22) -N (R c) C (O) R e,
[0450]
(23) -N (R c) C (O) OR e,
[0451]
(24) -N (R c) C (O) NR cR d,
[0452]
(25) -O (CH 2) pO-C 3-6cycloalkyl,
[0453]
(26) -O (CH 2) pO-C 2-10cycloheteroalkyl,
[0454]
(27) -CF 3,
[0455]
(28) -OCF 3,
[0456]
(29) -OCHF 2,
[0457]
(30) - (CH 2) p-C 3-6cycloalkyl,
[0458]
(31) - (CH 2) p-C 2-10cycloheteroalkyl,
[0459]
(32) - (CH 2) p-aryl, and
[0460]
(33) - (CH 2) p-heteroaryl,
[0461]
wherein each R b is unsubstituted or substituted with one to five substituents selected from R k
[0462]
each R c and R d is independently selected from the group consisting of:
[0463]
(1) hydrogen,
[0464]
(2) -C 1-10alkyl,
[0465]
(3) -C 2-10alkenyl,
[0466]
(4) -C 3-6cycloalkyl,
[0467]
(5) C 3-6 cycloalkyl-C 1-10alkyl-,
[0468]
(6) -C 2-6cycloheteroalkyl,
[0469]
(7) C 2-6cycloheteroalkyl-C 1-10alkyl-,
[0470]
(8) aryl,
[0471]
(9) heteroaryl,
[0472]
(10) aryl-C 1-10alkyl-, and
[0473]
(11) heteroaryl-C 1-10alkyl-, or
[0474]
R c and R d together with the atom (s) to which they are attached form a cycloheteroalkyl ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R g, and wherein each R c and R d is unsubstituted or substituted with one to three substituents independently selected from R f
[0475]
each R e is independently selected from the group consisting of:
[0476]
(1) hydrogen,
[0477]
(2) -C 1-10alkyl,
[0478]
(3) -C 2-10 alkenyl,
[0479]
(4) -C 3-6 cycloalkyl,
[0480]
(5) -C 3-6 cycloalkyl-C 1-10alkyl-,
[0481]
(6) -C 2-5cycloheteroalkyl,
[0482]
(7) -C 2-5cycloheteroalkyl-C 1-10alkyl-,
[0483]
(8) aryl,
[0484]
(9) heteroaryl,
[0485]
(10) aryl-C 1-10alkyl-, and
[0486]
(11) heteroaryl-C 1-10alkyl-,
[0487]
wherein each R e is unsubstituted or substituted with one to three substituents selected from R h
[0488]
each R f is selected from the group consisting of:
[0489]
(1) halogen,
[0490]
(2) -C 1-10alkyl,
[0491]
(3) -OH,
[0492]
(4) -OC 1-6alkyl,
[0493]
(5) -S (O) m-C 1-4alkyl,
[0494]
(6) -CN,
[0495]
(7) -CF 3,
[0496]
(8) -OCHF 2, and
[0497]
(9) -OCF 3,
[0498]
wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S (O) 2CH 3
[0499]
each R g is selected from the group consisting of:
[0500]
(1) hydrogen,
[0501]
(2) -C (O) R e, and
[0502]
(3) -C 1-10alkyl,
[0503]
wherein alkyl is unsubstituted or substituted with one to five fluorines;
[0504]
each R h is selected from the group consisting of:
[0505]
(1) halogen,
[0506]
(2) -C 1-10alkyl,
[0507]
(3) -OH,
[0508]
(4) -O-C 1-4alkyl,
[0509]
(5) -S (O) m-C 1-4alkyl,
[0510]
(6) -CN,
[0511]
(7) -CF 3,
[0512]
(8) -OCHF 2, and
[0513]
(9) -OCF 3,
[0514]
wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and –S (O) 2CH 3
[0515]
R i is independently selected from the group consisting of:
[0516]
(1) -C 1-6alkyl,
[0517]
(2) -OR e,
[0518]
(3) -N (R c) S (O) mR e,
[0519]
(4) halogen,
[0520]
(5) -S (O) mR e,
[0521]
(6) -S (O) mNR cR d,
[0522]
(7) -NR cR d,
[0523]
(8) -C (O) R e,
[0524]
(9) -OC (O) R e,
[0525]
(10) -CO 2R e,
[0526]
(11) -CN,
[0527]
(12) -C (O) NR cR d,
[0528]
(13) -N (R c) C (O) R e,
[0529]
(14) -N (R c) C (O) OR e,
[0530]
(15) -N (R c) C (O) NR cR d,
[0531]
(16) -CF 3,
[0532]
(17) -OCF 3,
[0533]
(18) -OCHF 2,
[0534]
(19) -C 3-6cycloalkyl, and
[0535]
(20) -C 2-5cycloheteroalkyl;
[0536]
R j is independently selected from the group consisting of:
[0537]
(1) -C 1-6alkyl,
[0538]
(2) -OR e,
[0539]
(3) -N (R c) S (O) mR e,
[0540]
(4) halogen,
[0541]
(5) -S (O) mR e,
[0542]
(6) -S (O) mNR cR d,
[0543]
(7) -NR cR d,
[0544]
(8) -C (O) R e,
[0545]
(9) -OC (O) R e,
[0546]
(10) -CO 2R e,
[0547]
(11) -CN,
[0548]
(12) -C (O) NR cR d,
[0549]
(13) -N (R c) C (O) R e,
[0550]
(14) -N (R c) C (O) OR e,
[0551]
(15) -N (R c) C (O) NR cR d,
[0552]
(16) -CF 3,
[0553]
(17) -OCF 3,
[0554]
(18) -OCHF 2,
[0555]
(19) -C 3-6cycloalkyl, and
[0556]
(20) -C 2-5cycloheteroalkyl;
[0557]
each R k is independently selected from the group consisting of:
[0558]
(1) halogen,
[0559]
(2) -C 1-6alkyl,
[0560]
(3) -OH,
[0561]
(4) oxo,
[0562]
(5) -OC 1-6alkyl,
[0563]
(6) -SO 2-C 1-6 alkyl,
[0564]
(7) -C 1-6alkyl-SO 2C 1-6alkyl,
[0565]
(8) -CN,
[0566]
(9) -CF 3,
[0567]
(10) -OCHF 2,
[0568]
(11) -OCF 3,
[0569]
(12) -NH 2,
[0570]
(13) -NHSO 2C 1-6alkyl,
[0571]
(14) –NHC (O) C 1-6alkyl,
[0572]
(15) =N (OCH 3) ,
[0573]
(16) -P (O) (OH) 2, and
[0574]
(17) -P (O) (OC 1-6alkyl) 2,
[0575]
wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl;
[0576]
R L is selected from the group consisting of:
[0577]
(1) –C 1-6alkyl,
[0578]
(2) halogen,
[0579]
(3) -OR e,
[0580]
(4) -N (R c) S (O) mR e,
[0581]
(5) -S (O) mR e,
[0582]
(6) -S (O) mNR cR d,
[0583]
(7) -NR cR d,
[0584]
(8) -C (O) R e,
[0585]
(9) -OC (O) R e,
[0586]
(10) -CO 2R e,
[0587]
(11) -CN,
[0588]
(12) -C (O) NR cR d,
[0589]
(13) -N (R c) C (O) R e,
[0590]
(14) -N (R c) C (O) OR e,
[0591]
(15) -N (R c) C (O) NR cR d,
[0592]
(16) -CF 3,
[0593]
(17) -OCF 3,
[0594]
(18) -OCHF 2,
[0595]
(19) -C 3-6cycloalkyl, and
[0596]
(20) -C 2-5cycloheteroalkyl;
[0597]
each R m is independently selected from the group consisting of:
[0598]
(1) halogen,
[0599]
(2) -C 1-6 alkyl,
[0600]
(3) -OH,
[0601]
(4) oxo,
[0602]
(5) -OC 1-6alkyl,
[0603]
(6) -SO 2-C 1-6 alkyl,
[0604]
(7) -C 1-6alkyl-SO 2C 1-6alkyl,
[0605]
(8) -CN,
[0606]
(9) -CF 3,
[0607]
(10) -OCHF 2,
[0608]
(11) -OCF 3,
[0609]
(12) -NH 2,
[0610]
(13) -NHSO 2C 1-6alkyl,
[0611]
(14) –NHC (O) C 1-6alkyl,
[0612]
(15) =N (OCH 3) ,
[0613]
(16) -P (O) (OH) 2, and
[0614]
(17) -P (O) (OC 1-6alkyl) 2,
[0615]
wherein each C 1-10 alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl;
[0616]
n is independently 0, 1, 2 or 3;
[0617]
each m is independently 0, 1 or 2;
[0618]
each p is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and q is independently selected from: 1, 2 or 3.
[0619]
The invention has numerous embodiments, which are summarized below. The invention includes the compounds as shown, and also includes individual diastereoisomers, enantiomers, and epimers of the compounds, and mixtures of diastereoisomers and/or enantiomers thereof including racemic mixtures.
[0620]
In one embodiment of the present invention, X is oxygen. In another embodiment of the present invention, X is NR 7. In a class of this embodiment, X is NH.
[0621]
In another embodiment of the present invention, T is selected from the group consisting of: CH and N; U is selected from the group consisting of: CH and N; V is selected from the group consisting of: CH and N; and W is selected from the group consisting of: CH and N, provided that one or two of T, U, V and W are N. In another embodiment of the present invention, T is selected from the group consisting of: CH and N; U is selected from the group consisting of: CH and N; V is selected from the group consisting of: CH and N; and W is selected from the group consisting of: CH and N, provided that one or none of T, U, V and W is N. In another embodiment of the present invention, T is selected from the group consisting of: CH and N; U is selected from the group consisting of: CH and N; V is selected from the group consisting of: CH and N; and W is selected from the group consisting of: CH and N, provided that one of T, U, V and W is N. In another embodiment of the present invention, T is selected from the group consisting of: CH and N; U is selected from the group consisting of: CH and N; V is selected from the group consisting of: CH and N;and W is selected from the group consisting of: CH and N, provided that two of T, U, V and W are N.
[0622]
In another embodiment of the present invention, T is CH, U is CH; V is N or N-oxide; and W is CH. In a class of this embodiment, T is CH, U is CH; V is N; and W is CH. In another embodiment of the present invention, T is selected from the group consisting of: CH, N and N-oxide. In a class of this embodiment, T is selected from the group consisting of: CH and N. In another class of this embodiment, T is CH. In another class of this embodiment, T is N or N-oxide. In another class of this embodiment, T is N.
[0623]
In another embodiment of the present invention, U is selected from the group consisting of: CH, N and N-oxide. In a class of this embodiment, U is selected from the group consisting of: CH and N. In another class of this embodiment, U is CH. In another class of this embodiment, U is N or N-oxide. In another class of this embodiment, U is N.
[0624]
In another embodiment of the present invention, V is selected from the group consisting of: CH, N and N-oxide. In a class of this embodiment, V is selected from the group consisting of: CH and N. In another class of this embodiment, V is CH. In another class of this embodiment, V is N or N-oxide. In another class of this embodiment, V is N.
[0625]
In another embodiment of the present invention, W is selected from the group consisting of: CH, N and N-oxide. In a class of this embodiment, W is selected from the group consisting of: CH and N. In another class of this embodiment, W is CH. In another class of this embodiment, W is N or N-oxide. In another class of this embodiment, W is N.
[0626]
In another embodiment of the present invention, T is CH, U is CH, V is N or N-oxide, and W is CH. In a class of this embodiment, T is CH, U is CH, V is N, and W is CH. In another class of this embodiment, T is CH, V is N or N-oxide, and W is CH. In another class of this embodiment, T is CH, V is N, and W is CH. In another class of this embodiment, U is CH, V is N or N-oxide, and W is CH. In another class of this embodiment, U is CH, V is N, and W is CH. In another class of this embodiment, T is CH, U is CH, and V is N or N-oxide. In another class of this embodiment, T is CH, U is CH, and V is N.
[0627]
In another embodiment of the present invention, T is CH, U is N or N-oxide, V is CH, and W is CH. In a class of this embodiment, T is CH, U is N, V is CH, and W is CH. In another class of this embodiment, T is CH, U is N or N-oxide, and W is CH. In another class of this embodiment, T is CH, U is N, and W is CH. In another class of this embodiment, U is N or N-oxide, V is CH, and W is CH. In another class of this embodiment, U is N, V is CH, and W is CH. In another class of this embodiment, T is CH, U is N or N-oxide, and V is CH. In another class of this embodiment, T is CH, U is N, and V is CH.
[0628]
In another embodiment of the present invention, T is N or N-oxide, U is CH, V is CH, and W is CH. In a class of this embodiment, T is N, U is CH, V is CH, and W is CH. In another class of this embodiment, T is N or N-oxide, V is CH, and W is CH. In another class of this embodiment, T is N, V is CH, and W is CH. In another class of this embodiment, T is N or N-oxide, U is CH, and W is CH. In another class of this embodiment, T is N, U is CH, and W is CH. In another class of this embodiment, T is N or N-oxide, U is CH, and V is CH. In another class of this embodiment, T is N, U is CH, and V is CH.
[0629]
In another embodiment of the present invention, T is CH, U is CH, V is CH, and W is N or N-oxide. In a class of this embodiment, T is CH, U is CH, V is CH, and W is N. In another class of this embodiment, T is CH, V is CH, and W is N or N-oxide. In another class of this embodiment, T is CH, V is CH, and W is N. In another class of this embodiment, T is CH, U is CH, and W is N or N-oxide. In another class of this embodiment, T is CH, U is CH, and W is N. In another class of this embodiment, U is CH, V is CH, and W is N or N-oxide. In another class of this embodiment, U is CH, V is CH, and W is N.
[0630]
In another embodiment of the present invention, A is a bicyclic aryl ring, wherein each bicyclic aryl ring is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring, or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH.
[0631]
In another embodiment of the present invention, A is a bicyclic heteroaryl ring, wherein each bicyclic heteroaryl ring is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring, or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH.
[0632]
In another embodiment of the present invention, A is selected from the group consisting of:
[0633]


[0634]
wherein A is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected_from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH. In a class of this embodiment, A is unsubstituted or substituted with one to four substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl ring and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH.
[0635]
In another class of this embodiment, A is unsubstituted or substituted with one to three substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl ring and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH. In another class of this embodiment, the 3-6 membered cycloalkyl ring and the 3-6 membered cycloheteroalkyl ring formed by two R a substituents on A together with the carbon atom to which they are attached is selected from: cyclopropyl, cyclobutyl, oxetane and dioxane. In subclass of this class, the 3-6 membered cycloalkyl ring and the 3-6 membered cycloheteroalkyl ring formed by two R a substituents on A together with the carbon atom to which they are attached is selected from: cyclopropyl, cyclobutyl, oxetane and 1, 3 dioxane. In another class of this embodiment, A is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring, and wherein each 3-6 membered cycloalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH. In a subclass of this class, the 3-6 membered cycloalkyl ring formed by two R a substituents on A together with the carbon atom to which they are attached is selected from: cyclopropyl, and cyclobutyl. In another class of this embodiment, A is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1- 6alkyl, -O-C 1-6alkyl, halogen and OH. In a subclass of this class, the 3-6 membered cycloheteroalkyl ring formed by two R a substituents on A together with the carbon atom to which they are attached is selected from: oxetane and dioxane. In another subclass of this class, the 3-6 membered cycloheteroalkyl ring formed by two R a substituents on A together with the carbon atom to which they are attached is selected from: oxetane and 1, 3 dioxane.
[0636]
In another embodiment of the present invention, A is selected from the group consisting of:
[0637]


[0638]


[0639]
wherein A is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl ring and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH. In another class, A is unsubstituted or substituted with one to four substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl ring and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH. In another class, A is unsubstituted or substituted with one to three substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl ring and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH. In another class of this embodiment, the 3-6 membered cycloalkyl ring and the 3-6 membered cycloheteroalkyl ring formed by two R a substituents on A together with the carbon atom to which they are attached is selected from: cyclopropyl, cyclobutyl, oxetane and dioxane. In subclass of this class, the 3-6 membered cycloalkyl ring and the 3-6 membered cycloheteroalkyl ring formed by two R a substituents on A together with the carbon atom to which they are attached is selected from: cyclopropyl, cyclobutyl, oxetane and 1, 3 dioxane. In another class of this embodiment, A is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring, and wherein each 3-6 membered cycloalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1- 6alkyl, -O-C 1-6alkyl, halogen and OH. In a subclass of this class, the 3-6 membered cycloalkyl ring formed by two R a substituents on A together with the carbon atom to which they are attached is selected from: cyclopropyl, and cyclobutyl. In another class of this embodiment, A is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH. In a subclass of this class, the 3-6 membered cycloheteroalkyl ring formed by two R a substituents on A together with the carbon atom to which they are attached is selected from: oxetane and dioxane.
[0640]
In another embodiment of the present invention, A is selected from the group consisting of:
[0641]


[0642]
wherein A is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring, which is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH. In a class of this embodiment, A is unsubstituted or substituted with one to four substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring, which is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1- 6alkyl, halogen and OH. In another class of this embodiment, A is unsubstituted or substituted with one to three substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring, which is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH. In another class of this embodiment, the 3-6 membered cycloalkyl ring formed by two R a substituents on A together with the carbon atom to which they are attached is selected from: cyclopropyl, and cyclobutyl.
[0643]
In another embodiment of the present invention, A is selected from the group consisting of:
[0644]


[0645]


[0646]
wherein A is unsubstituted or substituted with one to six substituents selected from R a.
[0647]
In certain embodiments of the invention, A is bonded to the carbon substituted with R 3 and R 4, or when n is 0 A is bonded to X.
[0648]
In another embodiment of the present invention, B is selected from the group consisting of: aryl, aryl-O-, C 3-6cycloalkyl-, C 3-6cycloalkyl-C 1-10alkyl-, C 3-6cycloalkyl-C 1-10alkyl-O-, C 2- 5cycloheteroalkyl-, heteroaryl, heteroaryl-O-, aryl-C 1-10 alkyl-, and heteroaryl-C 1-10 alkyl-; wherein B is unsubstituted or substituted with one to six substituents selected from R b. In another embodiment of the present invention, B is selected from the group consisting of: aryl, aryl-O-, heteroaryl, heteroaryl-O-, aryl-C 1-10 alkyl-, and heteroaryl-C 1-10 alkyl-; wherein B is unsubstituted or substituted with one to six substituents selected from R b. In another embodiment of the present invention, B is selected from the group consisting of: aryl, heteroaryl, aryl-C 1-10 alkyl-and heteroaryl-C 1-10 alkyl-; wherein B is unsubstituted or substituted with one to six substituents selected from R b.
[0649]
In another embodiment of the present invention, B is selected from the group consisting of: aryl, and heteroaryl, wherein each aryl and heteroaryl is unsubstituted or substituted with one to six substituents selected from R b. In a class of this embodiment, B is selected from the group consisting of: phenyl, pyridine and benzimidazole, wherein each phenyl, pyridine and benzimidazole is unsubstituted or substituted with one to six substituents selected from R b. In another class of this embodiment, B is selected from the group consisting of: phenyl and pyridine, wherein each phenyl and pyridine is unsubstituted or substituted with one to six substituents selected from R b. In another class of this embodiment, B is unsubstituted or substituted with one to five substituents selected from R b. In another class of this embodiment, B is unsubstituted or substituted with one to four substituents selected from R b. In another class of this embodiment, B is unsubstituted or substituted with one to three substituents selected from R b. In another class of this embodiment, B is unsubstituted or substituted with one to two substituents selected from R b.
[0650]
In another embodiment of the present invention, each R 1 is independently selected from the group consisting of: hydrogen, halogen, -OR e, -CN, and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R i. In another embodiment of the present invention, each R 1 is independently selected from the group consisting of: hydrogen, halogen, -CN, and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R i. In another embodiment of the present invention, each R 1 is independently selected from the group consisting of: hydrogen, halogen and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R i. In a class of this embodiment, each R 1 is independently selected from the group consisting of: hydrogen, halogen and -C 1-6alkyl.
[0651]
In another embodiment of the present invention, each R 1 is independently selected from the group consisting of: hydrogen and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R i. In a class of this embodiment, each R 1 is independently selected from the group consisting of: hydrogen and -C 1-6alkyl. In another embodiment of the present invention, each R 1 is halogen. In another embodiment of the present invention, each R 1 is -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R i. In another embodiment of the present invention, each R1 is hydrogen.
[0652]
In another embodiment of the present invention, R 2 is selected from the group consisting of: hydrogen and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R j. In a class of this embodiment, R 2 is selected from the group consisting of: hydrogen and -C 1-6alkyl. In another embodiment of the present invention, R 2 is -C 1- 6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R j. In a class of this embodiment, R 2 is -C 1-6alkyl. In another embodiment of the present invention, R 2 is hydrogen.
[0653]
In another embodiment of the present invention, each R 3 is independently selected from the group consisting of: hydrogen, halogen, -OR e, -C 1-6alkyl, -C 2-6alkenyl and -C 2-6alkynyl, wherein each alkyl, alkenyl and alkynyl is unsubstituted or substituted with one to three substituents selected from R L. In a class of this embodiment, each R 3 is independently selected from the group consisting of: hydrogen, halogen, -OR e, -C 1-6alkyl, -C 2-6alkenyl and -C 2-6alkynyl. In another embodiment of the present invention, each R 3 is independently selected from the group consisting of:hydrogen, halogen, -OR e and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R L. In a class of this embodiment, each R 3 is independently selected from the group consisting of: hydrogen, halogen, -OR e and -C 1-6alkyl.
[0654]
In another embodiment of the present invention, each R 3 is independently selected from the group consisting of: hydrogen, halogen and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R L. In a class of this embodiment, each R 3 is independently selected from the group consisting of: hydrogen, halogen and -C 1-6alkyl. In another embodiment of the present invention, each R 3 is independently selected from the group consisting of: hydrogen and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R L. In a class of this embodiment, each R 3 is independently selected from the group consisting of: hydrogen and -C 1-6alkyl. In another embodiment of the present invention, each R 3 is -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R L. In a class of this embodiment, each R 3 is -C 1-6alkyl. In another embodiment of the present invention, each R 3 is hydrogen.
[0655]
In another embodiment of the present invention, each R 4 is independently selected from the group consisting of: hydrogen, halogen, -OR e, -C 1-6alkyl, -C 2-6alkenyl and -C 2-6alkynyl, wherein each alkyl, alkenyl and alkynyl is unsubstituted or substituted with one to three substituents selected from R L. In a class of this embodiment, each R 4 is independently selected from the group consisting of: hydrogen, halogen, -OR e, -C1-6alkyl, -C 2-6alkenyl and -C 2-6alkynyl.
[0656]
In another embodiment of the present invention, each R 4 is independently selected from the group consisting of: hydrogen, halogen, -OR e and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R L. In a class of this embodiment, each R 4 is independently selected from the group consisting of: hydrogen, halogen, -OR e and -C 1-6alkyl. In another embodiment of the present invention, each R 4 is independently selected from the group consisting of: hydrogen, halogen and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R L. In a class of this embodiment, each R 4 is independently selected from the group consisting of: hydrogen, halogen and -C 1-6alkyl.
[0657]
In another embodiment of the present invention, each R 4 is independently selected from the group consisting of: hydrogen and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R L. In a class of this embodiment, each R 4 is independently selected from the group consisting of: hydrogen and -C 1-6alkyl. In another embodiment of the present invention, each R 4 is -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R L. In a class of this embodiment, each R 4 is -C 1-6alkyl. In another embodiment of the present invention, each R 4 is hydrogen.
[0658]
In another embodiment of the present invention, R 5 is selected from the group consisting of: hydrogen, and halogen. In a class of this embodiment, R 5 is selected from the group consisting of: hydrogen and F. In another embodiment of the present invention, R 5 is halogen. In a class of this embodiment, R 5 is F. In another embodiment of the present invention, R 5 is hydrogen.
[0659]
In another embodiment of the present invention, R 6 is selected from the group consisting of: hydrogen, -C 1-3alkyl, and halogen. In another embodiment of the present invention, R 6 is selected from the group consisting of: hydrogen, and halogen. In a class of this embodiment, R 6 is selected from the group consisting of: hydrogen and F. In another embodiment of the present invention, R 6 is halogen. In a class of this embodiment, R 6 is F. In another embodiment of the present invention, R 6 is hydrogen.
[0660]
In another embodiment of the present invention, R 7 is selected from the group consisting of: hydrogen, and -C 1-10alkyl, wherein -C 1-10alkyl is unsubstituted or substituted with one to five fluorines. In a class of this embodiment, R 7 is selected from the group consisting of: hydrogen and -C 1-10alkyl. In another embodiment of the present invention, R 7 is -C 1-10alkyl, wherein -C 1- 10alkyl is unsubstituted or substituted with one to five fluorines. In a class of this embodiment, R 7 is -C 1-10alkyl. In another embodiment of the present invention, R 7 is hydrogen.
[0661]
In another embodiment of the present invention, each R 8 is selected from the group consisting of: hydrogen, and -C 1-10alkyl, wherein -C 1-10alkyl is unsubstituted or substituted with one to five fluorines. In a class of this embodiment, each R 8 is selected from the group consisting of: hydrogen and -C 1-10alkyl.
[0662]
In another embodiment of the present invention, each R 8 is -C 1-10alkyl, wherein -C 1- 10alkyl is unsubstituted or substituted with one to five fluorines. In a class of this embodiment, each R 8 is -C 1-10alkyl. In another embodiment of the present invention, each R 8 is hydrogen.
[0663]
In another embodiment of the present invention, each R 9 is -C 1-6alkyl, wherein -C 1-10alkyl is unsubstituted or substituted with one to five fluorines. In a class of this embodiment, each R 9 is -C 1-6alkyl. In a class of this embodiment, each R 9 is –CH 3. In another embodiment of the present invention, R 9 is –CH 3 or hydrogen. In another embodiment of the present invention, each R 9 is hydrogen.
[0664]
In another embodiment of the present invention, each R a is independently selected from the group consisting of: -C 1-6alkyl, -O-C 1-6alkyl, halogen, oxo, -OR e, -CO 2R e, - (CH 2) p-C 3- 6cycloalkyl, - (CH 2) p-C 2-5cycloheteroalkyl, - (CH 2) p-aryl and - (CH 2) p-heteroaryl, wherein R a is unsubstituted or substituted with one to three substituents selected from R m. In a class of this embodiment, each R a is independently selected from the group consisting of: -C 1-6alkyl, -O-C 1- 6alkyl, halogen, oxo, -OR e, -CO 2R e, -C 3-6cycloalkyl, -C 2-5cycloheteroalkyl, aryl, and heteroaryl, wherein R a is unsubstituted or substituted with one to three substituents selected from R m.
[0665]
In another embodiment of the present invention, each R a is independently selected from the group consisting of: -C 1-6alkyl, -O-C 1-6alkyl, halogen, oxo, -OR e, -CO 2R e, - (CH 2) p-C 3- 6cycloalkyl, - (CH 2) p-aryl and - (CH 2) p-heteroaryl, wherein R a is unsubstituted or substituted with one to three substituents selected from R m. In a class of this embodiment of the present invention, each R a is independently selected from the group consisting of: -C 1-6alkyl, -O-C 1-6alkyl, halogen, oxo, -OR e, -CO 2R e, -C 3-6cycloalkyl, -aryl and -heteroaryl, wherein R a is unsubstituted or substituted with one to three substituents selected from R m. In another embodiment of the present invention, each R a is independently selected from the group consisting of: -C 1-6alkyl, halogen, oxo, -OR e, -CO 2R e, - (CH 2) p-C 3-6cycloalkyl, - (CH 2) p-aryl and - (CH 2) p-heteroaryl, wherein R a is unsubstituted or substituted with one to three substituents selected from R m. In a class of this embodiment, each R a is independently selected from the group consisting of: -C 1-6alkyl, halogen, oxo, -OR e, -CO 2R e, -C 3-6cycloalkyl, aryl and heteroaryl, wherein R a is unsubstituted or substituted with one to three substituents selected from R m. In another class of this embodiment, each R a is independently selected from the group consisting of: -CH 3, F, Br, oxo, -OH, -CO 2C (CH3) 3, cyclopropyl, phenyl and pyrazole, wherein R a is unsubstituted or substituted with one to three substituents selected from R m.
[0666]
In another embodiment of the present invention, each R a is independently selected from the group consisting of: -C 1-6alkyl, halogen, - (CH 2) p-aryl, and - (CH 2) p-heteroaryl, wherein R a is unsubstituted or substituted with one to three substituents selected from R m. In a class of this embodiment, each R a is independently selected from the group consisting of: -C 1-6alkyl, halogen, aryl, and heteroaryl, wherein R a is unsubstituted or substituted with one to three substituents selected from R m. In another class of this embodiment, each R a is independently selected from the group consisting of: -CH 3, F, Br, phenyl, and pyrazole, wherein R a is unsubstituted or substituted with one to three substituents selected from R m. In another embodiment of the present invention, each R a is independently selected from the group consisting of: -C 1-6alkyl, - (CH 2) p-aryl, and -(CH 2) p-heteroaryl, wherein R a is unsubstituted or substituted with one to three substituents selected from R m. In a class of this embodiment, , each R a is independently selected from the group consisting of: -C 1-6alkyl, aryl and heteroaryl, wherein R a is unsubstituted or substituted with one to three substituents selected from R m. In a class of this embodiment, each R a is independently selected from the group consisting of: -CH 3, phenyl, and pyrazole, wherein R a is unsubstituted or substituted with one to three substituents selected from R m.
[0667]
In another embodiment of the present invention, each R b is independently selected from the group consisting of: -C 1-10 alkyl, -O-C 1-10alkyl, -C 2-10 alkenyl, halogen, -OH, -OC 2-10 alkenyl, -O (CH 2) pOC 1-10alkyl, -N (R c) S (O) mR e, -S (O) mR e, -O (CH 2) p-S (O) mR e, -S (O) mNR cR d, -NRcRd, -C (O) R e, -OC (O) R e, -CO2R e, -CN, -C (O) NR cR d, -N (Rc) C (O) R e, -N (R c) C (O) OR e, -N (R c) C (O) NR cR d, -CF 3, -OCF 3, and -OCHF 2, wherein each R b is unsubstituted or substituted with one to five substituents selected from R k. In another embodiment of the present invention, each R b is independently selected from the group consisting of: -C 1-10 alkyl, -O-C 1-10alkyl, halogen, -OH, -N (R c) S (O) mR e, -S (O) mR e, -O (CH 2) p-S (O) mR e, -S (O) mNR cR d, -NR cR d, -C (O) R e, -OC (O) R e, -CO 2R e, -CN, -C (O) NR cR d, -N (R c) C (O) R e, -N (Rc) C (O) OR e, -N (R c) C (O) NR cR d, -CF 3, -OCF 3, and -OCHF 2, wherein each R b is unsubstituted or substituted with one to five substituents selected from R k.
[0668]
In another embodiment of the present invention, each R b is independently selected from the group consisting of: -C 1-10 alkyl, -O-C 1-10alkyl, halogen, -OH, -N (R c) S (O) mR e, -S (O) mR e, -O (CH 2) p-S (O) mR e, -S (O) mNR cR d, -NR cR d, -C (O) R e, -OC (O) R e, -CO 2R e, -CN, -CF 3, -OCF 3, and -OCHF 2, wherein each R b is unsubstituted or substituted with one to five substituents selected from R k. In another embodiment of the present invention, each R b is independently selected from the group consisting of: -C 1-10 alkyl, -O-C 1-10alkyl, halogen, -OH, -S (O) mR e, -O (CH 2) p-S (O) mR e, -CN, -CF 3, -OCF 3, and -OCHF 2, wherein each R b is unsubstituted or substituted with one to five substituents selected from R k.
[0669]
In another embodiment of the present invention, each R b is independently selected from the group consisting of: -C 1-10 alkyl, -O-C 1-10alkyl, halogen, -OH, -S (O) mR e, -O (CH 2) p-S (O) mR e, and -CF 3, wherein each R b is unsubstituted or substituted with one to five substituents selected from R k. In a class of this embodiment of the present invention, each R b is independently selected from the group consisting of: -CH 3, -OCH 3, -O (CH 2) 2C (CH3) 2CH 3, -O (CH 2) 2C (CH 3) 3, -O (CH 2) 2C (CH 3) 2OH, -O-CH 2 (CH 3) C (CH 3) 2OH, F, Cl, -OH, -SO 2CH 3, -O (CH 2) 3-SO 2CH 3, and -CF 3.
[0670]
In another embodiment of the present invention, each R b is independently selected from the group consisting of: -O-C 1-10alkyl and -CF 3, wherein each R b is unsubstituted or substituted with one to five substituents selected from R k. In a class of this embodiment, each R b is independently selected from the group consisting of: -OCH 3 and -CF 3.
[0671]
In another embodiment of the present invention, each R c and R d is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, -C 2-10alkenyl, -C 3-6cycloalkyl, C 3-6 cycloalkyl-C 1-10alkyl-, -C 2-6cycloheteroalkyl, C 2-6cycloheteroalkyl-C 1-10alkyl-, aryl, heteroaryl, aryl-C 1-10alkyl-and heteroaryl-C 1-10alkyl-, wherein each R c and R d is unsubstituted or substituted with one to three substituents independently selected from R f.
[0672]
In another embodiment of the present invention, each R c and R d is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, -C 2-10alkenyl, -C 3-6cycloalkyl, -C 2- 6cycloheteroalkyl, wherein each R c and R d is unsubstituted or substituted with one to three substituents independently selected from R f.
[0673]
In another embodiment of the present invention, each R c and R d is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, and -C 2-10alkenyl, wherein each R c and R d is unsubstituted or substituted with one to three substituents independently selected from R f. In another embodiment of the present invention, each R c and R d is independently selected from the group consisting of: hydrogen, and -C 1-10alkyl, wherein each R c and R d is unsubstituted or substituted with one to three substituents independently selected from R f. In another embodiment of the present invention, each R c and R d is hydrogen.
[0674]
In another embodiment of the present invention, each R c and R d is independently selected from the group consisting of: -C 1-10alkyl, wherein each R c and R d is unsubstituted or substituted with one to three substituents independently selected from R f. In another embodiment of the present invention, each R c and R d is independently selected from the group consisting of: -C 1-10alkyl.
[0675]
In another embodiment of the present invention, each R c is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, -C 2-10alkenyl, -C 3-6cycloalkyl, C 3-6 cycloalkyl-C 1- 10alkyl-, -C 2-6cycloheteroalkyl, C 2-6cycloheteroalkyl-C 1-10alkyl-, aryl, heteroaryl, aryl-C 1- 10alkyl-and heteroaryl-C 1-10alkyl-, wherein each R c is unsubstituted or substituted with one to three substituents independently selected from R f.
[0676]
In another embodiment of the present invention, each R c is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, -C 2-10alkenyl, -C 3-6cycloalkyl, -C 2-6cycloheteroalkyl, wherein each R c is unsubstituted or substituted with one to three substituents independently selected from R f. In another embodiment of the present invention, each R c is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, and -C 2-10alkenyl, wherein each R c is unsubstituted or substituted with one to three substituents independently selected from R f.
[0677]
In another embodiment of the present invention, each R c is independently selected from the group consisting of: hydrogen, and -C 1-10alkyl, wherein each R c is unsubstituted or substituted with one to three substituents independently selected from R f.
[0678]
In another embodiment of the present invention, each R c is hydrogen.
[0679]
In another embodiment of the present invention, each R c is independently selected from the group consisting of: -C 1-10alkyl, wherein each R c is unsubstituted or substituted with one to three substituents independently selected from R f. In another embodiment of the present invention, each R c is independently selected from the group consisting of: -C 1-10alkyl.
[0680]
In another embodiment of the present invention, each R d is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, -C 2-10alkenyl, -C 3-6cycloalkyl, C 3-6 cycloalkyl-C 1- 10alkyl-, -C 2-6cycloheteroalkyl, C 2-6cycloheteroalkyl-C 1-10alkyl-, aryl, heteroaryl, aryl-C 1- 10alkyl-and heteroaryl-C 1-10alkyl-, wherein each R d is unsubstituted or substituted with one to three substituents independently selected from R f.
[0681]
In another embodiment of the present invention, each R d is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, -C 2-10alkenyl, -C 3-6cycloalkyl, -C 2-6cycloheteroalkyl, wherein each R d is unsubstituted or substituted with one to three substituents independently selected from R f. In another embodiment of the present invention, each R d is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, and -C 2-10alkenyl, wherein each R d is unsubstituted or substituted with one to three substituents independently selected from R f. In another embodiment of the present invention, each R d is independently selected from the group consisting of: hydrogen, and -C 1-10alkyl, wherein each R d is unsubstituted or substituted with one to three substituents independently selected from R f.
[0682]
In another embodiment of the present invention, each R d is hydrogen.
[0683]
In another embodiment of the present invention, each R d is independently selected from the group consisting of: -C 1-10alkyl, wherein each R d is unsubstituted or substituted with one to three substituents independently selected from R f. In another embodiment of the present invention, each R d is independently selected from the group consisting of: -C 1-10alkyl.
[0684]
In another embodiment of the present invention, each R e is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, -C 2-10 alkenyl, -C 3-6 cycloalkyl, -C 2- 5cycloheteroalkyl, aryl, and heteroaryl, wherein each R e is unsubstituted or substituted with one to three substituents selected from R h.
[0685]
In another embodiment of the present invention, each R e is independently selected from the group consisting of: hydrogen, -C 1-10alkyl, and -C 2-10 alkenyl, wherein each R e is unsubstituted or substituted with one to three substituents selected from R h. In another embodiment of the present invention, each R e is independently selected from the group consisting of: hydrogen, and -C 1- 10alkyl, wherein each R e is unsubstituted or substituted with one to three substituents selected from R h. In a class of this embodiment, each R e is independently selected from the group consisting of: hydrogen, -CH 3, and -C (CH 3) 3.
[0686]
In another embodiment of the present invention, each R e is -C 1-10alkyl, wherein each R e is unsubstituted or substituted with one to three substituents selected from R h. In a class of this embodiment, each R e is -C 1-10alkyl. In a subclass of this class, each R e is independently selected from the group consisting of: -CH 3, and -C (CH 3) 3.
[0687]
In another embodiment of the present invention, each R e is hydrogen.
[0688]
In another embodiment of the present invention, each R f is selected from the group consisting of: halogen, -C 1-10alkyl, -OH, -OC 1-6alkyl, -CN, -CF 3, -OCHF 2, and -OCF 3, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S (O) 2CH 3.
[0689]
In another embodiment of the present invention, each R f is selected from the group consisting of: halogen, -C 1-10alkyl, -CN, -CF 3, -OCHF 2, and -OCF 3, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S (O) 2CH 3. In another embodiment of the present invention, each R f is selected from the group consisting of: halogen, -C 1-10alkyl, and -CF 3, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S (O) 2CH 3.
[0690]
In another embodiment of the present invention, each R f is selected from the group consisting of: halogen, and -C 1-10alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S (O) 2CH 3. In a class of this embodiment, each R f is selected from the group consisting of: halogen, and -C 1-10alkyl.
[0691]
In another embodiment of the present invention, each R f is selected from the group consisting of: halogen. In another embodiment of the present invention, each R f is -C 1-10alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S (O) 2CH 3. In a class of this embodiment, each R f is -C 1- 10alkyl.
[0692]
In another embodiment of the present invention, each R g is selected from the group consisting of: hydrogen, and -C 1-10alkyl, wherein -C 1-10alkyl is unsubstituted or substituted with one to five fluorines.
[0693]
In another embodiment of the present invention, each R g is selected from: -C 1-10alkyl, wherein -C 1-10alkyl is unsubstituted or substituted with one to five fluorines. In a class of this embodiment, each R g is selected from: -C 1-10alkyl. In another embodiment of the present invention, each R g is hydrogen.
[0694]
In another embodiment of the present invention, each R h is selected from the group consisting of: halogen, -C 1-10alkyl, -OH, -O-C 1-4alkyl, -CN, -CF 3, –OCHF 2, and -OCF 3, wherein each C 1-10 alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and –S (O) 2CH 3.
[0695]
In another embodiment of the present invention, each R h is selected from the group consisting of: halogen, -C 1-10alkyl, -OH, -CN, -CF 3, –OCHF 2, and -OCF 3, wherein each C 1-10 alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and –S (O) 2CH 3. In another embodiment of the present invention, each R h is selected from the group consisting of: halogen, and -C 1-10alkyl, wherein each C 1-10 alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and –S (O) 2CH 3. In a class of this embodiment, each R h is selected from the group consisting of: halogen, and -C 1-10alkyl.
[0696]
In another embodiment of the present invention, each R h is selected from the group consisting of: -C 1-10alkyl, wherein each C 1-10 alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and –S (O) 2CH 3. In a class of this embodiment, each R h is selected from the group consisting of: -C 1-10alkyl. In another embodiment of the present invention, each R h is selected from the group consisting of halogen.
[0697]
In another embodiment of the present invention, R i is selected from the group consisting of: –C 1-6alkyl, halogen, -OR e, -NR cR d, -C (O) R e, -OC (O) R e, -CO 2R e, -CN, -CF 3, -OCF 3, and –OCHF 2. In another embodiment of the present invention, R i is selected from the group consisting of: -C 1-6alkyl, halogen, -CN, -CF 3, -OCF 3, and –OCHF 2. In another embodiment of the present invention, R i is selected from the group consisting of: -C 1-6alkyl, halogen, and -CF 3. In a class of this embodiment, R i is selected from the group consisting of: halogen. In another class of this embodiment, R i is selected from the group consisting of: -C 1-6alkyl. In another class of this embodiment, R i is -CF 3.
[0698]
In another embodiment of the present invention, R j is selected from the group consisting of: -C 1-6alkyl, halogen, -OR e, -NR cR d, -C (O) R e, -OC (O) R e, -CO 2R e, -CN, -CF 3, -OCF 3, and -OCHF 2. In another embodiment of the present invention, R j is selected from the group consisting of: -C 1-6alkyl, halogen, -CN, -CF 3, -OCF 3, and -OCHF 2. In another embodiment of the present invention, R j is selected from the group consisting of: -C 1-6alkyl, halogen, and -CF 3. In a class of this embodiment, R j is selected from the group consisting of: halogen. In another class of this embodiment, R j is selected from the group consisting of: -C 1-6alkyl. In another class of this embodiment, R j is -CF 3.
[0699]
In another embodiment of the present invention, each R k is independently selected from the group consisting of: halogen, -C 1-6alkyl, -OH, oxo, -OC 1-6alkyl, -SO 2-C 1-6 alkyl, -C 1-6alkyl-SO 2C 1-6alkyl, -CN, -CF 3, -OCHF 2, -OCF 3, -NH 2, -NHSO 2C 1-6alkyl, and -NHC (O) C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl.
[0700]
In another embodiment of the present invention, each R k is independently selected from the group consisting of: halogen, -C 1-6alkyl, -OH, -OC 1-6alkyl, -CN, -CF 3, -OCHF 2, -OCF 3, and -NH 2, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl.
[0701]
In another embodiment of the present invention, each R k is independently selected from the group consisting of: halogen, -C 1-6alkyl, -OC 1-6alkyl, and -OH, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1- 6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl. In a class of this embodiment, each R k is independently selected from the group consisting of: halogen, -C 1-6alkyl, -OC 1-6alkyl, and -OH, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, and cyano. In another class of this embodiment, each R k is independently selected from the group consisting of: halogen, -C 1-6alkyl, -OC 1-6alkyl, and -OH. In another class of this embodiment, each R k is independently selected from the group consisting of: F, -CH 3, -OCH 3, and -OH.
[0702]
In another embodiment of the present invention, each R k is independently selected from the group consisting of: halogen, -C 1-6alkyl, and -OH, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl. In a class of this embodiment, each R k is independently selected from the group consisting of: halogen, -C 1-6alkyl, and -OH. In another class of this embodiment, each R k is independently selected from the group consisting of: F, -CH 3, and -OH.
[0703]
In another embodiment of the present invention, each R k is independently selected from the group consisting of: halogen and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl. In a class of this embodiment, each R k is independently selected from the group consisting of: halogen and -C 1-6alkyl. In another class of this embodiment, each R k is independently selected from the group consisting of: F and -CH 3.
[0704]
In another embodiment of the present invention, each R k is independently selected from the group consisting of: -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl. In a class of this embodiment, each R k is independently selected from the group consisting of: -C 1- 6alkyl. In another class of this embodiment, each R k is -CH 3.
[0705]
In another embodiment of the present invention, each R k is independently selected from the group consisting of: halogen. In another class of this embodiment, each R k is F.
[0706]
In another embodiment of the present invention, R L is selected from the group consisting of: -C 1-6alkyl, halogen, -OR e, -N (R c) S (O) mR e, -S (O) mR e, -S (O) mNR cR d, -NR cR d, -C (O) R e, -OC (O) R e, -CO 2R e, -CN, -C (O) NR cR d, -N (R c) C (O) R e, -N (R c) C (O) OR e, -N (R c) C (O) NR cR d, -CF 3, -OCF 3, and -OCHF 2.
[0707]
In another embodiment of the present invention, R L is selected from the group consisting of: -C 1-6alkyl, halogen, -OR e, -S (O) mR e, -S (O) mNR cR d, -NR cR d, -CO 2R e, -CN, -CF 3, -OCF 3, and -OCHF 2. In another embodiment of the present invention, R L is selected from the group consisting of: -C 1-6alkyl, halogen, -OR e, -CN, -CF 3, -OCF 3, and -OCHF 2.
[0708]
In another embodiment of the present invention, R L is selected from the group consisting of: -C 1-6alkyl, halogen, -OR e, and -CF 3. In another embodiment of the present invention, R L is selected from the group consisting of: -C 1-6alkyl, halogen, and -CF 3. In another embodiment of the present invention, R L is selected from the group consisting of: -C 1-6alkyl, and halogen. In another embodiment of the present invention, R L is selected from the group consisting of: halogen. In another embodiment of the present invention, R L is selected from the group consisting of: -C 1- 6alkyl.
[0709]
In another embodiment of the present invention, each R m is independently selected from the group consisting of: halogen, -C 1-6alkyl, -OH, oxo, -OC 1-6alkyl, -SO 2-C 1-6 alkyl, -C 1-6alkyl-SO 2C 1-6alkyl, -CN, -CF 3, -OCHF 2, -OCF 3, -NH 2, -NHSO 2C 1-6alkyl, and -NHC (O) C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl.
[0710]
In another embodiment of the present invention, each R m is independently selected from the group consisting of: halogen, -C 1-6alkyl, -OH, -OC 1-6alkyl, -CN, -CF 3, -OCHF 2, -OCF 3, and -NH 2, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl. In another embodiment of the present invention, each R m is independently selected from the group consisting of: halogen, -C 1-6alkyl, -OC 1-6alkyl, and -OH, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1- 6alkyl. In a class of this embodiment, each R m is independently selected from the group consisting of: halogen, -C 1-6alkyl, -OC 1-6alkyl, and -OH, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, and cyano. In another class of this embodiment, each R m is independently selected from the group consisting of: halogen, -C 1-6alkyl, -OC 1-6alkyl, and -OH. In another class of this embodiment, each R m is independently selected from the group consisting of: F, -CH 3, -OCH 3, and -OH.
[0711]
In another embodiment of the present invention, each R m is independently selected from the group consisting of: halogen, -C 1-6alkyl, and -OH, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl. In a class of this embodiment, each R m is independently selected from the group consisting of: halogen, -C 1-6alkyl, and -OH. In another class of this embodiment, each R m is independently selected from the group consisting of: F, -CH 3, and -OH. In another embodiment of the present invention, each R m is independently selected from the group consisting of: halogen and -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl. In a class of this embodiment, each R m is independently selected from the group consisting of: halogen and -C 1-6alkyl. In another class of this embodiment, each R m is independently selected from the group consisting of: F and -CH 3.
[0712]
In another embodiment of the present invention, each R m is independently selected from the group consisting of: -C 1-6alkyl, wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, -OC 1-6alkyl, halogen, cyano, and –S (O) 2C 1-6alkyl. In a class of this embodiment, each R m is independently selected from the group consisting of: -C 1- 6alkyl. In another class of this embodiment, each R m is -CH 3. In another embodiment of the present invention, each R m is independently selected from the group consisting of: halogen. In another class of this embodiment, each R m is F. .
[0713]
In another embodiment of the present invention, each n is independently selected from: 0, 1, 2 or 3. In a class of this embodiment, each n is independently selected from: 1, 2 or 3. In another class of this embodiment, each n is independently selected from: 0, 1 or 3. In another class of this embodiment, each n is independently selected from: 0, 2 or 3. In another class of this embodiment, each n is independently selected from: 0 or 3. In another class of this embodiment, n is 0, 1 or 2. In a class of this embodiment, n is 0 or 1. In another class of this embodiment, n is 1 or 2. In another class of this embodiment, n is 0 or 2. In another class of this embodiment, n is 0. In another class of this embodiment, n is 1. In another class of this embodiment, n is 2. In another class of this embodiment, n is 3.
[0714]
In another embodiment of the present invention, m is 0, 1 or 2. In a class of this embodiment, m is 0 or 1. In another class of this embodiment, m is 0 or 2. In another class of this embodiment, m is 1 or 2. In another class of this embodiment, m is 0. In another class of this embodiment, m is 1. In another class of this embodiment, m is 2.
[0715]
In another embodiment of the present invention, p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In another embodiment of the present invention, p is 0, 1, 2, 3, 4, 5, 6, 7 or 8. In another embodiment of the present invention, p is 0, 1, 2, 3, 4, 5 or 6. In another embodiment of the present invention, p is 0, 1, 2, 3 or 4. a class of this embodiment, p is 0, 1, 2 or 3. In a class of this embodiment, p is 0, 1 or 2. In another embodiment of the present invention, p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In another embodiment of the present invention, p is 1, 2, 3, 4, 5, 6, 7 or 8. In another embodiment of the present invention, p is 1, 2, 3, 4, 5 or 6. In another embodiment of the present invention, p is 1, 2, 3 or 4. In a class of this embodiment, p is 1, 2 or 3. In a class of this embodiment, p is 1 or 2. In another class of this embodiment, p is 0 or 1. In another class of this embodiment, p is 0 or 2. In another class of this embodiment, p is 0. In another class of this embodiment, p is 1. In another class of this embodiment, p is 2. In another class of this embodiment, p is 3. In another class of this embodiment, p is 4. In another class of this embodiment, p is 5. In another class of this embodiment, p is 6. In another class of this embodiment, p is 7. In another class of this embodiment, p is 8. In another class of this embodiment, p is 9. In another class of this embodiment, p is 10.
[0716]
In another embodiment of the present invention, each q is independently selected from: 1, 2 or 3. In another class of this embodiment, each q is independently selected from: 1 or 3. In another class of this embodiment, each q is independently selected from: 2 or 3. In another class of this embodiment, q is 1 or 2. In another class of this embodiment, q is 1. In another class of this embodiment, q is 2. In another class of this embodiment, q is 3.
[0717]
In another embodiment of the present invention, n is 1; and q is 0
[0718]
In another embodiment of the present invention, the invention relates to compounds of structural formula Ia:
[0719]


[0720]
or a pharmaceutically acceptable salt thereof.
[0721]
In another embodiment of the present invention, the invention relates to compounds of structural formula Ib:
[0722]


[0723]
or a pharmaceutically acceptable salt thereof.
[0724]
In another embodiment of the present invention, the invention relates to compounds of structural formula Ic:
[0725]


[0726]
or a pharmaceutically acceptable salt thereof.
[0727]
In another embodiment of the present invention, the invention relates to compounds of structural formula Id:
[0728]


[0729]
or a pharmaceutically acceptable salt thereof.
[0730]
In another embodiment of the present invention, the invention relates to compounds of structural formula Ie:
[0731]


[0732]
or a pharmaceutically acceptable salt thereof.
[0733]
In another embodiment of the present invention, the invention relates to compounds of structural formula If:
[0734]


[0735]
or a pharmaceutically acceptable salt thereof.
[0736]
In another embodiment of the present invention, the invention relates to compounds of structural formula Ig:
[0737]


[0738]
or a pharmaceutically acceptable salt thereof.
[0739]
In another embodiment of the present invention, the compounds of formula I have the absolute stereochemistry at the two stereogenic carbon centers as indicated in the compound of structural formula Ih:
[0740]


[0741]
and pharmaceutically acceptable salts thereof.
[0742]
In another embodiment of the present invention, the compounds of formula I have the absolute stereochemistry at the two stereogenic carbon centers as indicated in the compound of structural formula Ii:
[0743]


[0744]
and pharmaceutically acceptable salts thereof.
[0745]
References to the compound of structural formula I include or apply to the compounds of structural formulas Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, and II, and pharmaceutically acceptable salts, hydrates and solvates thereof.
[0746]
Another embodiment of the present invention relates to compounds of structural formula Ia
[0747]


[0748]
wherein:
[0749]
X is oxygen;
[0750]
T is selected from the group consisting of: CH and N;
[0751]
V is selected from the group consisting of: CH and N;
[0752]
W is selected from the group consisting of: CH and N,
[0753]
provided that one of T, U, V and W is N;
[0754]
A is selected from the group consisting of:
[0755]


[0756]
wherein A is unsubstituted or substituted with one to six substituents selected from R a, and wherein two R a substituents together with the carbon atom to which they are attached may form a 3-6 membered cycloalkyl ring or a 3-6 membered cycloheteroalkyl ring containing 0 to 3 heteroatoms independently selected from oxygen, sulfur, and NR 8, and wherein each 3-6 membered cycloalkyl ring and each 3-6 membered cycloheteroalkyl ring is unsubstituted or substituted with 1 to 4 substituents selected from: -C 1-6alkyl, -O-C 1-6alkyl, halogen and OH;
[0757]
B is selected from the group consisting of:
[0758]
(1) aryl, and
[0759]
(2) heteroaryl,
[0760]
wherein each aryl and heteroaryl is unsubstituted or substituted with one to six substituents selected from R b
[0761]
R 1 and R 2 are hydrogen;
[0762]
R 3 and R 4 are independently selected from the group consisting of:
[0763]
(1) hydrogen,
[0764]
(2) halogen, and
[0765]
(3) -C 1-6alkyl,
[0766]
wherein each alkyl is unsubstituted or substituted with one to three substituents selected from R L; R 5 and R 6 are selected from the group consisting of:
[0767]
(1) hydrogen, and
[0768]
(2) halogen; and
[0769]
n is 1;
[0770]
or a pharmaceutically acceptable salt thereof.
[0771]
Another embodiment of the present invention relates to compounds of structural formula Ia
[0772]


[0773]
wherein:
[0774]
X is oxygen;
[0775]
T is CH;
[0776]
V is N;
[0777]
W is CH;
[0778]
A is selected from the group consisting of:
[0779]


[0780]
wherein A is unsubstituted or substituted with one to six substituents selected from R a
[0781]
B is selected from the group consisting of:
[0782]
(1) phenyl,
[0783]
(2) pyridine, and
[0784]
(3) benzimidazole,
[0785]
wherein each phenyl, pyridine and benzimidazole is unsubstituted or substituted with one to six substituents selected from R b
[0786]
R 1, R 2, R 3, R 4, R 5 and R 6 are hydrogen; and
[0787]
n is 1;
[0788]
or a pharmaceutically acceptable salt thereof.
[0789]
Illustrative, but non-limiting, examples of the compounds of the present invention that are useful as agonists of G-protein-coupled receptor 40 (GPR40) are the following compounds:
[0790]


[0791]
and pharmaceutically acceptable salts thereof.
[0792]
Although the specific stereochemistries described above are preferred, other stereoisomers, including diastereoisomers, enantiomers, epimers, and mixtures of these may also have utility in treating GPR40 mediated diseases.
[0793]
Synthetic methods for making the compounds are disclosed in the Examples shown below. Where synthetic details are not provided in the examples, the compounds are readily made by a person of ordinary skill in the art of medicinal chemistry or synthetic organic chemistry by applying the synthetic information provided herein. Where a stereochemical center is not defined, the structure represents a mixture of stereoisomers at that center. For such compounds, the individual stereoisomers, including enantiomers, diastereoisomers, and mixtures of these are also compounds of the invention.
[0794]
Definitions:
[0795]
“Ac” is acetyl, which is CH 3C (=O) -.
[0796]
"Alkyl” means saturated carbon chains which may be linear or branched or combinations thereof, unless the carbon chain is defined otherwise. Other groups having the prefix "alk" , such as alkoxy and alkanoyl, also may be linear or branched, or combinations thereof, unless the carbon chain is defined otherwise. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like.
[0797]
"Alkenyl" means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched, or combinations thereof, unless otherwise defined. Examples of alkenyl include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.
[0798]
"Alkynyl" means carbon chains which contain at least one carbon-carbon triple bond, and which may be linear or branched, or combinations thereof, unless otherwise defined. Examples of alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl and the like.
[0799]
“Bicyclic aryl ring” means a bicyclic aromatic ring system containing 5-14 carbon atoms, wherein at least one of the rings is an aryl ring and in which the aryl ring is fused to a C 3- 6cycloalkyl ring, or a C 2-6 cycloheteroalkyl ring containing at least one ring heteroatom selected from N, NH, S, SO, SO 2, and O. Examples of bicyclic aryl rings include but are not limited to, indane, and 1, 2, 3, 4-tetrahydronaphthalene. In one embodiment of the present invention, the bicyclic aryl ring is indane.
[0800]
“Bicyclic heteroaryl ring” means a bicyclic aromatic ring system containing 5-14 carbon atoms, wherein at least one of the rings is a heteroaryl ring and in which the heteroaryl ring is fused to a C 3-6cycloalkyl ring, or a C 2-6cycloheteroalkyl ring containing at least one ring heteroatom selected from N, NH, S, SO, SO 2, and O. Examples of bicyclic heteroaryl rings include, but are not limited to, chromane, 1, 2, 3, 4-tetrahydroisoquinoline, 2, 3-dihydrobenzofuran, indoline and indole.
[0801]
"Cycloalkyl" means a saturated monocyclic, bicyclic or bridged carbocyclic ring, having a specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. In one embodiment of the present invention, cycloalkyl is selected from: cyclopropane, cyclobutane and cyclohexane. In another embodiment, cycloalkyl is cyclopropyl. In one embodiment of the present invention, a 3-6 membered cycloalkyl ring is selected from: cyclopropyl, and cyclobutyl.
[0802]
"Cycloalkenyl" means a nonaromatic monocyclic or bicyclic carbocylic ring containing at least one double bond. Examples of cycloalkenyl include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooxtenyl and the like.
[0803]
"Cycloheteroalkyl" means a saturated or partly unsaturated non-aromatic monocyclic, bicyclic or bridged carbocyclic ring or ring system containing at least one ring heteroatom selected from N, NH, S (including SO and SO 2) and O. The cycloheteroalkyl ring may be substituted on the ring carbons and/or the ring nitrogen (s) . Examples of cycloheteroalkyl include tetrahydrofuran, pyrrolidine, tetrahydrothiophene, azetidine, piperazine, piperidine, morpholine, oxetane and tetrahydropyran, hexose, pentose, isosorbide and isomannide, dianhydromannitol, 1, 4: 3, 6-dianhydromannitol, 1, 4: 3, 6-dianhydro [D] mannitol, hexahydrofuro [3, 2-b] furan, and 2, 3, 3a, 5, 6, 6a-hexahydrofuro [3, 2-b] furan. In one embodiment of the present invention, a 3-6 membered cycloheteroalkyl ring is selected from: oxetane, dioxane and 1, 3 dioxane.
[0804]
"Cycloheteroalkenyl" means a nonaromatic monocyclic, bicyclic or bridged carbocyclic ring or ring system containing at least one double bond and contaiing at least one heteroatom selected from N, NH, S and O.
[0805]
"Aryl" means a monocyclic, bicyclic or tricyclic carbocyclic aromatic ring or ring system containing 5-14 carbon atoms, wherein at least one of the rings is aromatic. Examples of aryl include phenyl and naphthyl. In one embodiment of the present invention, aryl is phenyl. “Aryl” includes bicyclic aryl ring.
[0806]
"Heteroaryl" means a monocyclic, bicyclic or tricyclic ring or ring system containing 1-14 carbon atoms and containing at least one ring heteroatom selected from N, NH, S (including SO and SO 2) and O, wherein at least one of the heteroatom containing rings is aromatic. Examples of heteroaryl include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl (including S-oxide and dioxide) , furo (2, 3-b) pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, dibenzofuranyl, and the like. In one embodiment of the present invention, heteroaryl is selected from: pyridine and benzimidazole. In another embodiment of the present invention, heteroaryl is pyridine. In another embodiment of the present invention, heteroaryl is benzimidazole. In another embodiment of the present invention, heteroaryl is pyrazole. In another embodiment of the present invention, heteroaryl is indazole. In another embodiment of the present invention, heteroaryl is indole. In another embodiment of the present invention, heteroaryl is 2, 3-dihydro-indene. “Heteroaryl” includes bicyclic heteroaryl ring.
[0807]
"Halogen" includes fluorine, chlorine, bromine and iodine. In one embodiment of the present invention, halogen is bromine, chlorine or fluorine. In another embodiment of the present invention, halogen is chlorine or fluorine. In another embodiment of the present invention, halogen is bromine. In another embodiment of the present invention, halogen is chlorine. In another embodiment of the present invention, halogen is fluorine.
[0808]
“Me” represents methyl.
[0809]
“Oxo” means =O.
[0810]
When any variable (e.g., R 1, R a, etc. ) occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. A squiggly line across a bond in a substituent variable represents the point of attachment.
[0811]
Under standard nomenclature used throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment. For example, a C 1-5 alkylcarbonylamino C 1-6 alkyl substituent is equivalent to:
[0812]


[0813]
For example, -NR cC (O) R e is equivalent to –N (R c) C (O) R e.
[0814]
Unless expressly depicted or described otherwise, substituents depicted in a structural formula with a “floating” bond, such as but not limited to R 1 and the sidechain
[0815]


[0816]
are permitted on any available carbon atom in the ring to which the substituent is attached. In one embodiment of the present invention, R 1 and the above sidechain may be substituted on any CH in the ring to which R 1 and the above sidechain are attached. In another embodiment of the present invention, U is CH, wherein CH is substituted with the sidechain:
[0817]


[0818]
In choosing compounds of the present invention, one of ordinary skill in the art will recognize that the various substituents, i.e. R 1, R 2, etc., are to be chosen in conformity with well-known principles of chemical structure connectivity and stability.
[0819]
The term "substituted" shall be deemed to include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.
[0820]
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, salts and/or dosage forms which are, using sound medical judgment, and following all applicable government regulations, safe and suitable for administration to a human being or an animal.
[0821]
The term “%enantiomeric excess” (abbreviated “ee” ) shall mean the %major enantiomer less the %minor enantiomer. Thus, a 70%enantiomeric excess corresponds to formation of 85%of one enantiomer and 15%of the other. The term “enantiomeric excess” is synonymous with the term “optical purity. ”
[0822]
Compounds of Formula I may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of Formula I.
[0823]
Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
[0824]
Tautomers are defined as compounds that undergo rapid proton shifts from one atom of the compound to another atom of the compound. Some of the compounds described herein may exist as tautomers with different points of attachment of hydrogen. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of Formula I.
[0825]
In the compounds of general formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominately found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of structural formula I. For example, different isotopic forms of hydrogen (H) include protium ( 1H) , deuterium ( 2H) , and tritium ( 3H) . Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Tritium is radioactive and may therefore provide for a radiolabeled compound, useful as a tracer in metabolic or kinetic studies. Isotopically-enriched compounds within structural formula I, can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
[0826]
The independent syntheses of optical isomers and diastereoisomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
[0827]
If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well-known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereoisomeric mixture, followed by separation of the individual diastereoisomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base. The diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
[0828]
Alternatively, any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
[0829]
Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of this invention.
[0830]
It is generally preferable to administer compounds of the present invention as enantiomerically pure formulations. Racemic mixtures can be separated into their individual enantiomers by any of a number of conventional methods. These include chiral chromatography, derivatization with a chiral auxiliary followed by separation by chromatography or crystallization, and fractional crystallization of diastereomeric salts.
[0831]
Salts:
[0832]
It will be understood that, as used herein, references to the compounds of the present invention are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or their pharmaceutically acceptable salts or in other synthetic manipulations.
[0833]
The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salt" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed within the term "pharmaceutically acceptable salt" refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts of basic compounds of the present invention include, but are not limited to, the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate) , palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N, N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
[0834]
Also, in the case of a carboxylic acid (-COOH) or alcohol group being present in the compounds of the present invention, pharmaceutically acceptable esters of carboxylic acid derivatives, such as methyl, ethyl, or pivaloyloxymethyl, or acyl derivatives of alcohols, such as O-acetyl, O-pivaloyl, O-benzoyl, and O-aminoacyl, can be employed. Included are those esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations.
[0835]
Solvates, and in particular, the hydrates of the compounds of the present invention are included in the present invention as well.
[0836]
Utilities
[0837]
The compounds of the present invention are potent agonists of the GPR40 receptor. The compounds, and pharmaceutically acceptable salts thereof, may be efficacious in the treatment of diseases that are modulated by GPR40 ligands, which are generally agonists. Many of these diseases are summarized below.
[0838]
One or more of these diseases may be treated by the administration of a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, to a patient in need of treatment. Also, the compounds of the present invention may be used for the manufacture of a medicament which may be useful for treating one or more of these diseases: (1) non-insulin dependent diabetes mellitus (Type 2 diabetes) ; (2) hyperglycemia; (3) insulin resistance; (4) Metabolic Syndrome; (5) obesity; (6) hypercholesterolemia; (7) hypertriglyceridemia (elevated levels of triglyceride-rich-lipoproteins) ; (8) mixed or diabetic dyslipidemia; (9) low HDL cholesterol; (10) high LDL cholesterol; (11) hyperapo-B liproteinemia; and (12) atherosclerosis.
[0839]
Preferred uses of the compounds may be for the treatment of one or more of the following diseases by administering a therapeutically effective amount to a patient in need of treatment. The compounds may be used for manufacturing a medicament for the treatment of one or more of these diseases: (1) Type 2 diabetes, and specifically hyperglycemia associated with Type 2 diabetes; (2) Metabolic Syndrome; (3) obesity; and (4) hypercholesterolemia.
[0840]
The compounds may be effective in lowering glucose and lipids in diabetic patients and in non-diabetic patients who have impaired glucose tolerance and/or are in a pre-diabetic condition. The compounds may ameliorate hyperinsulinemia, which often occurs in diabetic or pre-diabetic patients, by modulating the swings in the level of serum glucose that often occurs in these patients. The compounds may also be effective in treating or reducing insulin resistance. The compounds may be effective in treating or preventing gestational diabetes.
[0841]
The compounds may also be effective in treating or preventing lipid disorders. The compounds may be effective in treating or preventing diabetes related disorders. The compounds may also be effective in treating or preventing obesity related disorders.
[0842]
The compounds of this invention may also have utility in improving or restoring β-cell function, so that they may be useful in treating Type 1 diabetes or in delaying or preventing a patient with Type 2 diabetes from needing insulin therapy.
[0843]
The invention also includes pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions comprising the compounds and a pharmaceutically acceptable carrier. The compounds may be useful in treating insulin resistance, Type 2 diabetes, hypperglycemia, and dyslipidemia that is associated with Type 2 diabetes and insulin resistance. The compounds may also be useful for the treatment of obesity.
[0844]
A compound of the present invention, or a pharmaceutically acceptable salt thereof, may be used in the manufacture of a medicament for the treatment of Type 2 diabetes in a human or other mammalian patient.
[0845]
A method of treating Type 2 diabetes comprises the administration of a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound, to a human or other mammal subject or patient in need of treatment. Other medical uses of the compounds of the present invention are described herein.
[0846]
The term "diabetes, " as used herein, includes both insulin-dependent diabetes mellitus (i.e., IDDM, also known as type 1 diabetes) and non-insulin-dependent diabetes mellitus (i.e., NIDDM, also known as Type 2 diabetes) . Type 1 diabetes, or insulin-dependent diabetes, is the result of an absolute deficiency of insulin, the hormone which regulates glucose utilization. Type 2 diabetes, or insulin-independent diabetes (i.e., non-insulin-dependent diabetes mellitus) , often occurs in the face of normal, or even elevated levels of insulin and appears to be the result of the inability of tissues to respond appropriately to insulin. Most of the Type 2 diabetics are also obese. The compositions of the present invention may be useful for treating both Type 1 and Type 2 diabetes. The term “diabetes associated with obesity” refers to diabetes caused by obesity or resulting from obesity.
[0847]
Diabetes is characterized by a fasting plasma glucose level of greater than or equal to 126 mg/dl. A diabetic subject has a fasting plasma glucose level of greater than or equal to 126 mg/dl. A pre diabetic subject is someone suffering from prediabetes. Prediabetes is characterized by an impaired fasting plasma glucose (FPG) level of greater than or equal to 110 mg/dl and less than 126 mg/dl; or impaired glucose tolerance; or insulin resistance. A prediabetic subject is a subject with impaired fasting glucose (afasting plasma glucose (FPG) level of greater than or equal to 110 mg/dl and less than 126 mg/dl) ; or impaired glucose tolerance (a 2 hour plasma glucose level of≥140 mg/dl and <200 mg/dl) ; or insulin resistance, resulting in an increased risk of developing diabetes.
[0848]
Treatment of diabetes mellitus refers to the administration of a compound or combination of the present invention to treat a diabetic subject. One outcome of treatment may be decreasing the glucose level in a subject with elevated glucose levels. Another outcome of treatment may be decreasing insulin levels in a subject with elevated insulin levels. Another outcome of treatment may be decreasing plasma triglycerides in a subject with elevated plasma triglycerides. Another outcome of treatment is decreasing LDL cholesterol in a subject with high LDL cholesterol levels. Another outcome of treatment may be increasing HDL cholesterol in a subject with low HDL cholesterol levels. Another outcome of treatment is increasing insulin sensivity. Another outcome of treatment may be enhancing glucose tolerance in a subject with glucose intolerance. Yet another outcome of treatment may be decreasing insulin resistance in a subject with increased insulin resistance or elevated levels of insulin. Prevention of diabetes mellitus, in particular diabetes associated with obesity, refers to the administration of a compound or combination of the present invention to prevent the onset of diabetes in a subject in need thereof. A subject in need of preventing diabetes is a prediabetic subject that is overweight or obese.
[0849]
The term "diabetes related disorders" should be understood to mean disorders that are associated with, caused by, or result from diabetes. Examples of diabetes related disorders include retinal damage, kidney disease, and nerve damage.
[0850]
The term “atherosclerosis” as used herein encompasses vascular diseases and conditions that are recognized and understood by physicians practicing in the relevant fields of medicine. Atherosclerotic cardiovascular disease, coronary heart disease (also known as coronary artery disease or ischemic heart disease) , cerebrovascular disease and peripheral vessel disease are all clinical manifestations of atherosclerosis and are therefore encompassed by the terms "atherosclerosis" and "atherosclerotic disease. " The combination comprised of a therapeutically effective amount of an anti-obesity agent in combination with a therapeutically effective amount of an anti-hypertensive agent may be administered to prevent or reduce the risk of occurrence, or recurrence where the potential exists, of a coronary heart disease event, a cerebrovascular event, or intermittent claudication. Coronary heart disease events are intended to include CHD death, myocardial infarction (i.e., a heart attack) , and coronary revascularization procedures. Cerebrovascular events are intended to include ischemic or hemorrhagic stroke (also known as cerebrovascular accidents) and transient ischemic attacks. Intermittent claudication is a clinical manifestation of peripheral vessel disease. The term "atherosclerotic disease event" as used herein is intended to encompass coronary heart disease events, cerebrovascular events, and intermittent claudication. It is intended that persons who have previously experienced one or more non-fatal atherosclerotic disease events are those for whom the potential for recurrence of such an event exists. The term "atherosclerosis related disorders" should be understood to mean disorders associated with, caused by, or resulting from atherosclerosis.
[0851]
The term “hypertension” as used herein includes essential, or primary, hypertension wherein the cause is not known or where hypertension is due to greater than one cause, such as changes in both the heart and blood vessels; and secondary hypertension wherein the cause is known. Causes of secondary hypertension include, but are not limited to obesity; kidney disease; hormonal disorders; use of certain drugs, such as oral contraceptives, corticosteroids, cyclosporin, and the like. The term “hypertension” encompasses high blood pressure, in which both the systolic and diastolic pressure levels are elevated (≥140 mmHg/≥90 mmHg) , and isolated systolic hypertension, in which only the systolic pressure is elevated to greater than or equal to 140 mm Hg, while the diastolic pressure is less than 90 mm Hg. Normal blood pressure may be defined as less than 120 mmHg systolic and less than 80 mmHg diastolic. A hypertensive subject is a subject with hypertension. A pre-hypertensive subject is a subject with a blood pressure that is between 120 mmHg over 80 mmHg and 139 mmHg over 89 mmHg. One outcome of treatment is decreasing blood pressure in a subject with high blood pressure. Treatment of hypertension refers to the administration of the compounds and combinations of the present invention to treat hypertension in a hypertensive subject. Treatment of hypertension-related disorder refers to the administration of a compound or combination of the present invention to treat the hypertension-related disorder. Prevention of hypertension, or a hypertension related disorder, refers to the administration of the combinations of the present invention to a pre-hypertensive subject to prevent the onset of hypertension or a hypertension related disorder. The hypertension-related disorders herein are associated with, caused by, or result from hypertension. Examples of hypertension-related disorders include, but are not limited to: heart disease, heart failure, heart attack, kidney failure, and stroke.
[0852]
Dyslipidemias and lipid disorders are disorders of lipid metabolism including various conditions characterized by abnormal concentrations of one or more lipids (i.e. cholesterol and triglycerides) , and/or apolipoproteins (i.e., apolipoproteins A, B, C and E) , and/or lipoproteins (i.e., the macromolecular complexes formed by the lipid and the apolipoprotein that allow lipids to circulate in blood, such as LDL, VLDL and IDL) . Hyperlipidemia is associated with abnormally high levels of lipids, LDL and VLDL cholesterol, and/or triglycerides. Treatment of dyslipidemia refers to the administration of the combinations of the present invention to a dyslipidemic subject. Prevention of dyslipidemia refers to the administration of the combinations of the present invention to a pre-dyslipidemic subject. A pre-dyslipidemic subject is a subject with higher than normal lipid levels, that is not yet dyslipidemic.
[0853]
The terms "dyslipidemia related disorders" and "lipid disorder related disorders" should be understood to mean disorders associated with, caused by, or resulting from dyslipidemia or lipid disorders. Examples of dylipidemia related disorder and lipid disorder related disorders include, but are not limited to: hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high density lipoprotein (HDL) levels, high plasma low density lipoprotein (LDL) levels, atherosclerosis and its sequelae, coronary artery or carotid artery disease, heart attack, and stroke.
[0854]
The term “obesity” as used herein is a condition in which there is an excess of body fat. The operational definition of obesity is based on the Body Mass Index (BMI) , which is calculated as body weight per height in meters squared (kg/m 2) . “Obesity” refers to a condition whereby an otherwise healthy subject has a Body Mass Index (BMI) greater than or equal to 30 kg/m 2, or a condition whereby a subject with at least one co-morbidity has a BMI greater than or equal to 27 kg/m 2. An “obese subject” is an otherwise healthy subject with a Body Mass Index (BMI) greater than or equal to 30 kg/m 2 or a subject with at least one co-morbidity with a BMI greater than or equal to 27 kg/m 2. An overweight subject is a subject at risk of obesity. A “subject at risk of obesity” is an otherwise healthy subject with a BMI of 25 kg/m 2 to less than 30 kg/m 2 or a subject with at least one co-morbidity with a BMI of 25 kg/m 2 to less than 27 kg/m 2.
[0855]
The increased risks associated with obesity occur at a lower Body Mass Index (BMI) in Asians. In Asian countries, including Japan, “obesity” refers to a condition whereby a subject with at least one obesity-induced or obesity-related co-morbidity, that requires weight reduction or that would be improved by weight reduction, has a BMI greater than or equal to 25 kg/m 2. In Asian countries, including Japan, an “obese subject” refers to a subject with at least one obesity-induced or obesity-related co-morbidity that requires weight reduction or that would be improved by weight reduction, with a BMI greater than or equal to 25 kg/m 2. In Asia-Pacific, a “subject at risk of obesity” is a subject with a BMI of greater than 23 kg/m 2 to less than 25 kg/m 2.
[0856]
As used herein, the term “obesity” is meant to encompass all of the above definitions of obesity.
[0857]
Obesity-induced or obesity-related co-morbidities include, but are not limited to, diabetes mellitus, non-insulin dependent diabetes mellitus -type 2, diabetes associated with obesity, impaired glucose tolerance, impaired fasting glucose, insulin resistance syndrome, dyslipidemia, hypertension, hypertension associated with obesity, hyperuricacidemia, gout, coronary artery disease, myocardial infarction, angina pectoris, sleep apnea syndrome, Pickwickian syndrome, fatty liver; cerebral infarction, cerebral thrombosis, transient ischemic attack, orthopedic disorders, arthritis deformans, lumbodynia, emmeniopathy, and infertility. In particular, co-morbidities include: hypertension, hyperlipidemia, dyslipidemia, glucose intolerance, cardiovascular disease, sleep apnea, and other obesity-related conditions.
[0858]
Treatment of obesity and obesity-related disorders refers to the administration of the compounds of the present invention to reduce or maintain the body weight of an obese subject. One outcome of treatment may be reducing the body weight of an obese subject relative to that subject’s body weight immediately before the administration of the compounds of the present invention. Another outcome of treatment may be preventing body weight regain of body weight previously lost as a result of diet, exercise, or pharmacotherapy. Another outcome of treatment may be decreasing the occurrence of and/or the severity of obesity-related diseases. The treatment may suitably result in a reduction in food or calorie intake by the subject, including a reduction in total food intake, or a reduction of intake of specific components of the diet such as carbohydrates or fats; and/or the inhibition of nutrient absorption; and/or the inhibition of the reduction of metabolic rate; and in weight reduction in patients in need thereof. The treatment may also result in an alteration of metabolic rate, such as an increase in metabolic rate, rather than or in addition to an inhibition of the reduction of metabolic rate; and/or in minimization of the metabolic resistance that normally results from weight loss.
[0859]
Prevention of obesity and obesity-related disorders refers to the administration of the compounds of the present invention to reduce or maintain the body weight of a subject at risk of obesity. One outcome of prevention may be reducing the body weight of a subject at risk of obesity relative to that subject’s body weight immediately before the administration of the compounds of the present invention. Another outcome of prevention may be preventing body weight regain of body weight previously lost as a result of diet, exercise, or pharmacotherapy. Another outcome of prevention may be preventing obesity from occurring if the treatment is administered prior to the onset of obesity in a subject at risk of obesity. Another outcome of prevention may be decreasing the occurrence and/or severity of obesity-related disorders if the treatment is administered prior to the onset of obesity in a subject at risk of obesity. Moreover, if treatment is commenced in already obese subjects, such treatment may prevent the occurrence, progression or severity of obesity-related disorders, such as, but not limited to, arteriosclerosis, Type II diabetes, polycystic ovarian disease, cardiovascular diseases, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, and cholelithiasis.
[0860]
The obesity-related disorders herein are associated with, caused by, or result from obesity. Examples of obesity-related disorders include overeating and bulimia, hypertension, diabetes, elevated plasma insulin concentrations and insulin resistance, dyslipidemias, hyperlipidemia, endometrial, breast, prostate and colon cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease, abnormal heart rhythms and arrythmias, myocardial infarction, congestive heart failure, coronary heart disease, sudden death, stroke, polycystic ovarian disease, craniopharyngioma, the Prader-Willi Syndrome, Frohlich’s syndrome, GH-deficient subjects, normal variant short stature, Turner’s syndrome, and other pathological conditions showing reduced metabolic activity or a decrease in resting energy expenditure as a percentage of total fat-free mass, e.g, children with acute lymphoblastic leukemia. Further examples of obesity-related disorders are metabolic syndrome, also known as syndrome X, insulin resistance syndrome, sexual and reproductive dysfunction, such as infertility, hypogonadism in males and hirsutism in females, gastrointestinal motility disorders, such as obesity-related gastro-esophageal reflux, respiratory disorders, such as obesity-hypoventilation syndrome (Pickwickian syndrome) , cardiovascular disorders, inflammation, such as systemic inflammation of the vasculature, arteriosclerosis, hypercholesterolemia, hyperuricaemia, lower back pain, gallbladder disease, gout, and kidney cancer. The compounds of the present invention are also useful for reducing the risk of secondary outcomes of obesity, such as reducing the risk of left ventricular hypertrophy.
[0861]
The term “metabolic syndrome” , also known as syndrome X, is defined in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III) , National Institutes of Health, 2001, NIH Publication No. 01-3670. E.S. Ford et al., JAMA, vol. 287 (3) , Jan. 16, 2002, pp 356-359. Briefly, a person is defined as having metabolic syndrome if the person has three or more of the following disorders: abdominal obesity, hypertriglyceridemia, low HDL cholesterol, high blood pressure, and high fasting plasma glucose. The criteria for these are defined in ATP-III. Treatment of metabolic syndrome refers to the administration of the combinations of the present invention to a subject with metabolic syndrome. Prevention of metabolic syndrome refers to the administration of the combinations of the present invention to a subject with two of the disorders that define metabolic syndrome. A subject with two of the disorders that define metabolic syndrome is a subject that has developed two of the disorders that define metabolic syndrome, but has not yet developed three or more of the disorders that define metabolic syndrome.
[0862]
The terms "administration of" and or "administering a" compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to a human or mammal in need of treatment.
[0863]
The administration of the compound of structural formula I in order to practice the present methods of therapy is carried out by administering an effective amount of the compound of structural formula I to the mammal in need of such treatment or prophylaxis. The need for a prophylactic administration according to the methods of the present invention is determined via the use of well known risk factors. The effective amount of an individual compound is determined, in the final analysis, by the physician or veterinarian in charge of the case, but depends on factors such as the exact disease to be treated, the severity of the disease and other diseases or conditions from which the patient suffers, the chosen route of administration other drugs and treatments which the patient may concomitantly require, and other factors in the physician's judgment.
[0864]
The usefulness of the present compounds in these diseases or disorders may be demonstrated in animal disease models that have been reported in the literature.
[0865]
Administration and Dose Ranges
[0866]
Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. Preferably compounds of the present invention are administered orally.
[0867]
In the treatment or prevention of conditions which require agonism of GPR40 receptor activity, an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 mg of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0.20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
[0868]
When treating or preventing diabetes mellitus and/or hyperglycemia or hypertriglyceridemia or other diseases for which compounds of the present invention are indicated, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from about 0.1 mg to about 100 mg per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 1.0 mg to about 1000 mg, preferably from about 1 mg to about 50 mg. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 mg to about 350 mg. This dosage regimen may be adjusted to provide the optimal therapeutic response.
[0869]
It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
[0870]
The compounds of this invention may be used in pharmaceutical compositions comprising (a) the compound (s) or pharmaceutically acceptable salts thereof, and (b) a pharmaceutically acceptable carrier. The compounds of this invention may be used in pharmaceutical compositions that include one or more other active pharmaceutical ingredients. The compounds of this invention may also be used in pharmaceutical compositions in which the compound of the present invention or a pharmaceutically acceptable salt thereof is the only active ingredient.
[0871]
The term "composition, " as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient (s) , and the inert ingredient (s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
[0872]
Combination Therapy
[0873]
The compounds of the present invention are further useful in methods for the prevention or treatment of the aforementioned diseases, disorders and conditions in combination with other therapeutic agents.
[0874]
The compounds of the present invention may be used in combination with one or more other drugs in the treatment, prevention, suppression or amelioration of diseases or conditions for which compounds of formula I or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone. Such other drug (s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of formula I. When a compound of formula I is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of formula I is preferred. However, the combination therapy may also include therapies in which the compound of formula I and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of the present invention and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of formula I.
[0875]
Examples of other active ingredients that may be administered separately or in the same pharmaceutical composition in combination with a compound of the formulas described herein include, but are not limited to: (1) dipeptidyl peptidase-IV (DPP-4) inhibitors (e.g., sitagliptin, alogliptin, omarigliptin, linagliptin, vildagliptin, saxagliptin, tenegliptin) ; (2) insulin sensitizers, including (i) PPARγ agonists, such as the glitazones (e.g. pioglitazone, AMG 131, MBX2044, mitoglitazone, lobeglitazone, IDR-105, rosiglitazone, and balaglitazone) , and other PPAR ligands, including (1) PPARα/γ dual agonists (e.g., ZYH2, ZYH1, GFT505, chiglitazar, muraglitazar, aleglitazar, sodelglitazar, and naveglitazar) ; (2) PPARα agonists such as fenofibric acid derivatives (e.g., gemfibrozil, clofibrate, ciprofibrate, fenofibrate, bezafibrate) , (3) selective PPARγ modulators (SPPARγM’s ) , (e.g., such as those disclosed in WO 02/060388, WO 02/08188, WO 2004/019869, WO 2004/020409, WO 2004/020408, and WO 2004/066963) ; and (4) PPARγ partial agonists; (ii) biguanides, such as metformin and its pharmaceutically acceptable salts, in particular, metformin hydrochloride, and extended-release formulations thereof, such as Glumetza TM, Fortamet TM, and GlucophageXR TM; and (iii) protein tyrosine phosphatase-1B (PTP-1B) inhibitors (e.g., ISIS-113715 and TTP814) ; (3) insulin or insulin analogs (e.g., insulin detemir, insulin glulisine, insulin degludec, insulin glargine, insulin lispro and inhalable formulations of each) ; (4) leptin and leptin derivatives and agonists; (5) amylin and amylin analogs (e.g., pramlintide) ; (6) sulfonylurea and non-sulfonylurea insulin secretagogues (e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, meglitinides, nateglinide and repaglinide) ; (7) α-glucosidase inhibitors (e.g., acarbose, voglibose and miglitol) ; (8) glucagon receptor antagonists (e.g., MK-3577, MK-0893, LY-2409021 and KT6-971) ; (9) incretin mimetics, such as GLP-1, GLP-1 analogs, derivatives, and mimetics; and GLP-1 receptor agonists (e.g., dulaglutide, semaglutide, albiglutide, exenatide, liraglutide, lixisenatide, taspoglutide, CJC-1131, and BIM-51077, including intranasal, transdermal, and once-weekly formulations thereof) ; (10) LDL cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (e.g., simvastatin, lovastatin, pravastatin, crivastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin) , (ii) bile acid sequestering agents (e.g., colestilan, colestimide, colesevalam hydrochloride, colestipol, cholestyramine, and dialkylaminoalkyl derivatives of a cross-linked dextran) , (iii) inhibitors of cholesterol absorption, (e.g., ezetimibe) , and (iv) acyl CoA: cholesterol acyltransferase inhibitors, (e.g., avasimibe) ; (11) HDL-raising drugs, (e.g., niacin and nicotinic acid receptor agonists, and extended-release versions thereof; MK-524A, which is a combination of niacin extended-release and the DP-1 antagonist MK-524) ; (12) antiobesity compounds; (13) agents intended for use in inflammatory conditions, such as aspirin, non-steroidal anti-inflammatory drugs or NSAIDs, glucocorticoids, and selective cyclooxygenase-2 or COX-2 inhibitors; (14) antihypertensive agents, such as ACE inhibitors (e.g., lisinopril, enalapril, ramipril, captopril, quinapril, and tandolapril) , A-II receptor blockers (e.g., losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisartan, and eprosartan) , renin inhibitors (e.g., aliskiren) , beta blockers, and calcium channel blockers; (15) glucokinase activators (GKAs) (e.g., AZD6370) ; (16) inhibitors of 11β-hydroxysteroid dehydrogenase type 1, (e.g., such as those disclosed in U. S. Patent No. 6,730,690, and LY-2523199) ; (17) CETP inhibitors (e.g., anacetrapib, torcetrapib, and AT-03) ; (18) inhibitors of fructose 1, 6-bisphosphatase, (e.g., MB-07803, and such as those disclosed in U.S. Patent Nos. 6,054,587; 6,110,903; 6,284,748; 6,399,782; and 6,489,476) ; (19) inhibitors of acetyl CoA carboxylase-1 or 2 (ACC1 or ACC2) ; (20) AMP-activated Protein Kinase (AMPK) activators (e.g., MB-11055) ; (21) other agonists of the G-protein-coupled receptors: (i) GPR-109, (ii) GPR-119 (e.g., MBX2982 and PSN821) , (iii) GPR-40 (e.g., fasiglifam, JTT-851, P-11187, 5- [4- [ [ (1R) -4- [6- (3-hydroxy-3-methylbutoxy) -2-methylpyridine-3-yl] -2, 3-dihydro-1H-indene-1-yl] oxy] phenyl] isothiazole-3-ol 1-oxide, 5- (4- ( (3- (2, 6-dimethyl-4- (3- (methylsulfonyl) propoxy) -phenyl) phenyl) methoxy) phenyl) isothiazole-3-ol 1-oxide, 5- (4- ( (3- (2-methyl-6- (3-hydroxypropoxy) pyridine-3-yl) -2-methylphenyl) methoxy) phenyl) isothiazole-3-ol 1-oxide, and 5- [4- [ [3- [4- (3-aminopropoxy) -2, 6-dimethylphenyl] phenyl] methoxy] phenyl] isothiazole-3-ol 1-oxide) , and (iv) GPR-120 (e.g., KDT-501) ; (22) SSTR3 antagonists (e.g., pasireotide, and such as those disclosed in WO 2009/011836) ; (23) neuromedin U receptor agonists (e.g., such as those disclosed in WO 2009/042053, including, but not limited to, neuromedin S (NMS) ) ; (24) SCD inhibitors; (25) GPR-105 antagonists (e.g., such as those disclosed in WO 2009/000087) ; (26) SGLT inhibitors (e.g., LIK-066, ASP1941, SGLT-3, ertugliflozin, empagliflozin, dapagliflozin, canagliflozin, BI-10773, PF-04971729, remogloflozin, luseogliflozin, tofogliflozin, ipragliflozin, and LX-4211) ; (27) inhibitors of (i) acyl coenzyme A: diacylglycerol acyltransferase 1, DGAT-1 (e.g., pradigastat, and P-7435) and acyl coenzyme A: diacylglycerol acyltransferase 2, DGAT-2; (28) inhibitors of fatty acid synthase; (29) inhibitors of acyl coenzyme A: monoacylglycerol acyltransferase 1 and 2 (MGAT-1 and MGAT-2) ; (30) agonists of the TGR5 receptor (also known as GPBAR1, BG37, GPCR19, GPR131, and M-BAR) (eg., sodium taurocholate) ; (31) ileal bile acid transporter inhibitors (eg., elobixibat) ; (32) PACAP, PACAP mimetics, and PACAP receptor 3 agonists; (33) PPAR agonists; (34) protein tyrosine phosphatase-1B (PTP-1B) inhibitors; (35) IL-1b antibodies and inhibitors, (e.g., gevokizumab, canakinumab, danazol, AC-201, and BLX-1002) ; and (36) bromocriptine mesylate and rapid-release formulations thereof.
[0876]
Of particular interest are dipeptidyl peptidase-IV (DPP-4) inhibitors that can be used in combination with compounds of the present invention. Such inhibitors include, without limitation, sitagliptin (disclosed in US Patent No. 6,699,871) , omarigliptin, trelagliptin, teneligliptin, bisegliptin, anagliptin, LC15-0444, vildagliptin, saxagliptin, alogliptin, melogliptin, linagliptin, gosogliptin, evogliptin, gemigliptin, and pharmaceutically acceptable salts thereof, and fixed-dose combinations of these compounds with metformin hydrochloride, pioglitazone, rosiglitazone, simvastatin, atorvastatin, or a sulfonylurea.
[0877]
Other GPR-40 agonists that can be used in combination with compounds of the formulas described herein include, but are not limited to: (1) 5- [4- [ [ (1R) -4- [6- (3-hydroxy-3-methylbutoxy) -2-methylpyridine-3-yl] -2, 3-dihydro-1H-indene-1-yl] oxy] phenyl] isothiazole-3-ol 1-oxide; (2) 5- (4- ( (3- (2,6-dimethyl-4- (3- (methylsulfonyl) propoxy) phenyl) phenyl) -methoxy) -phenyl) isothiazole-3-ol 1-oxide; (3) 5- (4- ( (3- (2-methyl-6- (3-hydroxypropoxy) -pyridine-3-yl) -2-methylphenyl) methoxy) phenyl) isothiazole-3-ol 1-oxide; and (4) 5- [4- [ [3- [4- (3-aminopropoxy) -2, 6-dimethylphenyl] phenyl] methoxy] phenyl] isothiazole-3-ol 1-oxide, and pharmaceutically acceptable salts thereof.
[0878]
Other dipeptidyl peptidase-IV (DPP-4) inhibitors that can be used in combination with compounds of the formulas described herein include, but are not limited to: (1) (2R, 3S, 5R) -5- (1-methyl-4, 6-dihydropyrrolo [3, 4-c] pyrazol-5 (1H) -yl) -2- (2, 4, 5-trifluorophenyl) tetrahydro-2H-pyran-3-amine; (2) (2R, 3S, 5R) -5- (1-methyl-4, 6-dihydropyrrolo [3, 4-c] pyrazol-5 (1H) -yl) -2- (2, 4, 5-trifluorophenyl) tetrahydro-2H-pyran-3-amine; (3) (2R, 3S, 5R) -2- (2, 5-difluorophenyl) tetrahydro) -5- (4,6-dihydropyrrolo [3, 4-c] pyrazol-5 (1H) -yl) tetrahydro-2H-pyran-3-amine; (4) (3R) -4- [ (3R) -3-amino-4- (2, 4, 5-trifluorophenyl) butanoyl] -hexahydro-3-methyl-2H-1, 4-diazepin-2-one; (5) 4- [ (3R) -3-amino-4- (2, 5-difluorophenyl) butanoyl] hexahydro-1-methyl-2H-1, 4-diazepin-2-one hydrochloride; and (6) (3R) -4- [ (3R) -3-amino-4- (2, 4, 5-trifluorophenyl) butanoyl] -hexahydro-3- (2, 2, 2-trifluoroethyl) -2H-1, 4-diazepin-2-one; and pharmaceutically acceptable salts thereof.
[0879]
Antiobesity compounds that can be combined with compounds of formula I include topiramate; zonisamide; naltrexone; phentermine; bupropion; the combination of bupropion and naltrexone; the combination of bupropion and zonisamide; the combination of topiramate and phentermine; fenfluramine; dexfenfluramine; sibutramine; lipase inhibitors, such as orlistat and cetilistat; melanocortin receptor agonists, in particular, melanocortin-4 receptor agonists; CCK-1 agonists; melanin-concentrating hormone (MCH) receptor antagonists; neuropeptide Y 1 or Y 5 antagonists (such as MK-0557) ; CB1 receptor inverse agonists and antagonists (such as rimonabant) ; β 3 adrenergic receptor agonists; ghrelin antagonists; bombesin receptor agonists (such as bombesin receptor subtype-3 agonists) ; and 5-hydroxytryptamine-2c (5-HT2c) agonists, such as lorcaserin. For a review of anti-obesity compounds that can be combined with compounds of the present invention, see S. Chaki et al., “Recent advances in feeding suppressing agents: potential therapeutic strategy for the treatment of obesity, ” Expert Opin. Ther. Patents, 11: 1677-1692 (2001) ; D. Spanswick and K. Lee, “Emerging antiobesity drugs, ” Expert Opin. Emerging Drugs, 8: 217-237 (2003) ; J. A. Fernandez-Lopez, et al., “Pharmacological Approaches for the Treatment of Obesity, ” Drugs, 62: 915-944 (2002) ; and K. M. Gadde, et al., "Combination pharmaceutical therapies for obesity, " Exp. Opin. Pharmacother., 10: 921-925 (2009) .
[0880]
Glucagon receptor antagonists that can be used in combination with the compounds of formula I include, but are not limited to: (1) N- [4- ( (1S) -1- {3- (3, 5-dichlorophenyl) -5- [6-(trifluoromethoxy) -2-naphthyl] -1H-pyrazol-1-yl} ethyl) benzoyl] -β-alanine; (2) N- [4- ( (1R) -1- {3- (3, 5-dichlorophenyl) -5- [6- (trifluoromethoxy) -2-naphthyl] -1H-pyrazol-1-yl} ethyl) benzoyl] -β-alanine; (3) N- (4- {1- [3- (2, 5-dichlorophenyl) -5- (6-methoxy-2-naphthyl) -1H-pyrazol-1-yl] ethyl} benzoyl) -β-alanine; (4) N- (4- { (1S) -1- [3- (3, 5-dichlorophenyl) -5- (6-methoxy-2-naphthyl) -1H-pyrazol-1-yl] ethyl} benzoyl) -β-alanine; (5) N- (4- { (1S) -1- [ (R) - (4-chlorophenyl) (7-fluoro-5-methyl-1H-indol-3-yl) methyl] butyl} benzoyl) -β-alanine; and (6) N- (4- { (1S) -1- [ (4-chlorophenyl) (6-chloro-8-methylquinolin-4-yl) methyl] butyl} benzoyl) -β-alanine; and pharmaceutically acceptable salts thereof.
[0881]
Another embodiment of the present invention relates to a pharmaceutical composition comprising one or more of the following agents: (a) a compound of structural formula I; (b) one or more compounds selected from the group consisting of: (1) dipeptidyl peptidase-IV (DPP-4) inhibitors; (2) insulin sensitizers, including (i) PPARγ agonists, such as the glitazones (e.g. AMG 131, MBX2044, mitoglitazone, lobeglitazone, IDR-105, pioglitazone, rosiglitazone, and balaglitazone) and other PPAR ligands, including (1) PPARα/γ dual agonists, such as ZYH1, YYH2, chiglitazar, GFT505, muraglitazar, aleglitazar, sodelglitazar, and naveglitazar, (2) PPARα agonists, such as fenofibric acid derivatives (e.g., gemfibrozil, clofibrate, ciprofibrate, fenofibrate and bezafibrate) , (3) selective PPARγ modulators (SPPARγM’s ) , and (4) PPARγ partial agonists; (ii) biguanides, such as metformin and its pharmaceutically acceptable salts, in particular, metformin hydrochloride, and extended-release formulations thereof, such as

and

(iii) protein tyrosine phosphatase-1B (PTP-1B) inhibitors, such as ISI-113715, and TTP814; (3) sulfonylurea and non-sulfonylurea insulin secretagogues, (e.g., tolbutamide, glyburide, glipizide, glimepiride, mitiglinide, and meglitinides, such as nateglinide and repaglinide) ; (4) α-glucosidase inhibitors (e.g., acarbose, voglibose and miglitol) ; (5) glucagon receptor antagonists; (6) LDL cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (e.g., lovastatin, simvastatin, pravastatin, cerivastatin, fluvastatin, atorvastatin, pitavastatin, and rosuvastatin) , (ii) bile acid sequestering agents (e.g., colestilan, cholestyramine, colestimide, colesevelam hydrochloride, colestipol, and dialkylaminoalkyl derivatives of a cross-linked dextran) , (iii) inhibitors of cholesterol absorption, (e.g., ezetimibe) , and (iv) acyl CoA: cholesterol acyltransferase inhibitors (e.g., avasimibe) ; (7) HDL-raising drugs, such as niacin or a salt thereof and extended-release versions thereof; MK-524A, which is a combination of niacin extended-release and the DP-1 antagonist MK-524; and nicotinic acid receptor agonists; (8) antiobesity compounds; (9) agents intended for use in inflammatory conditions, such as aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) , glucocorticoids, and selective cyclooxygenase-2 (COX-2) inhibitors; (10) antihypertensive agents, such as ACE inhibitors (e.g., enalapril, lisinopril, ramipril, captopril, quinapril, and tandolapril) , A-II receptor blockers (e.g., losartan, candesartan, irbesartan, olmesartan medoxomil, valsartan, telmisartan, and eprosartan) , renin inhibitors (e.g., aliskiren) , beta blockers (e.g., calcium channel blockers) ; (11) glucokinase activators (GKAs) (e.g., AZD6370, GKM-001, TMG-123, HMS-5552, DS-7309, PF-04937319, TTP-399, ZYGK-1) ; (12) inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (e.g., such as those disclosed in U. S. Patent No. 6, 730, 690; WO 03/104207; and WO 04/058741) ; (13) inhibitors of cholesteryl ester transfer protein (CETP) , (e.g., torcetrapib, anacetrapib, and AT-03) ; (14) inhibitors of fructose 1, 6-bisphosphatase (e.g., MB-07803, and such as those disclosed in U.S. Patent Nos. 6,054,587; 6,110,903; 6,284,748; 6,399,782; and 6,489,476) ; (15) inhibitors of acetyl CoA carboxylase-1 or 2 (ACC1 or ACC2) ; (16) AMP-activated Protein Kinase (AMPK) activators (e.g., MB-11055) ; (17) agonists of the G-protein-coupled receptors: (i) GPR-109, (ii) GPR-119 (e.g., MBX2982, and PSN821) , (iii) GPR-40 (e.g., fasiglifam, JTT-851, P-11187, 5- [4- [ [ (1R) -4- [6- (3-hydroxy-3-methylbutoxy) -2-methylpyridine-3-yl] -2, 3-dihydro-1H-indene-1-yl] oxy] phenyl] isothiazole-3-ol 1-oxide, 5- (4- ( (3- (2, 6-dimethyl-4- (3- (methylsulfonyl) propoxy) phenyl) phenyl) methoxy) phenyl) isothiazole-3-ol 1-oxide, 5- (4- ( (3- (2-methyl-6- (3-hydroxypropoxy) pyridine-3-yl) -2-methylphenyl) methoxy) phenyl) -isothiazole-3-ol 1-oxide, and 5- [4- [ [3- [4- (3-aminopropoxy) -2, 6-dimethylphenyl] phenyl] -methoxy] phenyl] isothiazole-3-ol 1-oxide) , and (iv) GPR-120 (e.g., KDT-501) ; (18) SSTR3 antagonists (e.g., pasireotide, and such as those disclosed in WO 2009/011836) ; (19) neuromedin U receptor agonists (e.g., such as those disclosed in WO2009/042053, including, but not limited to, neuromedin S (NMS) ) ; (20) inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) ; (21) GPR-105 antagonists (e.g., such as those disclosed in WO 2009/000087) ; (22) inhibitors of glucose uptake, such as sodium-glucose transporter (SGLT) inhibitors and its various isoforms, such as SGLT-1; SGLT-2 (e.g., LIK-066, ertuglifozin, ASP1941, luseogliflozin, BI10773, tofogliflozin, LX4211, canagliflozin, dapagliflozin and remogliflozin; and SGLT-3) ; (23) inhibitors of (i) acyl coenzyme A: diacylglycerol acyltransferase 1, DGAT-1 (e.g., pradigastat, and P-7435) and acyl coenzyme A: diacylglycerol acyltransferase 2, DGAT-2; (24) inhibitors of fatty acid synthase; (25) inhibitors of acyl coenzyme A: monoacylglycerol acyltransferase 1 and 2 (MGAT-1 and MGAT-2) ; (26) agonists of the TGR5 receptor (also known as GPBAR1, BG37, GPCR19, GPR131, and M-BAR) (eg., sodium taurocholate) ; (28) bromocriptine mesylate and rapid-release formulations thereof, and (29) IL-1b antibodies and inhibitors (e.g., gevokizumab, canakinumab, danazol, AC-201, and BLX-1002) ; and (c) a pharmaceutically acceptable carrier.
[0882]
Specific compounds of use in combination with a compound of the present invention include: simvastatin, mevastatin, ezetimibe, atorvastatin, rosuvastatin, sitagliptin, omarigliptin, metformin, sibutramine, orlistat, topiramate, naltrexone, bupriopion, phentermine, losartan, losartan with hydrochlorothiazide, canagliflozin, dapagliflozin, ipragliflozin and ertugliflozin.
[0883]
The above combinations include combinations of a compound of the present invention not only with one other active compound, but also with two or more other active compounds. Non-limiting examples include combinations of compounds with two or more active compounds selected from biguanides, sulfonylureas, HMG-CoA reductase inhibitors, PPARγ agonists, DPP-4 inhibitors, anti-obesity compounds, and anti-hypertensive agents.
[0884]
The present invention also provides a method for the treatment or prevention of a G-protein coupled receptor 40 (GPR40) mediated disease, which method comprises administration to a patient in need of such treatment or at risk of developing a GPR40 mediated disease of an amount of a GPR40 agonist and an amount of one or more active ingredients, such that together they give effective relief.
[0885]
In a further aspect of the present invention, there is provided a pharmaceutical composition comprising a GPR40 agonist and one or more active ingredients, together with at least one pharmaceutically acceptable carrier or excipient.
[0886]
Thus, according to a further aspect of the present invention there is provided the use of a GPR40 agonist and one or more active ingredients for the manufacture of a medicament for the treatment or prevention of a GPR40 mediated disease. In a further or alternative aspect of the present invention, there is therefore provided a product comprising a GPR40 agonist and one or more active ingredients as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a GPR40 mediated disease. Such a combined preparation may be, for example, in the form of a twin pack.
[0887]
It will be appreciated that for the treatment or prevention of diabetes, obesity, hypertension, Metabolic Syndrome, dyslipidemia, cancer, atherosclerosis, and related disorders thereof, a compound of the present invention may be used in conjunction with another pharmaceutical agent effective to treat that disorder.
[0888]
The present invention also provides a method for the treatment or prevention of diabetes, obesity, hypertension, Metabolic Syndrome, dyslipidemia, cancer, atherosclerosis, and related disorders thereof, which method comprises administration to a patient in need of such treatment an amount of a compound of the present invention and an amount of another pharmaceutical agent effective to threat that disorder, such that together they give effective relief.
[0889]
The present invention also provides a method for the treatment or prevention of diabetes, obesity, hypertension, Metabolic Syndrome, dyslipidemia, cancer, atherosclerosis, and related disorders thereof, which method comprises administration to a patient in need of such treatment an amount of a compound of the present invention and an amount of another pharmaceutical agent useful in treating that particular condition, such that together they give effective relief.
[0890]
The term "therapeutically effective amount" means the amount the compound of structural formula I that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disorder being treated. The novel methods of treatment of this invention are for disorders known to those skilled in the art. The term “mammal” includes humans, and companion animals such as dogs and cats.
[0891]
The weight ratio of the compound of the Formula I to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the Formula I is combined with a DPIV inhibitor the weight ratio of the compound of the Formula I to the DPIV inhibitor will generally range from about 1000: 1 to about 1: 1000, preferably about 200: 1 to about 1: 200. Combinations of a compound of the Formula I and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
[0892]
Methods of Synthesis of the Compounds of the Present Invention:
[0893]
The following reaction schemes and Examples illustrate methods which may be employed for the synthesis of the compounds of structural formula I described in this invention. Those skilled in the art will readily understand that known variations of protecting groups, as well as of the conditions and processes of the following preparative procedures, can be used to prepare these compounds. It is also understood that whenever a chemical reagent such as a boronic acid or a boronate is not commercially available, such a chemical reagent can be readily prepared following one of numerous methods described in the literature. All temperatures are degrees Celsius unless otherwise noted. Mass spectra (MS) were measured either by electrospray ion-mass spectroscopy (ESMS) or by atmospheric pressure chemical ionization mass spectroscopy (APCI) . All temperatures are degrees Celsius unless otherwise noted.
[0894]
List of Abbreviations
[0895]
Ac is acetyl; AcO is acetoxy; AcOK is potassium acetate; AcONa is sodium acetate; HOAc or AcOH is acetic acid; aq or aq. is aqueous; Alk is alkyl; APCI is atmospheric pressure chemical ionization; AgNO 3 is silver nitrate; aq or aq. is aqueous; Ar is aryl; atm is atmosphere; BH 3 DMS is borane dimethylsulfide complex; BINAP is 2, 2' -bis (diphenylphosphino) -1, 1' -binaphthyl; Boc is tert-butoxycarbonyl; Boc 2O is di-tert-butylcarbonate; br is broad; n-BuLi is n-butyl lithium; s-Bu is sec-butyl; t-Bu is tert-butyl; t-BuO is tert-butoxide; t-BuOK is potassium tert-butoxide; t-BuOH is tert-butyl alcohol; t-BuONa is sodium tert-butoxide; Brett-Phos Palladacycle is chloro [2- (dicyclohexylphosphino) -3, 6-dimethoxy-2' , 4' , 6' -tri-i-propyl-1, 1' -biphenyl] [2- (2-aminoethyl) phenyl] palladium (II) ; ℃ is degrees celsius; CO is carbon monoxide; conc or conc. is concentrated; Cu (OTf) 2 is copper triflate; d is doublet; DAST is (diethylamino) sulfur trifluoride; DCM is dichloromethane; DEA is diethylamine; DIAD is diisopropyl azodicarboxylate; DIBAL-H is di-isobutylaluminum hydride; DIPEA is N, N-diisopropylethylamine; DMAP is 4-dimethylaminopyridine; DMF is N, N-dimethylformamide; DMSO is dimethylsulfoxide; DMP is N-methyl-2-pyrrolidone; DPPA is diphenylphosphoryl-azide; dppf is 1, 1' -bis (diphenyl-phosphino) ferrocene; DTBPF-PdCl 2 is [1, 1′ -Bis (di-tert-butylphosphino) ferrocene] dichloropalladium (II) ; ESI is electrospray ionization; EA or EtOAc is ethyl acetate; Et is ethyl; EtOH is ethanol; Et 3N is triethylamine; Et 3SiH is triethylsilane; g or gm is gram (s) ; h or hr or hrs is hour (s) ; HMPA is hexamethylphosphoramide; HPLC is high pressure liquid chromatography; kg is kilogram (s) ; KHMDS is potassium bis (trimethylsilyl) amide; L is liter; LC-MS is liquid chromatography-mass spectroscopy; LAH is lithium aluminum hydride; LDA is lithium diisopropyl amide; LHMDS and LiHMDS is lithium bis (trimethylsilyl) amide; MeMgBr is methylmagnesium bromide; m is multiplet; mL or ml is milliliter; m-CPBA, MCPBA, or mCPBA is meta chloroperbenzoic acid; mg is milligram (s) ; min or mins is minute (s) ; mol is mole (s) ; mmol is mmole (s) ; MeI is methyl iodide; MeOH is methyl alcohol; Me 2S is dimethylsulfide; MS is mass spectroscopy; MsCl or Ms-Cl is methane sulfonyl chloride; MOMCl is methoxymethyl chloride; MTBE is methyl tert-butyl ether; ; N is normal; NaHMDS is sodium hexamethyldisilazide; NBS is N-bromo succinamide; NFSI is N-fluorobenzene-sulfonimide; NIS is N-iodo succinamide; NMP is 1-methyl-2-pyrrolidinone; NMR is nuclear magnetic resonance spectroscopy; PCC is pyridinium chlorochromate; PE is petroleum ether; Pd (OAc) 2 is palladium (II) acetate; P (Cy) 3 is tricyclohexyl phosphine; Pd 2 (dba) 3 is tris (dibenzylidene-acetone) dipalladium (0) ; Pd (dppf) Cl 2 is [1, 1' -bis (diphenylphosphino) -ferrocene] dichloro-palladium (II) ; PdCl 2 (dffp) is 1, 1' -Bis (diphenylphosphino) ferrocene-palladium (II) dichloride dichloromethane complex; Pd (dtbpf) Cl 2 is [1, 1’ -bis (di-tert-butylphosphino) -ferrocene] dichloro-palladium (II) ; Pd (PPh 3) 4 is tetrakis (triphenylphosphine) -palladium (0) ; PG is protecting group; Tf 2NPh and PhNTf 2 and PhN(Tf) 2 is N-phenylbis (trifluoromethanesulfonimide; PMB is para-methoxybenzyl; PMBCl is para-methoxybenzyl chloride; PPh 3 is triphenyl phosphine; PPA is polyphosphoric acid; PPTS is pyridinium p-toluenesulfonate; Rh (PPh) 3Cl is chlorotris (triphenylphosphine) -rhodium (I) ; Rh (OAc) 2 is rhodium (II) acetate; prep. TLC or preparative TLC is preparative thin layer chromatography; RBF is round bottom flask; RCM is ring closing metathesis reaction; rt or rt. or r. t. or RT is room temperature; s is singlet; SFC is supercritical fluid chromatography; s-phos is 2-dicyclohexylphosphino-2' , 6' -dimethoxybiphenyl; t is triplet; T3P is propylphosphonic anhydride; TEA is triethyl amine; THF is tetrahydrofuran; TFA is trifluoroacetic acid; TFAA is trifluoroacetic anhydride; Tf 2O is trifluoromethanesulfonic anhydride; Tf 2NPh is N-Phenylbis (trifluoromethanesulfonimide; TIPS is triisopropylsilyl; TIPSCl is chloro triisopropylsilane; TLC is thin-layer chromatography; TMSCl is trimethyl silyl chloride TMSCN is trimethylsilyl cyanide; tol is toluene; TosCl is p-toluene sulfonyl chloride; p-TsOH is p-toluenesulfonic acid, Xant-phos is 4, 5-Bis (diphenylphosphino) -9, 9-dimethylxanthene, and xphos is 2-Dicyclohexylphosphino-2′ , 4′ , 6′ -triisopropylbiphenyl.
[0896]
Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples. Starting materials are either commercially available or made by known procedures in the literature or as illustrated. The present invention further provides processes for the preparation of compounds of structural formula I as defined above. In some cases the order of carrying out the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products. The following Examples are provided to illustrate the invention and are not to be construed as limiting the invention in any manner. The scope of the invention is defined by the appended claims.
[0897]
INTERMEDIATE 1-9
[0898]
4-Hydroxy-1, 1a, 6, 6a-tetrahydro-3-aza-cyclopropa [a] indene-1-carboxylic acid ethyl ester (1-9)
[0899]


[0900]
Step A: (4-Bromo-pyridin-2-yl) -bis- (4-methoxy-benzyl) -amine (1-2)
[0901]
To a suspension of sodium hydride (60%in oil, 93 g, 2.32 mol) in DMF (1.8 L) , was added 4-bromo-2-aminopyridine 1-1 (100 g, 0.58 mol) in DMF (500 mL) slowly at 0 ℃. Then the resulting mixture was allowed to stir at r. t. for 0.5 h under N 2 protection. PMBCl (227 g, 1.45 mol) was added to the above mixture and the temperature was kept between 0-10 ℃. After addition, the mixture was allowed to stir at room temperature for 2 h. Then the mixture was carefully poured into ice water, and the resulting solid precipitate was collected, filtered and washed with PE (150 mL x 3) . The resulting filtrate was concentrated to afford compound 1-2. MS (ESI) m /e (M+H +) : 414.1/416.1.
[0902]
Step B: (4-Bromo-5-iodo-pyridin-2-yl) -bis- (4-methoxy-benzyl) -amine (1-3)
[0903]
To a stirred solution of compound 1-2 (140 g, 0.34 mol) in DMF (2.8 L) was added NIS (115 g, 0.51 mmol) in portions. Then the resulting mixture was heated to 40 ℃ and stirred for 24 h. The mixture was cooled, poured into ice water and stirred constantly. The resulting solid precipitate was collected, filtered and washed with PE (100 mL x 3) . The resulting filtrate was concentrated in vacuo to afford compound 1-3. MS (ESI) m /e (M+H +) : 540, 541 (M+H +) .
[0904]
Step C: (4-Bromo-5-vinyl-pyridin-2-yl) -bis- (4-methoxy-benzyl) -amine (1-4)
[0905]
To a stirred solution of compound 1-3 (144 g, 267 mmol) in toluene (2 L) was added tributyl (vinyl) tin (85 g, 267 mmol) , Pd (PPh 3) 4 (15.4 g, 13.4 mmol) , and KF (31 g, 534 mmol) . The resulting mixture was heated to reflux for 18 h under N 2. The mixture was then cooled, KF (300 mL, 2 mol/L) was added and the mixture was stirred for 20 minutes. The mixture was then filtered and the filtrate layers were separated. The organic layer was collected and evaporated in vacuo to give a residue, which was purified by column chromatography on silica gel (eluting with PE: EA = 20: 1) to give compound 1-4. MS (ESI) m /e (M+H +) : 439.8/441 8.
[0906]
Step D: (4-Allyl-5-vinyl-pyridin-2-yl) -bis- (4-methoxy-benzyl) -amine (1-5)
[0907]
To a stirred solution of compound 1-4 (90 g, 205 mmol) in THF (2 L) , was added Cs 2CO 3 (134 g, 410 mmol) , Pd (dppf) Cl 2 (7.5 g, 10.3 mmol) , and allyltributyltin (136 g, 410 mmol) . The resulting mixture was heated to reflux for 18 h under N 2. Then the mixture was cooled, KF (300 mL, 2 mol/L) was added and the mixture was stirred for 20 min. The mixture was then filtered and the filtrate layers were separated. The organic layer was collected and evaporated in vacuo to give a residue, which was purified by column chromatography on silica gel (eluting with PE: EA=30: 1) to give compound 1-5. MS (ESI) m /e (M+H +) : 440.1.
[0908]
Step E: Bis- (4-methoxy-benzyl) - (5H- [2] pyrindin-3-yl) -amine (1-6)
[0909]
To a stirred solution of compound 1-5 (55 g, 138 mmol) in DCM (700 mL) , was added Grubbs reagent (II) (3.5 g, 4.14 mmol) in one portion. The resulting mixture was heated at reflux for 3 h under N 2. The mixture was then cooled and the crude compound 1-6 as solution was used directly in the next step. MS (ESI) m /e (M+H +) : 373.2.
[0910]
Step F: 4- [Bis- (4-methoxy-benzyl) -amino] -1, 1a, 6, 6a-tetrahydro-3-aza-cyclopropa [a] -indene-1- carboxylic acid ethyl ester (1-7) To a stirred solution of crude compound 1-6 (52 g, 138 mmol) in DCM (0.7 L) was added Rh (OAc) 2 (1.6 g, 6.9 mmol) in one portion. The mixture was stirred for 15 min, then ethyl diazoacetate (126 g, 1.1 mol) was added slowly to the mixture under gentle reflux over 3 h. The resulting mixture was allowed to stir at r. t for 1h. Then the mixture evaporated in vacuo to give the crude product, which was purified by column chromatography on silica gel (eluting with PE: EA=10: 1) to give a trans-isomeric mixture of 1-7. The trans-isomeric mixture of 1-7 was separated by chiral column chromatography (SFC resolution conditions: Instrument: Thar 200; Column: AD 250mm x 50mm, 10um; Mobile Phase: A Supercritical CO 2, B EtOH (0.05%NH 3·H 2O) , A/B=60/40 at 200mL/min; Column Temp: 38 ℃; Nozzle Pressure: 100 bar; Nozzle Temp: 60 ℃; Evaporator Temp: 20 ℃; Trimmer Temp: 25 ℃; Wavelength: 220nm) to give the desired enantiomer 1-7. MS (ESI) m /e (M+H +) : 459.1.
[0911]
Step G: 4-Amino-1, 1a, 6, 6a-tetrahydro-3-aza-cyclopropa [a] indene-1-carboxylic acid ethyl ester (1-8)
[0912]
To a stirred solution of compound 1-7 (19 g, 41.4 mmol) in DCM (130 mL) was added TFA (130 mL) in one portion. The resulting mixture was stirred at r. t overnight. The mixture was then evaporated in vacuo to give compound 1-8, which was used directly in the next step. MS (ESI) m /e (M+H +) : 219.1.
[0913]
Step H: 4-Hydroxy-1, 1a, 6, 6a-tetrahydro-3-aza-cyclopropa [a] indene-1-carboxylic acid ethyl ester (1- 9) To a stirred solution of compound 1-8 (23 g, crude) in H 2SO 4 (200 mL, 15%) was added NaNO 2 (14.4 g, 209 mmol) in several portions at 0 ℃. The resulting mixture was allowed to stir at r. t for 2 h. The mixture was then basified with 2N NaOH to pH=5-6, and aqueous NaHCO 3 was added to adjust the filtrate to pH=7. The resulting suspension was extracted with DCM (300 mL x 3) , and the combined organic layers were washed with brine, dried over Na 2SO 4, and concentrated in vacuo. The resulting residue was purified by column chromatography over silica gel (eluting with DCM: MeOH = 50: 1 to 20: 1) to afford intermediate 1-9. MS (ESI) m /e (M+H +) : 220 (M+H +) . 1H-NMR (400 MHz, CDCl 3) δ: 12.52 (s, 1H) , 7.28 (s, 1H) , 6.38. (s, 1H) , 4.14 (dd, 2H, J=7.2 and 14.4 Hz) , 3.18 (dd, 1H, J=6.0 and 12.0 Hz) , 2.94 (d, 1H, J=8.8 Hz) , 2.77 (dd, 1H, J=2.4 and 6.4 Hz) , 2.43-2.39 (m, 1H) , 1.28-1.25 (m, 4H) .
[0914]
INTERMEDIATE 1-10
[0915]
(5aR, 6S, 6aS) -ethyl3-chloro-5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylate (1-10)
[0916]


[0917]
Step A: (5aR, 6S, 6aS) -ethyl3-chloro-5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine- 6-carboxylate (1-10) A mixture of intermediate 1-9 (5.0 g, 22.8 mmol) in POCl 3 (50 mL) was stirred at 110 ℃ for 18 h. After cooling to the room temperature, the excess POCl 3 was removed under reduced pressure. The resulting crude residue was diluted with EA, washed with saturated aqueous NaHCO 3 and brine, dried over anhydrous Na 2SO 4, filtered and the filtrate was concentrated in vacuo to provide a residue, which was purified by chromatography over silica gel (eluting with EA: PE=15: 85) to afford intermediate 1-10. MS (ESI) m /e (M+H +) : 238.5.
[0918]
INTERMEDIATE 1-11
[0919]
(5aR, 6S, 6aS) -tert-butyl 3-chloro-5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylate (1-11)
[0920]


[0921]
Step A: (E) -methyl 5- (3- (tert-butoxy) -3-oxoprop-1-en-1-yl) -2-chloroisonicotinate (1-11b)
[0922]
To a solution of 5-bromo-2-chloroisonicotinic acid 1-11a (Combi-Blocks, 100 g, 423 mmol) in THF (200 mL) and toluene (800 mL) was added DMF (1.6 mL, 21.15 mmol) . To the resulting slurry was added slowly oxalyl chloride (47 mL, 529 mmol) . The reaction was stirred over the weekend at room temperature. Then MeOH (100 mL) was added slowly while cooling in a water bath. After 2 h at room temperature, aqueous K 2HPO 4 (1 M, 423 mL, 423 mmol) was added slowly while still cooling in a water bath. The layers were separated and the aqueous layer was extracted with toluene (1 x 250 mL) . The combined organic layers were filtered through Solka-Floc cellulose, then washed with water (1 x 200 mL) , dried over MgSO 4 and concentrated in vacuo to give the crude methyl ester intermediate. To the methyl ester intermediate in toluene (2 L) was added chloro [tris (2-methylphenyl) phosphine] [2- (2' -amino-1, 1' -biphenyl) ] palladium (II) (2.6 g, 4.23 mmol, 1%) and N,N-dicyclohexylmethylamine (226 mL, 1057 mmol) . The reaction was degassed for 1 h, then t-Butyl acrylate was added in a single portion and the reaction mixture was heated to 80℃ overnight. Then additional chloro [tris (2-methylphenyl) phosphine] [2- (2' -amino-1, 1' -biphenyl) ] palladium (II) (1.3 g, 2.12 mmol, 0.5%) was added and the reaction was heated at 80℃ for 3 h. The reaction mixture was then cooled to room temperature and quenched with water (500 ml) . The layers were separated. The organic layer was washed with saturated brine (1 x 500 ml) , then filtered through a plug of silica gel (150 g) and rinsed with 20%EtOAc in hexanes. The filtrate was concentrated in vacuo to give a crude oil, which was recrystallized from EtOAc in hexane (1: 1) at -10℃ to provide compound 1-11b. MS (ESI) m/e (M+H +) : 242.2.
[0923]
Step B: (E) -5- (3- (tert-butoxy) -3-oxoprop-1-en-1-yl) -2-chloroisonicotinic acid (1-11c)
[0924]
To a solution of compound 1-11b (1 g, 3.36 mmol) in THF (10 ml) was added a solution of lithium hydroxide hydrate (0.155 g, 3.69 mmol) in water (2 ml) , and the reaction was stirred overnight at room temperature. The reaction was then concentrated in vacuo and the resulting residue was diluted with 5 mL water, and slowly acidified with ice-cold 1N HCl solution (4.03 mL) . The resulting white solid was filtered and dried under high vacuum to provide compound 1-11c. MS (ESI) m/e (M+H +) : 284.2.
[0925]
Step C: (E) -tert-butyl 3- (6-chloro-4- ( (E) -2-chloro-2-hydrazonoacetyl) pyridin-3-yl) acrylate (1-11d)
[0926]
DMF (25 μl, 0.323 mmol) was added to a suspension of compound 1-11c (1.73 g, 6.10 mmol) in dichloromethane (55 mL) and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was then concentrated in vacuo, and co-evaporated with 1, 2-dichloroethane. Then DCM (24 ml) was added to the residue, and the resulting solution was added to a solution of (isocyanoimino) triphenylphorphorante (2.77 g, 9.15 mmol) in DCM (14 mL) over 10 min. The reaction mixture was stirred at room temperature for 2 hours. Then water (6.6 ml, 366 mmol) was added and the mixture was stirred at room temperature overnight. Then the organic layer was separated, dried over MgSO 4 and concentrated in vacuo to provide a residue, which was purified by column chromatography over silica gel (eluting with EA: hexanes=0: 100 to 30: 70) to give compound 1-11d. MS (ESI) m/e (M+H +) : 344, 346, 348.
[0927]
Step D: (E) -tert-butyl 3- (6-chloro-4- (2-diazoacetyl) pyridin-3-yl) acrylate (1-11e)
[0928]
Anhydrous zinc bromide (325 mg, 1.443 mmol) was added to a solution of compound 1-11d (2.09 g, 6.07 mmol) in DCM (20 ml) , followed by the dropwise addition of diisopropylethylamine (1.2 ml, 8.42 mmol) . The reaction was stirred at room temperature for 1 hour, and then diluted with EtOAc. The organic layer was washed with 1%ethylenediamine tetraacetic acid tetrasodium salt, dried over anhydrous MgSO 4, and concentrated in vacuo. The resulting crude residue was purified by column chromatography over silica gel (eluting with EA: hexanes=0: 100 to 30: 70) to give compound 1-11e. MS (ESI) m/e (M+H +) : 308, 310.
[0929]
Step E: (5aR, 6R, 6aS) -tert-butyl 3-chloro-5-oxo-5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta- [1, 2-c] pyridine-6-carboxylate (1-11f) A solution of 2, 2-bis ( (S) -4-phenyl-4, 5-dihydrooxazol-2-yl)acetonitrile (5.17 mg, 0.016 mmol) , copper (I) trifluoromethanesulfonate toluene complex (3.36 mg, 6.50 μmol) and 2, 6-di-tert-butylpyridine (29.2 μl, 0.130 mmol) in THF (1 mL) was warmed to 25 ℃, then compound 1-11e (400 mg, 1.300 mmol) in THF (3 mL) was added dropwise over 5 min. After 2.5 hours, the reaction mixture was diluted with EtOAc (3 mL) and MTBE (3 mL) , washed with 0.5 M aqueous citric acid (6 mL) , and concentrated in vacuo to provide a residue. The residue was purified by chromatography over silica gel (eluting with EA: hexanes=0: 100 to 30: 70) to provide compound 1-11f. The ee was upgraded to 95%by dissolution in EtOAc (6 mL/g) and removal of the racemate by filtration. MS (ESI) m/e (M+H +) : 267.1.
[0930]
Step F: (5aR, 6S, 6aS) -tert-butyl 3-chloro-5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2- c] pyridine-6-carboxylate (1-11) Sodium borohydride (1.6 mg, 0.071 mmol) was added to a solution of compound 1-11e (20 mg, 0.071 mmol) in MeOH (0.4 mL) at 0 ℃. After 30 minutes, the reaction was quenched with saturated aqueous NH 4Cl and concentrated in vacuo. The resulting residue was re-dissolved in MTBE and washed once with water. The organic layer was separated, dried over MgSO 4 and concentrated in vacuo to give an alcohol intermediate. The alcohol intermediate was dissolved in THF (400 μL) and treated with trifluoroacetic anhydride (2 equiv, 0.142 mmol) for 30 minutes. The reaction was then cooled to 0 ℃, and concentrated aqueous HCl (5 equiv, 0.355 mmol) was added, followed by the portion wise addition of zinc dust (9.3 mg, 0.142 mmol) over 5 minutes. After stirring for 15 minutes, the reaction was diluted with water and extracted with MTBE twice. The combined organic layers were dried over MgSO 4 and concentrated in vacuo to give a residue, which was purified by column chromatography over silica gel (eluting with EA: hexanes=10: 90 to 20: 80) to provide intermediate 1-11. 1H NMR (400 MHz, CDCl 3) : δ 8.27 (s, 1H) , 7.05 (s, 1H) , 3.18 (dd, J = 6.35Hz, 12.2Hz, 1H) , 2.97 (d, J=18.5Hz, 1H) , 2.83 (d, J=6.35Hz, 1H) , 2.37 (m, 1H) , 1.39 (s, 9H) , 1.09 (br. s, 1H) . MS (ESI) m/e (M+H +) : 280.1.
[0931]
INTERMEDIATE 1-12
[0932]
(5aR, 6R, 6aS) -tert-butyl 3-chloro-5-difluoro-5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2- c] pyridine-6-carboxylate (1-12)
[0933]


[0934]
Step A: (5aR, 6R, 6aS) -tert-butyl 3-chloro-5-difluoro-5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] - cyclopenta [1, 2-c] pyridine-6-carboxylate (1-12) A solution of compound 1-11f (5g, 17.88 mmol) in DCM (50 mL) was treated with (diethylamino) difluorosulfonium tetrafluoroborate (16.37g, 4eq. ) , triethylamine trihydrofluoride (17.2 g, 6 eq. ) and triethylamine (3.6 g, 2eq. ) . The reaction mixture was stirred at room temperature for two days, then diluted with EtOAc (200 mL) , and washed with saturated aqueous NaHCO 3, water, and brine. The organic layer was separated, dried over Na 2SO 4 and concentrated in vacuo to give a residue, which was purified by chromatography over silica gel (eluting with EA: hexanes=0: 100 to 100: 0) to provide intermediate 1-12. MS (ESI) m/e (M+H +) : 302.2.
[0935]
INTERMEDIATE 2-7
[0936]
Ethyl 6-fluoro-1, 1-dimethyl-3-oxo-2, 3-dihydro-1H-indene-5-carboxylate (2-7)
[0937]


[0938]
Step A: (E) -ethyl 3- (4-bromo-3-fluorophenyl) acrylate (2-1)
[0939]
To a stirring solution of ethyl 2- (diethoxyphosphoryl) acetate (133.00 g, 591 mmol) in anhydrous THF (800 mL) was added sodium hydride (14.19 g, 591 mmol) portion wise at 0 ℃. After stirring for 90 min at 0 ℃, 4-bromo-3-fluorobenzaldehyde (80.00 g, 394 mmol) was added dropwise, and the resulting mixture was stirred at 0 ℃ for 3 hr. The reaction was then quenched with water carefully, and the resulting mixture was acidified with 1N HCl to pH=7. The mixture was partitioned between water and EtOAc, the layers were separated and the aqueous layer was extracted with EA two times. The combined organic layers were concentrated in vacuo to afford a residue, which was purified by column chromatography over silica gel (eluting with PE: EA=50: 1) to give compound 2-1.
[0940]
Step B: ethyl 3- (4-bromo-3-fluorophenyl) propanoate (2-2)
[0941]
A mixture of compound 2-1 (83.00 g, 304 mmol) and Rh (PPh) 3Cl (8.44 g, 9.12 mmol) in THF (400 mL) and t-BuOH (400 mL) was stirred overnight at 40 ℃ under a H 2 atmosphere (50 psi) . After filtration, the reaction mixture was concentrated in vacuo and the resulting residue was purified by silica gel column chromatography (eluting with PE: EA=50: 1) to give compound 2-2.
[0942]
Step C: 2- (4-bromophenyl) acetonitrile (2-3)
[0943]
A mixture of compound 2-2 (45.00 g, 164 mmol) and CF 3SO 3H (300 mL) was stirred at 100 ℃ for 16 hr. The reaction mixture was cooled to room temperature, poured into water (500 mL) and the resulting mixture was filtered to give a brown solid, which was purified by column chromatography over silica gel (eluting with PE: EA=10: 1 to 5: 1) to give compound 2-3.
[0944]
Step D: ethyl 6-fluoro-3-oxo-2, 3-dihydro-1H-indene-5-carboxylate (2-4)
[0945]
A mixture of compound 2-3 (30.00 g, 131 mmol) , sodium acetate (21.49 g, 262 mmol) and PdCl 2 (dppf) (4.79 g, 6.55 mmol) in EtOH (500 mL) was heated to 80 ℃ for 16 hr under CO atmosphere (55 psi) . After cooling to room temperature, the mixture was filtered and the insoluble part was removed. The filtrate was concentrated to afford a residue, which was partitioned between EtOAc and water. The organic layer was separated and the aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with water, dried over Na 2SO 4 and concentrated in vacuo to obtain a crude product, which was purified by column chromatography over silica gel (eluting with PE: EA=10: 1) to give compound 2-4.
[0946]
Step E: ethyl 3- ( (tert-butyldimethylsilyl) oxy) -6-fluoro-1H-indene-5-carboxylate (2-5)
[0947]
To a solution of compound 2-4 (15.00 g, 67.5 mmol) and triethylamine (20.49 g, 203 mmol) in THF (150 mL) in an ice bath was added tert-butyldimethylsilyl trifluoromethanesulfonate (35.71 g, 135 mmol) dropwise. The mixture was stirred at 0 ℃ for 2 hours, then aqueous NH 4Cl was added to the reaction. The aqueous layer was separated and extracted with EtOAc twice. Then the combined organic layers were concentrated in vacuo to give a residue, which was purified by column chromatography over silica gel (eluting with PE: EA=10: 1) to give compound 2-5.
[0948]
Step F: ethyl 3- ( (tert-butyldimethylsilyl) oxy) -6-fluoro-1, 1-dimethyl-1H-indene-5-carboxylate (2-6)
[0949]
To a solution of compound 2-5 (17.05 g, 50.5 mmol) and iodomethane (64.50 g, 455 mmol) in THF (170 mL) and HMPA (17 mL) at -78 ℃ was added LHMDS (1N in THF, 116 mL, 116 mmol) dropwise under a nitrogen atmosphere. After completion of the addition, the mixture was stirred at -78 ℃ for 2 hours. Then the reaction mixture was quenched with a saturated aqueous solution of NH 4Cl. The resulting mixture was extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford crude compound 2-6, which was used in the next step without further purification.
[0950]
Step G: ethyl 6-fluoro-1, 1-dimethyl-3-oxo-2, 3-dihydro-1H-indene-5-carboxylate (2-7)
[0951]
To a solution of compound 2-6 (38.03 g, 31.3 mmol) in DCM (150 mL) , was added TFA (10 mL) dropwise at 0 ℃. The mixture was stirred for 2 hours while warming to room temperature. Then aqueous NaHCO 3 was added to the reaction mixture to quench the reaction. The aqueous layer was separated and extracted with EtOAc twice. The organic layer was separated and concentrated to give a residue, which was purified by column chromatography over silica gel (eluting with PE:EA=5: 1 to give intermediate 2-7.
[0952]
INTERMEDIATE 3-6
[0953]
Methyl 3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylate (3-6)
[0954]


[0955]
Step A: 6-bromo-1- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-1-ol (3-2)
[0956]
To a solution of 1-bromo-2- (trifluoromethyl) benzene (495 mg, 2.2 mmol) in dry THF (10 mL) was added n-BuLi (2.5 M in hexane, 0.88 mL, 2.2 mmol) dropwise at -78 ℃ under a nitrogen atmosphere. After completion of the addition, the mixture was stirred at -78 ℃ for an hour. Then a solution of 7-bromo-1-indanone 3-1 (422 mg, 2.0 mmol) in dry THF (5 mL) was added dropwise and the reaction mixture was stirred at -78 ℃ for 3 hr. Then saturated aqueous NH 4Cl was added to the reaction and the mixture was extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated to afford a residue, which was purified by column chromatography over silica gel (eluting with PE: EA=10: 1 to 5: 1) to give compound 3-2.
[0957]
Step B: 3-hydroxy-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylic acid (3-3)
[0958]
To a stirring solution of compound 3-2 (1.0 g, 2.8 mmol) in dry THF (20 mL) was added n-BuLi (2.5 M in hexane, 3.4 mL, 8.4 mmol) dropwise at -78 ℃ under a nitrogen atmosphere. After completion of the addition, the mixture was stirred at -78 ℃ for 2 hours, then carbon dioxide was bubbled into the mixture for 30 min. The mixture was stirred at 78 ℃ for 1 h, then warmed to -20 ℃ slowly. The reaction mixture was quenched with water and acidified with diluted HCl (1N) to pH=2. The resulting mixture was extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated to afford a residue, which was purified by column chromatography over silica gel (eluting with PE: EA=10: 1 to 5: 1) to obtain compound 3-3.
[0959]
Step C: methyl 3-hydroxy-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylate (3-4)
[0960]
To a mixture of compound 3-3 (318 mg , 0.99 mmol) in DMF (6 mL) was added K 2CO 3 (178 mg, 1.98 mmol) in one portion at 0 ℃, followed by MeI (282 mg, 20 mmol) in one portion. The resulting mixture was stirred for 1 h, then warmed to room temperature over 2 h. The mixture was poured into water, and the resulting mixture was extracted with EtOAc (15 mL) three times. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford crude compound 3-4, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 319.3 (-17) .
[0961]
Step D: methyl 3- (2- (trifluoromethyl) phenyl) -1H-indene-5-carboxylate (3-5)
[0962]
A solution of compound 3-4 (317 mg, 0.94 mmol) and Et 3SiH (274 mg, 2.36 mmol) in dry DCM (5 mL) was stirred at room temperature for 30 min. The mixture was cooled to 0 ℃ and TFA (2 mL) was added in one portion. The resulting mixture was warmed to room temperature over one hour. Then saturated aqueous NaHCO 3 was added to neutralize the reaction and the mixture was extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by column chromatography over silica gel (eluting with PE: EA=10: 1) to obtain compound 3-5. MS (ESI) m /e (M+H +) : 319.3.
[0963]
Step E: methyl 3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylate (3-6)
[0964]
Palladium (10%) on carbon (20 mg) was added to a solution of compound 3-5 (120 mg) in MeOH (3 mL) and THF (3 mL) and the resulting mixture was stirred at 25 ℃ under 1 atm of H 2 for 16 hr. The reaction was filtered over Celite TM pad and the filtrate was concentrated in vacuo to afford intermediate 3-6, which was used in other steps without purification. MS (ESI) (ESI) m /e (M+H +) : 321.1.
[0965]
INTERMEDIATE 4-4
[0966]


[0967]
Step A: 6-bromo-3, 3-dimethyl-2, 3-dihydro-1H-inden-1-one (4-2)
[0968]
A mixture of bromobenzene (15 g, 0.1 mol) and 3-methylbut-2-enoic acid 4-1 (10 g, 0.1 mol ) in TsOH (80 mL) was heated to 100 ℃ and stirred for 3 hours. The resulting reaction mixture was cooled, and ice-water (1.5 L) was added to quench the reaction. The resulting mixture was extracted with DCM three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by silica gel chromatography (eluting with PE: EA=4: 1) to obtain compound 4-2.
[0969]
Step B: methyl 1, 1-dimethyl-3-oxo-2, 3-dihydro-1H-indene-5-carboxylate (4-3)
[0970]
To a mixture of compound 4-2 (2 g, 8.4 mmol) and Pd (dppf) Cl 2 (0.31 g, 0.42 mmol) in DMF (15 mL) and MeOH (15 mL) was added Et 3N (4.3 g, 42.0 mmol) . The mixture was then heated at 80 ℃ for 24 hr under a CO atmosphere (55 Psi) . After cooling to room temperature, the mixture was filtered and the insoluble part was removed. The filtrate was concentrated to afford a residue, which was partitioned with EA and water. The aqueous layer was separated and extracted with EA twice. The combined EA layers were washed with water, dried over Na 2SO 4 and concentrated in vacuo to obtain the crude product, which was purified by flash chromatography over silica gel (eluting with PE:EA=5: 1) to afford compound 4-3.
[0971]
Step C: methyl 1, 1-dimethyl-3- ( ( (trifluoromethyl) sulfonyl) oxy) -1H-indene-5-carboxylate (4-4)
[0972]
To a solution of compound 4-3 (110 mg, 0.5 mmol) in dry THF (6 mL) was added KHMDS (1 M in THF, 0.75 mL, 0.75 mmol) dropwise at -78 ℃ under a nitrogen atmosphere. The mixture was stirred for 2 hours, then Tf 2NPh (268 mg, 0.75 mmol) was added. The reaction mixture was then allowed to warm to room temperature and stirred for 16 hr. Then the mixture was quenched with water and neutralized with an aqueous solution of HCl (2N) to pH=7. The organic layer was isolated, and the aqueous layer was separated and extracted with EA two times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by silica gel preparative TLC (eluting with PE: EA=6: 1) to give intermediate 4-4.
[0973]
INTERMEDIATES (5-4) AND (5-5)
[0974]


[0975]
Step A: 2-bromoterephthalic acid (5-1)
[0976]
To a mixture of 3-bromo-4-methyl-benzoic acid (10.0g, 46.5 mmol) in t-BuOH (50 mL) and H 2O (50 ml) , was added KMnO 4 (43 g, 5.7 eq ) at room temperature. The mixture was refluxed overnight. After cooling to 50 ℃, the hot reaction was filtrated and the residue was washed with H 2O. The filtrate was acidified to pH=2 with concentrated HCl , and then concentrated to 100 ml and extracted with EtOAc (100 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford compound 5-1 which was used in the next step without further purification.
[0977]
Step B: (2-bromo-1, 4-phenylene) dimethanol (5-2)
[0978]
To a suspension of compound 5-1 (7.2 g, 29.3 mmol) in THF (80 mL) was added BH 3 (6.0 ml, 2.0 eq) dropwise, then the mixture was refluxed for 6 hr. The reaction was quenched with MeOH (anhydrous) at 0 ℃ slowly, and then concentrated in vacuo to afford compound 5-2, which was used in the next step without further purification. MS (ESI) m /e (M+H +) : 199.2/201.1.
[0979]
Step C: 2-bromo-1, 4-bis ( (methoxymethoxy) methyl) benzene (5-3)
[0980]
To a mixture of compound 5-2 (2.5 g, 11.52 mmol) and DIPEA (4.47 g, 3.0 eq) in DMF (15 mL) was added MOMCl (2.32 g, 3.0 eq) dropwise at 0 ℃ under nitrogen atmosphere. The mixture was stirred at room temperature overnight, then quenched with saturated aqueous NH 4Cl. The mixture was extracted with EtOAc (30 ml) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to obtain a residue, which was purified by chromatography over silica gel (eluting with PE: EA=3: 1) to afford compound 5-3.
[0981]
Step D: (2, 5-bis ( (methoxymethoxy) methyl) phenyl) (2- (trifluoromethyl) phenyl) methanol (5-4)
[0982]
To a solution of compound 5-3 (2.5 g, 8.24 mmol) in anhydrous THF (15 mL) was added n-BuLi (2.5 M in hexanes, 4.26 ml, 1.3 eq) at -78 ℃ under a N 2 atmosphere. The mixture was stirred at -20 ℃ for 2 hours, then 2- (trifluoromethyl) benzaldehyde (1.71 g, 1.2eq) was added dropwise. The mixture was stirred at -20 ℃ for 2 hr, then quenched with saturated aqueous NH 4Cl, diluted with EtOAc, and extracted with EtOAc twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to obtain a residue, which was purified by chromatography over silica gel (eluting with PE: EA=3: 1) to afford intermediate 5-4. MS (ESI) m /e (M+H +) : 400.0.
[0983]
Step E: (2, 5-bis ( (methoxymethoxy) methyl) phenyl) (2- (trifluoromethyl) phenyl) methanone (5-5)
[0984]
To a solution of intemediate 5-4 (1.0 g, 2.5 mmol) in DCM (10 mL) was added DMP (1.26 g, 1.3 eq) at 0 ℃. The mixture was stirred at room temperature for 2 hours. The resulting mixture was filtered over Celite TM, washed with DCM, then concentrated in vacuo to obtain a residue, which was purified by chromatography over silica gel (eluting with PE: EA=2: 1) to afford intermediate 5-5. MS (ESI) m /e (M+Na +) : 421.0.
[0985]
EXAMPLE 1
[0986]
(5aR, 6S, 6aS) -3- ( (3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclopropane-1, 1' -inden] -5' - yl)methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (compound A1-8)
[0987]


[0988]
Step A: methyl 1-oxo-3- (2- (trifluoromethyl) phenyl) -1H-indene-5-carboxylate (A1-1)
[0989]
To a mixture of compound 3-5 (1.0 g, 3.14 mmol) in 1, 4-dioxane (15 mL) was added SeO 2 (1.047g, 9.4 mmol) , and the resulting mixture was heated to reflux for 72 hours. After cooling to room temperature, MeOH was added to quench the reaction. The mixture was stirred for 30 min., and then filtered through Celite TM. The filtrate was concentrated in vacuo to afford to a residue, which was purified by chromatography over silica gel to afford compound A1-1. MS (ESI) m /e (M+H +) : 333.1.
[0990]
Step B: methyl 1-oxo-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylate (A1-2)
[0991]
Rh(PPh) 3Cl (118 mg, 1.27 mmol) was added to a solution of compound A1-1 (848 mg, 2.55 mmol) in a co-solvent of t-BuOH (10 mL) and THF (10 mL) , and the resulting mixture was stirred at 30 ℃ under a H 2 balloon atmosphere for 48 hr. The reaction was then concentrated in vacuo to afford a residue, which was purified by chromatography over silica gel to obtain compound A1-2. MS (ESI) m /e (M+H +) : 335.1.
[0992]
Step C: methyl 1-methylene-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylate (A1-3) Diiodomethane (400 mg, 1.5 mmol) was added at 25 ℃ to a stirring suspension of zinc powder (176 mg, 2.7 mmol) in THF (2 mL) under a nitrogen atmosphere. After 30 min, a dichloromethane solution of TiCl 4 (57 mg, 0.3 mmol, 0.3 mL) was added at 0 ℃, and the resulting dark brown mixture was stirred at 25 ℃ for 30 min. Then a solution of compound A1-2 (100 mg, 0.3 mmol) in THF (1 mL) was then added dropwise to the reaction. After stirring at 25 ℃ for 30 min, the reaction was diluted with EtOAc (10 mL) . The organic layer was separated and washed with 1N HCl (5 mL) and brine, dried over Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by chromatography over silica gel to afford compound A1-3. MS (ESI) m /e (M+H +) : 333.1.
[0993]
Step D: methyl 3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclopropane-1, 1' -indene] -5' - carboxylate (A1-4) A solution of diethylzinc (1.0 M, 1.2 mL, 1.2 mmol) was added to a round bottom flask filled with DCM (2 mL) and the mixture was cooled to 0 ℃. Then TFA (137 mg, 1.2 mmol) in DCM (0.3 mL) was added to the reaction and the reaction was stirred at 0 ℃ for 15 min. To the cooled reaction mixture was added CH 2I 2 (322 mg, 1.2 mmol) in DCM (0.3 mL) , and the mixture was stirred for an additional 15 min at 0 ℃. Then a solution of compound A1-3 (50 mg, 0.15 mmol) in DCM (0.3 mL) was added to the reaction. The reaction was stirred at 0 ℃ for 15 min, and then allowed to warmed to room temperature over 14 hr. The reaction was quenched with saturated aqueous NH 4Cl (10 mL) and diluted with DCM (10 mL) . The layers were separated and the aqueous layer was extracted with DCM (10 mL) twice. The combined DCM layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A1-4. MS (ESI) m /e (M+H +-18) : 347.1.
[0994]
Step E: (3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclopropane-1, 1' -inden] -5' -yl) methanol (A1-5) To a suspension of LiAlH 4 (46 mg, 1.2 mmol) in dry THF (2 mL) at 0 ℃ was added a solution of crude A1-4 (68 mg, 0.2 mmol) in THF (1 mL) dropwise. After completion of the addition, the reaction mixture was stirred at this temperature for 1 hour. The reaction was then quenched with saturated aqueous NH 4Cl and extracted with EtOAc twice. The combined EtOAc layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford crude compound A1-5, which was used in the next step without purification. MS (ESI) m /e (M+H +-18) : 301.1 (-17) .
[0995]
Step F: 5' - (bromomethyl) -3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclopropane-1, 1' - indene] (A1-6) To a solution of crude compound A1-5 (61 mg, 0.19 mmol) in dry THF (2 mL) at 0 ℃ was added PBr 3 (41 mg, 0.15 mmol) dropwise. The reaction solution was stirred at 0 ℃ for 1 hour, then warmed to 20 ℃ and stirred for another 3 hr. The mixture was then quenched with water, and saturated aqueous NaHCO 3 was added to neutralize the mixture to pH=7. The reaction was extracted with EtOAc twice. The combined EtOAc layers were washed with brine, dried over anhydrous Na 2SO 4, filtered and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A1-6.
[0996]
Step G: (5aR, 6S, 6aS) -ethyl 3- ( (3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclopropane- 1, 1' -inden] -5' -yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylate (A1-7) A mixture of compound A1-6 (40 mg, 0.10 mmol) , intermediate 1-9 (27 mg, 0.12 mmol) and Ag 2CO 3 (72 mg, 0.26 mmol) in toluene (1.5 mL) was heated to 100 ℃ for 2 hr. The reaction was then filtered and the filtrate was concentrated to give a residue, which was purified by preparative TLC over silica gel to afford compound A1-7. MS (ESI) m /e (M+H +) : 520.2.
[0997]
Step H: (5aR, 6S, 6aS) -3- ( (3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclopropane-1, 1' - inden] -5' -yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A1-8) To a mixture of compound A1-7 (40 mg, 0.077 mmol) in THF (1 mL) , MeOH (1 mL) and H 2O (1 mL) was added NaOH (24 mg, 0.8 mmol) , and the reaction mixture was stirred at room temperature for 2hr. The reaction was then acidified with HCl (2 N) to pH=7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford compound A1-8. 1H NMR (400 MHz, MeOD-d 4) δ: 7.90 (s, 1H) , 7.57 (d, J=8.0 Hz, 1H) , 7.435 (t, J=7.6 Hz, 1H) , 7.25 (t, J=7.6 Hz, 1H) , 7.16 (d, J=7.6 Hz, 1H) , 7.10 (d, J=8.0 Hz, 1H) , 6.79 (s, 1H) , 6.68 (d, J=8.0 Hz, 1H) , 6.51 (s, 1H) , 5.09 (m, 2H) , 4.82 (t, J=7.8 Hz, 1H) , 3.12 (dd, J=6.3, 18.4 Hz, 1H) , 2.91 (d, J=18.4 Hz 1H) , 2.81 (d, J=5.2 Hz, 1H), 2.49 (dd, J=9.0, 12.9 Hz, 1H) , 2.34 (m, 1H) , 2.06 (dd, J=7.0, 12.9 Hz, 1H) , 1.07-0.93 (m, 3H) , 0.86-0.76 (m, 2H) . MS (ESI) m /e (M+H +) : 492.1.
[0998]
Table 1. Example 2 (Compound A1-9) was prepared in a similar manner to Example 1 (compound A1-8) using the appropriate intermediates and commercially available materials, and including procedures described across this application when necessary.
[0999]


[1000]
EXAMPLE 3
[1001]
(5aR, 6S, 6aS) -3- ( (1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methoxy) - 5,5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A2-6)
[1002]


[1003]
Step A: methyl 1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -1H-indene-5-carboxylate (A2-1) To a stirred solution of compound 3-5 (0.1 g, 0.31 mmol) in THF (2 ml) and HMPA (0.4 ml) at -78 ℃ under a nitrogen atmosphere was added KHMDS (1.0 M in THF, 0.93 mL, 0.93 mmol) dropwise. After completion of the addition, the mixture was stirred for 2 hours, then a solution of MeI (107 mg, 0.75 mmol) in THF (0.2 mL) was added dropwise. The resulting mixture was stirred at -78 ℃ for 1 hr, then warmed to 0 ℃ slowly and stirred for another 30 min. The reaction was quenched with saturated aqueous NH 4Cl. Then the mixture was extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=4: 1) to obtain compound A2-1. MS (ESI) m /e (M+H +) : 347.
[1004]
Step B: methyl 1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylate (A2-2) Palladium (10%) on carbon (20 mg) was added to a solution of compound A2-1 (100 mg) in a mixture of MeOH (4 mL) and THF (2 mL) . The resulting mixture was stirred at 25 ℃ under a H 2 balloon atmosphere for 16 hr. The reaction was then filtered over Celite TM and the filtrate was concentrated in vacuo to afford crude compound A2-2, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 349.1.
[1005]
Step C: (1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methanol (A2-3) To a suspension of LiAlH 4 (58 mg, 1.5 mmol) in dry THF (2 mL) at 0 ℃ was added a solution of compound A2-2 (105 mg, 0.3 mmol) in THF (2 mL) dropwise. After completion of the addition, the reaction mixture was stirred for 1 hr, then saturated aqueous NH 4Cl was added and the mixture was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford compound A2-3, which was used in the next step without purification. MS (ESI) m /e (M+H +-18) : 303.1 (-17) .
[1006]
Step D: 5- (bromomethyl) -1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene (A2-4) To a solution of crude compound A2-3 (32 mg, 0.1 mmol) in dry THF (2 mL) at 0 ℃ was added PBr 3 (23 mg, 0.08mmol) dropwise. The reaction solution was stirred at at 0 ℃ for 1 hr then warm to at 20 ℃ and stirred for another 3 hrs. The mixture was quenched with water, diluted with saturated aqueous NaHCO 3 until pH=7, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=10: 1) to obtain compound A2-4.
[1007]
Step E: (5aR, 6S, 6aS) -ethyl 3- ( (1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden- 5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A2-5) A mixture of compound A2-4 (14 mg, 0.037 mmol) , intermediate 1-9 (8 mg, 0.037 mmol) and Ag 2CO 3 (25 mg, 0.091 mmol) in toluene (0.5 mL) was heated at 100 ℃ for 2 hrs. The reaction was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=4: 1) to afford compound A2-5. MS (ESI) m /e (M+H +) : 522.2.
[1008]
Step F: (5aR, 6S, 6aS) -3- ( (1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A2-6) To a mixture of A2-5 (12 mg, 0.023 mmol) in THF (0.5 mL) , MeOH (0.5 mL) and H 2O (0.5 mL) was added NaOH (10 mg, 0.25 mmol) , and the resulting mixture was stirred at room temperature for 2 hrs. The resulting solution was acidified by HCl (2 N) to pH=7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford compound A2-6. 1H NMR (400 MHz, MeOD-d 4) δ: 7.89 (s, 1H) , 7.60 (d, J=7.8 Hz, 1H) , 7.39 (t, J=8.0 Hz, 1H) , 7.28 (t, J=8.0 Hz, 1H) , 7.20 (d, J=8.0 Hz , 1H) , 7.14 (d, J=8.0 Hz, 1H) , 7.04 (m, 1H) , 6.67 (br. s., 1H) , 6.51 (s, 1H) , 5.11-5.04 (m, 2H) , 4.69 (t, J=8.8 Hz, 1H) , 3.11 (dd, J=4.9, 18.6 Hz, 1H) , 2.90 (d, J=18.4 Hz, 1H) , 2.79 (d, J=5.1 Hz, 1H) , 2.42-2.27 (m, 2H) , 1.81 (t, J=11.3 Hz, 1H) , 1.34 (s, 3H) , 1.15 (s, 3H) , 1.02 (br. s., 1H) . MS (ESI) m/e (M+H +) : 494.2.
[1009]
EXAMPLE 4
[1010]
(5aR, 6S, 6aS) -3- ( (1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methoxy) - 5,5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A3- 5)
[1011]


[1012]
Step A: (1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -1H-inden-5-yl) methanol (A3-2) To a suspension of LiAlH 4 (53 mg, 1.4 mmol) in dry THF (4 mL) at 0 ℃ was added a solution of compound A2-1 (100 mg, 0.3 mmol) in THF (2 mL) dropwise. After completion of the addition, the reaction mixture was stirred at this temperature for 1h. Saturated aqueous NH 4Cl was then added to quench the reaction and the mixture was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford compound A3-2, which was used in the next step without purification.
[1013]
Step B: 5- (bromomethyl) -1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene (A3-3) To a solution of crude compound A3-2 (90 mg, 0.3 mmol) in dry THF (5 mL) at 0 ℃ was added PBr 3 (80 mg, 0.3mmol) dropwise. The reaction was stirred for 1 h then warmed to at 20 ℃ and stirred for another 3 hrs. The final mixture was quenched with water, neutralized with saturated aqueous NaHCO 3 to pH = 7, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na 2SO 4, and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A3-3.
[1014]
Step C: (5aR, 6S, 6aS) -ethyl3- ( (1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A3-4) A mixture of compound A3-3 (80 mg, 0.21 mmol) , intermediate 1-9 (46 mg, 0.21 mmol) and Ag 2CO 3 (173 mg, 0.63 mmol) in toluene (0.3 mL) was heated to 100 ℃ for 2 hrs. The reaction was filtered and the filtrate was concentrated to give a residue, which was purified by preparative TLC over silica gel to afford compound A3-4. MS (ESI) m /e (M+H +) : 520.22.
[1015]
Step D: (5aR, 6S, 6aS) -3- ( (1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A3-5) To a mixture of compound A3-4 (60 mg, 0.12 mmol) in THF (2 mL) , MeOH (2 mL) and H 2O (2 mL) was added NaOH (23 mg, 0.58 mmol) , and the resulting mixture was stirred at room temperature for 2 hrs. The final mixture was acidified by HCl (2 N) to pH = 7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo. The residue was purified by preparative HPLC (on a GILSON 281 instrument fitted with a YMC-Actus Triart C18 (150*20mm*5um) using water and acetonitrile as the eluents. Mobile phase A: water, mobile phase B: acetonitrile. Gradient: 25-54%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to afford compound A3-5. 1H NMR (400 MHz, MeOD-d 4) δ:8.14 (s, 1H) , 7.80 (d, J=8.0 Hz, 1H) , 7.66 (t, J=7.6 Hz, 1H) , 7.55 (t, J=7.6 Hz, 1H) , 7.42 (t, J=9.2 Hz , 2H) , 7.34 (d, J=8.0 Hz, 1H) , 7.18 (s, 1H) , 6.95 (s., 1H) , 6.34 (s, 1H) , 5.32 (s, 2H) , 3.39 (dd, J=4.9, 18.6 Hz, 1H) , 3.18 (d, J=18.4 Hz, 1H) , 3.01 (d, J=4.8 Hz, 1H) , 2.54-2.50 (m, 1H) , 1.38 (s, 6H), 1.27 (s., 1H) . MS (ESI) m /e (M+H +) : 492.17.
[1016]
EXAMPLE 5
[1017]
(5aR, 6S, 6aS) -3- ( (1-methyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methoxy) - 5,5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A4-5)
[1018]


[1019]
Step A: methyl 1-methyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylate (A4-1) To a solution of compound A1-3 (44 mg, 0.13 mmol) in MeOH (5 mL) and THF (5 mL) was added 10%Pd/C (40 mg) at room temperature, and the mixture was stirred under H 2 (1 atm) for 2 h. The reaction was filtered and concentrated in vacuo to give compound A4-1.
[1020]
Step B: (1-methyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methanol (A4-2) To a suspension of LiAlH 4 (30 mg, 0.789 mmol) in dry THF (2 mL) at 0 ℃ was added a solution of crude compound A4-1 (35 mg, 0.104 mmol) in THF (1 mL) dropwise. After completion of the addition, the reaction mixture was stirred at this temperature for 1 hour. Saturated aqueous NH 4Cl was added to quench the reaction and the mixture were extracted with EtOAc twice. The EtOAc layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford crude compound A4-2, which was used in the next step without purification.
[1021]
Step C: 5- (bromomethyl) -1-methyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene (A4-3) To a solution of crude compound A4-2 (32 mg, 0.104 mmol) in dry THF (2 mL) at 0 ℃ was added PBr 3 (24 mg, 0.09 mmol) dropwise. The reaction solution was stirred at at 0 ℃ for 1 hour, then warmed to at 20 ℃ and stirred for another 3 hr. The reaction was then quenched with water, neutralized with saturated aqueous NaHCO 3 to pH=7, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A4-3. MS (ESI) m /e (M-Br) : 289.1.
[1022]
Step D: (5aR, 6S, 6aS) -ethyl 3- ( (1-methyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden -5- yl)methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A4-4) A mixture of compound A4-3 (36 mg, 0.10 mmol) , intermediate 1-9 (21.9 mg, 0.1 mmol) and Ag 2CO 3 (55 mg, 0.2 mmol) in toluene (1.5 mL) was heated at 100 ℃ for 2 hr. The reaction was then filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by HPLC to afford compound A4-4. MS (ESI) m /e (M+H +) : 508.2.
[1023]
Step E: (5aR, 6S, 6aS) -3- ( (1-methyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5- yl)methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A4-5) To a mixture of A4-4 (30 mg, 0.059 mmol) in THF (1 mL) , MeOH (1 mL) and H 2O (1 mL) was added NaOH (24 mg, 0.8 mmol) . The resulting mixture was stirred at room temperature for 2hr, then acidified with HCl (2 N) to pH=7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by preparative HPLC (on a GILSON 281 instrument fitted with a YMC-Actus Triart C18 (150*30mm*5um) using water and acetonitrile as the eluents. Mobile phase A:water, mobile phase B: acetonitrile. Gradient: 45-65%B, 0-10min; 100%B, 10.5-12.5min; 5%B,13-15min) to afford compound A4-5. 1H NMR (400 MHz, MeOD-d 4) δ: 8.06 (s, 1H) , 7.71 (d, 1H), 7.51 (m, 1H) , 7.39 (m, 1H) , 7.31 (m, 2H) , 7.18 (m, 1H) , 6.90 (m, 1H) , 6.80 (s, 1H) , 5.24 (m, 2H), 4.61-4.66 (m, 1H) , 3.25 (m, 2H) , 3.08 (m, 1H) , 2.95 (m, 1H) , 2.75-2.85 (m, 1H) , 2.5 (m, 1H) , 1.6 (m, 1H) , 1.4 (d, J=6.8 Hz, 2H) , 1.30 (d, J=7.2 Hz, 2H) , 1.2 (s, 1 H) . MS (ESI) m /e (M+H +) : 480.2.
[1024]
EXAMPLE 6
[1025]
(5aR, 6S, 6aS) -3- ( (3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclobutane-1, 1' -inden] -5' - yl)methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A5-6)
[1026]


[1027]
Step A: methyl 3' - (2- (trifluoromethyl) phenyl) spiro [cyclobutane-1, 1' -indene] -5'-carboxylate (A5-1) To a solution of compound 3-5 (320 mg, 1 mmol ) in THF/HMPA (4: 1) (10 mL) at -78 ℃ was added KHMDS (1 M/L, 2.5 ml, 2.5 mmol) dropwise and the mixture was stirred for 2 hours. Then 1,3-dibromopropane (240 mg, 1.2 mmol) was then added into the reaction and the mixture was allowed to warm to room temperature overnight. The reaction was quenched with saturated aqueous NH 4Cl and stirred for 20 minutes. The mixture was then extracted with EtOAc, and the organic layers were concentrated to afford a residue, which was purified by HPLC to afford compound A5-1. MS (ESI) m /e (M+H +) : 359.1.
[1028]
Step B: methyl3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclobutane-1, 1' -indene] -5' - carboxylate (A5-2) 10%Pd/C (5 mg) was added to a solution of compound A5-1 (36 mg, 1 mmol) in dry MeOH (5 ml) , and the resulting mixture was stirred at 30 ℃ under a H 2 (1 atm) for 24 hr. The reaction was then filtered and the filtrate was concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to afford compound A5-2.
[1029]
Step C: (3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclobutane-1, 1' -inden] -5' -yl) methanol (A5-3) To a suspension of LiAlH 4 (19 mg, 0.5 mmol) in dry THF (5 mL) at 0 ℃ was added a solution of compound A5-2 (36 mg, 0.1 mmol) in THF (5 mL) dropwise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 1 h. Then saturated aqueous NH 4Cl was added to quench the reaction and the mixture was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford compound A5-3, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 333.1.
[1030]
Step D: 5' - (bromomethyl) -3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclobutane-1, 1' - indene] (A5-4) To a solution of crude compound A5-3 (30 mg, 0.1 mmol) in dry THF (5 mL) at 0 ℃ was added PBr 3 (25 mg, 0.09mmol) dropwise. The reaction solution was stirred at 0 ℃ for 1 hr, then warmed to 20 ℃ and stirred for another 3 hr. The reaction was quenched with water, neutralized with saturated aqueous NaHCO 3 to pH=7, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, and concentrated in vacuo to afford a residue, which was purified by preparative silica TLC to obtain compound A5-4. MS (ESI) m /e (M+H +) : 395.26.
[1031]
Step E: (5aR, 6S, 6aS) -ethyl3- ( (3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclobutane-1, 1' - inden] -5' -yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A5-5) A mixture of compound A5-4 (32 mg, 0.08 mmol) , intermediate 1-9 (21 mg, 0.09 mmol) and Ag 2CO 3 (56 mg, 0.20 mmol) in toluene (3 mL) was heated at 100 ℃ for 3 hr. The mixture was filtered and the filtrate was concentrated in vacuo to give crude compound A5-5, which was used in the next step without further purification. MS (ESI) m /e (M+H +) : 535.2.
[1032]
Step F: (5aR, 6S, 6aS) -3- ( (3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [cyclobutane-1, 1' -inden] - 5' -yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A5-6) To a mixture of compound A5-5 (4 mg, 0.08 mmol) in THF (1 mL) , MeOH (1 mL) and H 2O (1 mL) was added NaOH (15 mg, 0.38 mmol) . The reaction mixture was stirred at room temperature for 2 hr, then acidified with HCl (2 N) to pH=7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a crude product, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a Waters XSELECT C18 (150*30mm*5um) using water and acetonitrile as the eluents. Mobile phase A: water, mobile phase B: acetonitrile. Gradient: 41-61%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to obtain compound A5-6. 1H NMR (400 MHz, MeOD-d 4) δ: 8.11 (s, 1H) , 7.69 (d, J=8.0 Hz, 1H) , 7.55 (d, J=8.0 Hz, 3H) , 7.45 (t, J=6.0 Hz, 1H) ; 7.40~7.32 (m , 2H) , 7.10 (s, 1H) , 7.02 (d, J=8 Hz, 1H) , 6.84 (s, 1H) , 5.28 (s, 2H) ; 4.67 (t, J=6 Hz, 1H), 3.39~3.32 (m, 1H) , 3.19~3.14 (m, 1H) , 3.00 (d, J=8.0 Hz, 1H) , 2.86~2.81 (m, 1H) ; 2.64~2.60 (m, 1H) ; 2.53~2.49 (m, 1H) , 2.32~2.26 (m, 1H) , 2.15~2.05 (m, 5H) , 1.25 (s, 1H) . MS (ESI) m/e (M+H +) : 506.2.
[1033]
EXAMPLES 7 and 8
[1034]
(Compounds A6-15 and A6-18)
[1035]


[1036]
Step A: 6-bromo-1- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-1-ol (A6-1) To a solution of 1-bromo-2- (trifluoromethyl) benzene (10 g, 47.4 mmol) in dry THF (100 mL) at -78 ℃ under a nitrogen atmosphere was added n-BuLi (2.5 M in hexane, 28.4 mL, 71 mmol) dropwise. The mixture was stirred at -78 ℃ for 1 hr, then a solution of 6-bromo-2, 3-dihydro-1H-inden-1-one (16 g, 71 mmol) in dry THF (25 mL) was added dropwise. The reaction mixture was stirred an additional 3hr at -78 ℃, then quenched with saturated aqueous NH 4Cl. The mixture was extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by silica gel chromatography (eluting with PE: EA=20: 1) to obtain compound A6-1. MS (ESI) m /e (M+H +) : 339.0 (-17) .
[1037]
Step B: 5-bromo-3- (2- (trifluoromethyl) phenyl) -1H-indene (A6-2) To a solution of compound A6-1 (9.2 g, 25.8 mmol) in toluene (100 mL) was added 4-methylbenzenesulfonic acid (500 mg, 2.6 mmol) in one portion. The reaction was stirred at 100 ℃ for 10 h and then quenched with aqueous saturated NaHCO 3 (50 mL) , and extracted with EtOAc (2×100 mL) . The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by chromatography over silica gel (eluting with PE: EA=10: 1) to give compound A6-2.
[1038]
Step C: dimethyl 5-bromo-3- (2- (trifluoromethyl) phenyl) -1H-indene-1, 1-dicarboxylate (A6-3) To a solution of compound A6-2 (2 g, 6 mmol) in dry THF (60 mL) at -78 ℃ under a nitrogen atmosphere was added n-BuLi (2.5 M in hexanes, 7.4 mL, 18 mmol) dropwise. After completion of the addition, the mixture was stirred at -78 ℃ for 2 hours. Then a solution of methyl 2-chloroacetate (3.8 g, 18 mmol) in dry THF (5 mL) was added dropwise. The resulting reaction was stirred at -78 ℃ for an additional 3hr, then quenched with saturated aqueous NH 4Cl, and extracted with EtOAc (50 mL) three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated to afford a residue, which was purified by chromatography over silica gel (eluting with PE: EA=20: 1) to obtain compound A6-3. MS (ESI) m /e (M+H +) : 455.0, 457.0.
[1039]
Step D: 5-ethyl 1, 1-dimethyl 3- (2- (trifluoromethyl) phenyl) -1H-indene-1, 1, 5-tricarboxylate (A6-4) To a mixture of A6-3 (4.5 g, 9.9 mmol) in EtOH (10 mL) were added NaOAc (1.62 g, 19.8 mmol) and Pd (dppf) Cl 2 (731 mg, 0.1 mmol ) and the reaction was stirred at 80 ℃ under CO pressure (50 psi) for 12 hours. The reaction mixture was filtrated and the filtrate was partitioned between EtOAc and water. The aqueous layer was separated, and washed by EtOAc twice. Then the combined organic layers were washed with brine, dried over anhydrous Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (eluting with PE: EA=100: 0 to 60: 40) to give compound A6-4. MS (ESI) m /e (M+H +) : 449.1.
[1040]
Step E: 5-ethyl 1, 1-dimethyl 3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-1, 1, 5- tricarboxylate (A6-5) Palladium (10%) on carbon (500 mg) was added to a solution of compound A6-4 (3.7 g, 8.2 mmol) in MeOH (150 mL) and the resulting mixture was stirred at 40 ℃ under H 2 (1 atm) for 12 hr. The reaction mixture was filtered through Celite TM and the filtrate was concentrated to give crude compound A6-5. MS (ESI) m /e (M+H +) : 451.1.
[1041]
Step F: (3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-1, 1, 5-triyl) trimethanol (A6-6) To a suspension of LiAlH 4 (2.5 g, 66.6 mmol) in dry THF (50 mL) at 0 ℃ was added a solution of A6-5 (2 g, 4.44 mmol) in THF (10 mL) dropwise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 12 h. The reaction was carefully quenched with water and 10%aq.NaOH, and then diluted with another 10 mL of THF. The resulting precipitate was removed by filtration and the filtrate was concentrated to give a residue. The residue was purified by column chromatography over silica gel (eluting with DCM: MeOH=50: 1 to 20: 1) to give compound A6-6. MS (ESI) m /e (M+H +) : 335.1 (-17) .
[1042]
Step G: (2, 2-dimethyl-3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [ [1, 3] dioxane-5, 1' -inden] -5' - yl)methanol (A6-7) To a solution of compound A6-6 (300 mg, 0.85 mmol) in 1, 2-dichloroethane (20 mL) at 0℃, was added a catalytic amount of PPTS (21 mg) , followed by the slow addition of 2- methoxypropene (92 mg, 1.26 mmol) . The reaction was stirred for 15 min at 0 ℃, and then warmed to room temperature. After 3 h at room temperature, triethylamine (0.6 mL) was added in one portion. The mixture was diluted with DCM (30 mL) and saturated aqueous NaHCO 3 (30 mL) . The layers were separated and the aqueous layer was extracted with DCM (50 mL) . The combined organic layers were washed with water (30 mL) and brine (30 mL) , dried over Na 2SO 4, filtered and concentrated in vacuo to afford crude product A6-7, which was used in the next step without further purification.
[1043]
Step H: 5' - ( (benzyloxy) methyl) -2, 2-dimethyl-3' - (2- (trifluoromethyl) phenyl) -2' , 3' - dihydrospiro [ [1, 3] dioxane-5, 1' -indene] (A6-8) To a solution of compound A6-7 in dry THF (20 mL) at 0℃ under N 2, was added 60%NaH (51 mg, 1.28 mmol) in three portions. The mixture was stirred for 30 min, then benzyl bromide (218 mg, 1.28 mmol) was added dropwise. The mixture was stirred for 20 min at 0 ℃ and then warmed to room temperature for 2 h. The mixture was heated to reflux for 12 h, then cooled and concentrated. The resulting residue was diluted with EtOAc (50 mL) and washed with saturated aqueous NaHCO 3 (30 mL) , and brine (30 mL) , then dried over anhydrous Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by column chromatography over silica gel (eluting with PE: EA=10: 1) to give compound A6-8.
[1044]
Step I: (5- ( (benzyloxy) methyl) -3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-1, 1- diyl) dimethanol (A6-9) To a solution of compound A6-8 (310 mg, 0.64 mmol) in THF (5 mL) at room temperature was added 1N HCl (2 mL) . The reaction mixture was stirred for 4 h, then 1N NaOH was added to quench the reaction by adjusting the pH to pH 7.0. The reaction mixture was then concentrated under reduced pressure and the resulting residue was purified by preparative TLC over silica gel (eluting with PE: EA=1: 1) to give compound A6-9.
[1045]
Step J: (5- ( (benzyloxy) methyl) -1- (hydroxymethyl) -3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H- inden-1-yl) methyl 4-methylbenzenesulfonate (A6-10) To a solution of compound A6-9 (100 mg, 0.2 mmol) in THF (5 mL) at -30 ℃ under nitrogen, was added n-butyllithium (2.5 M in hexane, 0.1 mL, 0.25 mmol) , followed, 20 min later, by a solution of tosyl chloride (47 mg, 0.25 mmol) in THF (1.0 mL) . The reaction mixture was stirred at -30 ℃ for another 20 min, then allowed to warm to room temperature over 12 h. The final mixture was quenched with saturated aqueous NH 4Cl and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4 and concentrated in vacuo to give the crude compound A6-10, which was used in the next step directly. MS (ESI) m /e (M+H +) : 619.2.
[1046]
Step K: 5- ( (benzyloxy) methyl) -3- (2- (trifluoromethyl) phenyl) -2, 3-dihydrospiro [indene-1, 3' -oxetane] (A6-11) The crude compound A6-10 was dissolved in tert-butyl alcohol (15 mL) , then t-BuOK (62 mg, 0.56 mmol) was added, and the mixture was heated under reflux for 12 h. After cooling, the solvent was removed by evaporation and the resulting residue was purified by preparative TLC over silica gel (eluting with PE: EA=15: 1) to afford compound A6-11.
[1047]
Step L: (3- (2- (trifluoromethyl) phenyl) -2, 3-dihydrospiro [indene-1, 3' -oxetan] -5-yl) methanol (A6-12) Palladium (10%) on carbon (10 mg) was added to a solution of compound A6-11 (35 mg, 0.08 mmol) in MeOH (10 mL) and the resulting mixture was stirred at room temperature under H 2 (1 atm) for 1 hr. The mixture was then filtered over Celite TM and the filtrate was concentrated. The resulting residue was purified by preparative TLC over silica gel (eluting with PE: EA=2: 1) to give compound A6-12. MS (ESI) m /e (M+H +) : 317.1.
[1048]
Step M: (3- (2- (trifluoromethyl) phenyl) -2, 3-dihydrospiro [indene-1, 3' -oxetan] -5-yl) methyl methanesulfonate (A6-13) To a stirred solution of compound A6-12 (33 mg, 0.1 mmol) in DCM (5 mL) at 0℃ was added MsCl (23 mg, 0.2 mmol) and Et 3N (20 mg, 0.2 mmol) . The mixture was stirred for 2 hr at room temperature, then diluted with saturated aqueous NaHCO 3. The mixture was extracted with DCM (50 mL) , and the organic layer was washed with brine, dried over anhydrous Na 2SO 4 and concentrated in vacuo to obtain crude compound A6-13, which was used in the next step without purification.
[1049]
Step N: (5aR, 6S, 6aS) -ethyl 3- ( (3- (2- (trifluoromethyl) phenyl) -2, 3-dihydrospiro [indene-1, 3' –ox etan] -5 -yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A6-14A)
[1050]


[1051]
To a mixture of crude compound A6-13 in toluene (10 mL) , was added tetrabutylammonium iodide (15 mg, 0.04 mmol) . The mixture was heated to 120 ℃ for 30 min. Then intermediate 1-9 (20 mg, 0.08mmol) and Ag 2CO 3 (74 mg, 0.27 mmol) were added. The mixture was stirred at 120 ℃ for 12 hours under N 2, then filtered and concentrated. The resulting residue was purified by preparative TLC over silica gel (eluting with PE: EA=5: 1) to afford compound A6-14A and compound A6-14B. MS (ESI) m /e (M+H +) : 536.
[1052]
Step O: (5aR, 6S, 6aS) -3- ( (3- (2- (trifluoromethyl) phenyl) -2, 3-dihydrospiro [indene-1, 3' -oxetan] -5- yl)methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A6- 15) To a mixture of compound A6-14A (28 mg, 0.05 mmol) in THF (2 mL) , MeOH (2 mL) and H 2O (2 mL) was added NaOH (41 mg, 1 mmol) and the reaction was stirred at room temperature for 12 hr. The reaction mixture was acidified with HCl (1 N) to pH=6, and extracted with EtOAc (50 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by preparative HPLC (on a GILSON 281 instrument fitted with a Waters XSELECT C18 (150*30mm*5um) using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 55-75%B, 0-10 min; 100%B, 10.5-12.5 min; 5%B, 13-15 min) to give compound A6-15. 1H NMR (400 MHz, MeOD-d 4) δ: 1.11 (br. s., 1 H) 2.28-2.37 (m, 1 H) 2.38-2.45 (m, 1 H) 2.89 (d, J=5.09 Hz, 1 H) 2.98-3.10 (m, 2 H) 3.21 (dd, J=18.59, 4.11 Hz, 1 H) 4.72-4.79 (m, 3 H) 4.91 (d, J=5.87 Hz, 1 H) 5.03 (d, J=6.26 Hz, 1 H) 5.20 (s, 2 H) 6.62 (s, 1 H) 6.83-6.93 (m, 2 H) 7.35-7.49 (m, 3 H) 7.71 (d, J=7.83 Hz, 1 H) 7.77 (d, J=7.83 Hz, 1 H) 7.99 (s, 1 H) . MS (ESI) m /e (M+H +) : 508.
[1053]
Step P: (2, 2-dimethyl-3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [ [1, 3] dioxane-5, 1' -inden] -5' - yl) methyl methanesulfonate (A6-16) To a solution of compound A6-7 (330 mg, 0.84 mmol) and TEA (170 mg, 1.68 mmol) in DCM (30 mL) was added MsCl (193 mg, 1.68 mmol) at 0 ℃. The mixture was stirred for 30 min at 0 ℃ , and then at room temperature for 2 hr. Then saturated aqueous NaHCO 3 was added to quench the reaction and the mixture was extracted with DCM. The DCM layer was washed with brine, dried over Na 2SO 4 and concentrated in vacuo to give crude compound A6-16, which was used in the next step without further purification.
[1054]
Step Q: (5aR, 6S, 6aS) -ethyl 3- ( (2, 2-dimethyl-3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [ [1, 3] dioxane-5, 1' -inden] -5' -yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2- c] pyridine-6-carboxylate (A6-17) To a mixture of crude compound A6-16 in toluene (10 mL) was added tetrabutylammonium iodide (15 mg, 0.04 mmol) and the reaction was heated at 100 ℃ for 30 min. Then intermediate 1-9 (205 mg, 0.94 mmol) and Ag 2CO 3 (774 mg, 2.8 mmol) were added. The reaction was stirred at 120 ℃ for 12 hours under N 2 and then filtrated. The filtrate was concentrated and the resulting residue was purified by preparative TLC over silica gel (eluting with PE: EA=5: 1) to afford compound A6-17. MS (ESI) m /e (M+H +) : 594.2.
[1055]
Step R: (5aR, 6S, 6aS) -3- ( (2, 2-dimethyl-3' - (2- (trifluoromethyl) phenyl) -2' , 3' -dihydrospiro [ [1, 3] dioxane-5, 1' -inden] -5' -yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine- 6-carboxylic acid (A6-18) To a solution of compound A6-17 (50 mg, 0.08 mmol) in THF (3 mL) , MeOH (3 mL) and H 2O (3 mL) , was added NaOH (67 mg, 1.7 mmol) . The reaction was stirred at room temperature for 12 h, hen neutralized with 1 M HCl to pH=6.0 and extracted with EtOAc (30 mL) twice. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by preparative TLC over silica gel (eluting with DCM: MeOH=20: 1) to give compound A6-18. 1H NMR (400 MHz, MeOD-d 4) δ: 1.11 (d, J=2.35 Hz, 1 H) 1.43 (s, 3 H) 1.56 (s, 3 H) 1.82-1.93 (m, 1 H) 2.36-2.47 (m, 1 H) 2.81-2.92 (m, 2 H) 2.95-3.03 (m, 1 H) 3.20 (dd, J=18.39, 4.70 Hz, 1 H) 3.70-3.81 (m, 2 H) 3.88 (d, J=11.35 Hz, 1 H) 4.25 (d, J=11.35 Hz, 1 H) 4.79 (t, J=8.80 Hz, 1 H) 5.15-5.21 (m, 2 H) 6.59 (s, 1 H) 6.83 (br. s., 1 H) 7.04-7.12 (m, 1 H) 7.28-7.34 (m, 1 H) 7.35-7.42 (m, 1 H) 7.44-7.51 (m, 1 H) 7.54 (d, J=7.83 Hz, 1 H) 7.70 (d, J=7.83 Hz, 1 H) 7.97 (s, 1 H) . MS (ESI) m /e (M+H +) : 566.2.
[1056]
EXAMPLE 9
[1057]
(5aR, 6S, 6aS) -3- ( (1, 1-dimethyl-3-phenyl-2, 3-dihydro-1H-inden-5-yl) methoxy) -5, 5a, 6, 6a- tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A7-7)
[1058]


[1059]
Step A: methyl 1, 1-dimethyl-3-phenyl-1H-indene-5-carboxylate (A7-2) A mixture of intermediate 4-4 (120 mg, 0.34 mmol) , phenylboronic acid (50 mg, 0.41 mmol) , K 3CO 3 (117 mg, 0.85 mmol) and PdCl 2 (dffp) (15 mg) in dioxane (3 mL) and water (1 mL) was heated in a microwave at 100 ℃ for 10 min under nitrogen atmosphere. After cooling to room temperature, the reaction was filtered over Celite TM and the filtrate was extracted with EtOAc twice. The combined organic layers were washed with water, dried over Na 2SO 4 and concentrated in vacuo to obtain crude compound A7-2, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 278.1.
[1060]
Step B: methyl 1, 1-dimethyl-3-phenyl-2, 3-dihydro-1H-indene-5-carboxylate (A7-3) Palladium (10%) on carbon (20 mg) was added to a solution of crude compound A7-2 (150 mg, crude) in MeOH (10 mL) , and the resulting mixture was stirred at 25 ℃ under H 2 (1 atm) for 16 h. Then the reaction mixture was filtered over Celite TM and the filtrate was concentrated in vacuo to afford crude compound A7-3, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 280.1.
[1061]
Step C: (1, 1-dimethyl-3-phenyl-2, 3-dihydro-1H-inden-5-yl) methanol (A7-4) To a suspension of LiAlH 4 (65 mg, 1.7 mmol) in dry THF (5 mL) at 0 ℃ was added a solution of compound A7-3 (120 mg, crude) in THF (10 mL) dropwise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 4 h. Then the reaction was quenched with saturated aqueous NH 4Cl and the mixture was extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by column chromatography over silica gel (eluting with PE: EA=5: 1) to give compound A7-4. MS (ESI) m/e (M+H +-18) : 252.1 (-17) .
[1062]
Step D: 5- (bromomethyl) -1, 1-dimethyl-3-phenyl-2, 3-dihydro-1H-indene (A7-5) To a solution of compound A7-4 (60 mg, 0.17 mmol) in dry DCM (5 mL) at 0 ℃ was added PBr 3 (46 mg, 0.17 mmol) dropwise. The resulting solution was stirred at 0 ℃ for an hour, then warmed to 20 ℃ and stirred for 2 hr. The reaction was then quenched with water, neutralized with saturated aqueous NaHCO 3 to pH=7, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, and concentrated in vacuo to afford crude compound A7-5, which was used in the next step without purification.
[1063]
Step E: (5aR, 6S, 6aS) -ethyl3- ( (1, 1-dimethyl-3-phenyl-2, 3-dihydro-1H-inden-5-yl) methoxy) - 5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A7-6) A mixture of compound A7-5 (80 mg, crude) , intermediate 1-9 (31 mg, 0.14 mmol) and Ag 2CO 3 (94 mg, 0.34 mmol) in toluene (8 mL) was heated at 110 ℃ for 2 h. The reaction was filtered and the filtrate was concentrated to give crude compound A7-6, which was purified via column chromatography over silica gel to give compound A7-6. MS (ESI) m /e (M+H +) : 454.6.
[1064]
Step F: (5aR, 6S, 6aS) -3- ( (1, 1-dimethyl-3-phenyl-2, 3-dihydro-1H-inden-5-yl) methoxy) -5, 5a, 6, 6a- tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A7-7) To a mixture of compound A7-6 (30 mg, 0.066 mmol) in THF (1 mL) , MeOH (1 mL) and H 2O (1 mL) was added NaOH (26 mg, 0.66 mmol) , and the resulting mixture was stirred at room temperature for 2 h. The reaction mixture was then acidified with HCl (2 N) to pH=7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to give compound A7-7. 1H NMR (400 MHz, MeOD-d 4) δ: 7.97-8.09 (m, 1 H) 7.27 (q, J=6.91 Hz, 3 H) 7.11-7.21 (m, 4 H) 6.73-6.84 (m, 1 H) 6.57-6.71 (m, 1 H) 5.13-5.27 (m, 2 H) 4.37 (t, J=8.61 Hz, 1 H) 3.15-3.28 (m, 1 H) 2.87-3.07 (m, 2 H) 2.34-2.46 (m, 2 H) 1.93 (t, J=11.15 Hz, 1 H) 1.40 (s, 3 H) 1.23 (br. s., 3 H) 1.10-1.17 (m, 1 H) . MS (ESI) m /e (M+H +) : 426.2.
[1065]
Table 2. Examples 10-17 (compounds A7-8 to A7-16) were prepared in a similar manner to Example 9 (Compound A7-7) using the appropriate intermediates and commercially available materials, and including procedures described across this application when necessary.
[1066]


[1067]


[1068]


[1069]
EXAMPLES 18 and 19
[1070]
(5aR, 6S, 6aS) -3- ( (1-phenyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methoxy) - 5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compounds A8- 7A and A8-7B)
[1071]


[1072]
Step A: ethyl 1- (2- (trifluoromethyl) phenyl) -3- ( ( (trifluoromethyl) sulfonyl) oxy) -1H-indene-6- carboxylate (A8-1) To a solution of compound A1-2 (1.0 g, 2.87 mmol) in DCM (20 mL) at room temperature was added 2, 6-di-tert-butyl-4-methylpyridine (1.179 g, 5.74 mmol) and trifluoromethanesulfonic anhydride (1.782 g, 6.32 mmol) under a nitrogen atmosphere. After completion of the addition, the mixture was stirred for 3 hours. Then the reaction mixture was quenched with water and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford compound A8-1. MS (ESI) m /e (M+H +) : 481.0.
[1073]
Step B: ethyl 3-phenyl-1- (2- (trifluoromethyl) phenyl) -1H-indene-6-carboxylate (A8-2) A mixture of compound A8-1 (1.2 g, 2.123 mmol) , phenylboronic acid (0.311 g, 2.55 mmol) , K 2CO 3 (0.734 g, 5.31 mmol) and PdCl 2 (dppf) (0.078 g, 0.106 mmol) in 1, 4-dioxane (4 ml) and water (1.5 ml) was microwaved at 100 ℃ for 30 min under a nitrogen atmosphere. After cooling to room temperature, the reaction was filtered and the filtrate was extracted with EtOAc. The organic layer was separated, washed with water, dried over Na 2SO 4 and concentrated in vacuo to obtain a residue, which was purified by column chromatography over silica gel to give compound A8-2. MS (ESI) m /e (M+H +) : 409.1.
[1074]
Step C: ethyl 1-phenyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylate (A8-3) 10%Pd/C (15.63 mg, 0.147 mmol) was added to a solution of compound A8-2 (600 mg, 1.469 mmol) in MeOH (30 ml) , and the resulting mixture was stirred at 50 ℃ under H 2 (50 psi) for 16 h. The reaction was then filtered through Celite TM and the filtrate was concentrated in vacuo to afford crude compound A8-3, which was used in the next step without purification. MS (ESI) m/e (M+H +) : 411.1.
[1075]
Step D: (1-phenyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methanol (A8-4) To a suspension of LiAlH 4 (277 mg, 7.31 mmol) in dry THF (20 mL) at 0 ℃ was added a solution of compound A8-3 (600 mg, 1.462 mmol) in THF (30 mL) dropwise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 3 h. Then the reaction was quenched with saturated aqueous NaOH and the mixture was extracted with EtOAc twice. The combined organic layers were washed and concentrated to afford a residue, which was purified by column chromatography over silica gel to obtain compound A8-4. MS (ESI) m /e (M+H +) : 368.1 (-17) .
[1076]
Step E: 5- (bromomethyl) -1-phenyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene (A8-5) To a solution of compound A8-4 (450 mg, 1.222 mmol) in dry DCM (20 mL) at 0 ℃ was added PBr 3 (0.115 ml, 1.222 mmol) dropwise. The resulting solution was stirred for an hour, then warmed to 20 ℃ and stirred for 2 h. The mixture was then quenched with water, neutralized with saturated aqueous NaHCO 3 to pH=7, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, and concentrated in vacuo to afford crude compound A8-5, which was used in the next step directly. MS (ESI) m /e (M+H +) : 430.1, 432.1.
[1077]
Step F: (5aR, 6S, 6aS) -ethyl 3- ( (1-phenyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A8-6) A mixture of Ag 2CO 3 (252 mg, 0.912 mmol) , compound A8-5 (315 mg, 0.547 mmol) and intermediate 1-9 (80 mg, 0.365 mmol) in toluene (5 mL) was heated to 110 ℃ for 2 hrs. The reaction was filtered and the filtrate was concentrated to give crude compound A8-6, which was used in the next step directly. MS (ESI) m /e (M+H +) : 570.2.
[1078]
Step G: (5aR, 6S, 6aS) -3- ( (1-phenyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A8- 7A and A8-7B)
[1079]


[1080]
To a mixture of compound A8-6 (40 mg, 0.070 mmol) in THF (2 ml) , MeOH (2 mL) and H 2O (2 mL) was added NaOH (28.1 mg, 0.702 mmol) , and the resulting mixture was stirred at room temperature for 2 hrs. The resulting mixture was acidified with HCl (2 N) to pH=7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to obtain a residue, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a Waters XSELECT C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B:acetonitrile. Gradient: 64-84%B, 0-10min; 100%B, 10.5-12.5 min; 5%B, 13-15min) to give compound A8-7A and compound A8-7B. Compound A8-7A: 1H NMR (400 MHz, MeOD-d 4) δ: 8.13 (s, 1 H) , 7.73 (d, J=7.53 Hz, 1 H) , 7.50 (m, 1 H) , 7.41 (m, 1 H) , 7.36 (m, 1 H) , 7.31 (s, 2 H) , 7.23 (d, J=7.53 Hz, 1 H) , 7.15 (d, J=7.53 Hz, 3 H) , 7.07 (m, 3 H) , 5.33 (m, 2 H) , 5.02 (t, J=7.03 Hz, 1 H) , 4.66 (m, 1 H) , 3.38 (m, 1 H) , 3.17 (m, 1 H) , 3.01 (d, J=5.02 Hz, 1 H) , 2.66 (m, 1 H) , 2.54 (m, 2 H), 1.26 (t, J=2.51 Hz, 1 H) . MS (ESI) m /e (M+H +) : 542.2; Compound A8-7B: 1H NMR (400 MHz, MeOD-d 4) δ: 8.17 (s, 1 H) , 7.71-7.78 (m, 1 H) , 7.56-7.64 (m, 1 H) , 7.45 (t, J=7.53 Hz, 1 H) , 7.34 (s, 7 H) , 7.20 (s, 1 H) , 6.93-7.00 (m, 2 H) , 5.34 (s, 2 H) , 4.77-4.85 (m, 1 H) , 4.39-4.47 (m, 1 H), 3.38-3.47 (m, 1 H) , 3.19-3.28 (m, 1 H) , 3.01-3.10 (m, 2 H) , 2.52-2.60 (m, 1 H) , 2.05 (s, 1 H), 1.29-1.31 (m, 1 H) . MS (ESI) m /e (M+H +) : 542.2.
[1081]
EXAMPLE 20
[1082]
(5aR, 6S, 6aS) -3- ( (6-fluoro-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5 -yl) methoxy) - 5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A9-9)
[1083]


[1084]
Step A: 6-bromo-5-fluoro-1- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-1-ol (A9-1) To a solution of 1-bromo-2- (trifluoromethyl) benzene (2.90 g, 13.1 mmol) in dry THF (50 mL) was added n-BuLi (2.5 M in hexanes, 5.24 mL, 13.1 mmol) dropwise at -78 ℃ under nitrogen atmosphere. After completion of the addition, the mixture was stirred at -78 ℃ for an hour. Then a solution of compound 2-3 (2 g, 8.73 mmol) in dry THF (20 mL) was added dropwise and the resulting reaction mixture was stirred at -78 ℃ for 3 h. Then the reaction was quenched with saturated aqueous NH 4Cl and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by chromatography over silica gel (eluting with PE: EA=50: 1 to 4: 1) to obtain compound A9-1. MS (ESI) m/e (M+H +) : 375.0.
[1085]
Step B: 6-fluoro-3-hydroxy-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylic acid (A9-2) To a solution of compound A9-1 (2.3 g, 6.1 mmol) in dry THF (50 mL) was added n-BuLi (2.5 M in hexanes, 7.32 mL, 18.3 mmol) dropwise at -78 ℃ under nitrogen atmosphere. After completion of the addition, the mixture was stirred at -78 ℃ for 2 hours. Carbon dioxide was then bubbled into the mixture for 30 min. The mixture was stirred at -78 ℃ for another hour, and then warmed to -20 ℃ slowly. The reaction mixture was quenched with water, then acidified with diluted HCl (1N) to pH=2, and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was washed with petroleum ether to give compound A9-2 which was used in the next step directly.
[1086]
Step C: methyl 6-fluoro-3-hydroxy-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5- carboxylate (A9-3) To a solution of compound A9-2 (1.1 g , 3.23 mmol) in DMF (15 mL) at 0 ℃was added K 2CO 3 (891 mg, 6.46 mmol) in one portion, followed by MeI (891 mg, 6.46 mmol) . The mixture was sitrred at 0 ℃ for 1 h, then warmed to room temperature over 2 hrs. The mixture was then poured into water, and extracted with EtOAc (30 mL) three times. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford compound A9-3, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 338.1 (-17) .
[1087]
Step D: methyl 6-fluoro-3- (2- (trifluoromethyl) phenyl) -1H-indene-5-carboxylate (A9-4) A solution of compound A9-3 (1g, 2.82 mmol) and TsOH (107 mg, 0.565 mmol) in dry toluene (20 mL) was stirred at reflux for 3 h, and then cooled to room temperature. The mixture was neutralized with saturated aqueous NaHCO 3 and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to obtain compound A9-4, which was used in the next step without purification. MS (ESI) m/e (M+H +) : 337.1.
[1088]
Step E: ethyl 6-fluoro-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylate (A9-5) To a solution of compound A9-4 (500 mg, 1.427 mmol) in MeOH (30 ml) ) was added 10%Pd/C (15.19 mg, 0.143 mmol) and the reaction was stirred at 25 ℃ under H 2 (1 atm) for 16 h. The mixture was then filtered and the filtrate was concentrated in vacuo to afford crude compound A9-5, which was used in the next step without purification.
[1089]
Step F: (6-fluoro-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methanol (A9-6) To a suspension of crude compound A9-5 (440 mg, 1.249 mmol) in dry THF (15 ml) at 0 ℃ was added lithium aluminum (III) hydride (95 mg, 2.498 mmol) portionwise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 3 h. The reaction was then quenched with saturated aqueous NaOH and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to give crude compound A9-6, which was used in the next step without purification.
[1090]
Step G: (6-fluoro-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methyl methanesulfonate (A9-7) To a solution of compound A9-6 (100 mg, 0.322 mmol) and triethylamine (98 mg, 0.967 mmol) in dry DCM (5 ml) at 0 ℃ was added methanesulfonyl chloride (73.8 mg, 0.645 mmol) dropwise. After completion of the addition, the mixture was stirred at this temperature for 16 h, then concentrated in vacuo to give crude compound A9-7, which was used in the next step without purification.
[1091]
Step H: (5aR, 6S, 6aS) -ethyl 3- ( (6-fluoro-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A9-8) A mixture of crude compound A9-7 (50 mg, 0.129 mmol) , intermediate 1-9 (28.2 mg, 0.129 mmol) and Ag 2CO 3 (35.5 mg, 0.129 mmol) in toluene (10 mL) was heated at 110 ℃ for 10 h. The reaction was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=5: 1) to afford compound A9-8. MS (ESI) m/e (M+H +) : 512.2.
[1092]
Step I: (5aR, 6S, 6aS) -3- ( (6-fluoro-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A9-9) To a mixture of compound A9-8 (52 mg, 0.102 mmol) in THF (2 mL) , MeOH (2 mL) and water (2 mL) was added lithium hydroxide (24.35 mg, 1.017 mmol) . The resulting mixture was stirred at room temperature for 2 h. Then the reaction mixture was acidified by HCl (2 N) to pH=4, and extracted with EtOAc (30 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a Waters XSELECT C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 53-68%B, 0-9min; 100%B, 9-11 min) to obtain compound A9-9. 1H NMR (400 MHz, MeOD-d 4) δ: 8.07-8.14 (m, 1H) , 7.68-7.75 (m, 1H) , 7.46-7.53 (m, 1H) , 7.36-7.45 (m, 1H) , 7.07-7.18 (m, 2H) , 7.01-7.06 (m, 1H) , 6.90-6.96 (m, 1H) , 5.33 (s, 2H) , 4.71-4.78 (m, 1H), 3.34-3.42 (m, 1H) , 3.08-3.21 (m, 2H) , 2.97-3.08 (m, 2H) , 2.63-2.75 (m, 1H) , 2.48-2.56 (m, 1H) , 2.00-2.13 (m, 1H) , 1.20-1.28 (m, 1H) . MS (ESI) m /e (M+H +) : 484.1.
[1093]
Table 3. Example 21 (compound A9-10) was prepared in a similar manner to Example 20 (Compound A9-9) using the appropriate intermediates and commercially available materials, but without Steps D and E, and including procedures described across this application when necessary.
[1094]


[1095]


[1096]
EXAMPLES 22 and 23
[1097]
(5aR, 6S, 6aS) -3- ( (6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compounds A10-6A and A10-6B)
[1098]


[1099]
Step A: methyl 6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -1H-indene-5-carboxylate (A10- 1) To a stirring solution of compound A9-4 (757 mg, 2.25 mmol) in THF (20 mL) and HMPA (3 mL) was added KHMDS (1.0 M in THF, 6.75 mL, 6.75 mmol) dropwise at-78 ℃ under nitrogen atmosphere. After completion of the addition, the mixture was stirred at this temperature for 2 h, then a solution of MeI (0.43 mL, 6.75 mmol) was added dropwise. The resulting mixture was stirred at-78 ℃ for 1 h, then warmed to 0 ℃ slowly and stirred for another 30 min. The final mixture was quenched with saturated aqueous NH 4Cl and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by chromatography over silica gel (eluting with PE: EA=20: 1) to obtain compound A10-1.
[1100]
Step B: methyl 6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5- Carboxylate (A10-2) Palladium (10%) on carbon (120 mg) was added to a solution of compound A10-1 (657 mg) in MeOH (20 mL) and THF (10 mL) , and the resulting mixture was stirred at 25 ℃ under H 2 (1 atm) for 24 hrs. The reaction was filtered over Celite TM, and the filtrate was concentrated in vacuo to afford crude compound A10-2, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 367.1.
[1101]
Step C: (6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methanol (A10-3) To a suspension of LiAlH 4 (87 mg, 2.30 mmol) in dry THF (20 mL) at 0 ℃ was added a solution of compound A10-2 (560 mg, 1.53 mmol) in THF (2 mL) dropwise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 1 h. The reaction was then quenched with saturated aqueous NH 4Cl and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford compound A10-3, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 322.1 (-17) .
[1102]
Step D: 5- (chloromethyl) -6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H- indene (A10-4) To a solution of crude compound A10-3 (200 mg, 0.59 mmol) in dry DCM (5 mL) at 0 ℃ was added Et 3N (171 mg, 1.77 mmol) and SOCl 2 (105 mg, 0.885 mmol) dropwise. The reaction was stirred at 0 ℃ for 2 h, then quenched with water and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=10: 1) to obtain compound A10-4.
[1103]
Step E: (5aR, 6S, 6aS) -ethyl 3- ( (6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihy dro- 1H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylate (A10-5) A mixture of compound A10-4 (150 mg, 0.42 mmol) , intermediate 1-9 (92 mg, 0.42 mmol) and Ag 2CO 3 (347 mg, 1.26 mmol) in toluene (4 mL) was heated at 100 ℃ for 17 hrs. The reaction was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=6: 1) to afford compound A10-5. MS (ESI) m /e (M+H +) : 540.2.
[1104]
Chiral SFC resolution of compound A10-5 (compounds A10-5A and A10-5B) :
[1105]


[1106]
Compound A10-5 was purified by chiral preparative SFC (column: Chiralcel OD-3 150×4.6 mm I.D., 3 um; Mobile phase: iso-propanol (0.05%DEA) in CO 2 from 5%to 40%; Flow rate: 2.5 mL/min; Wavelength: 220nm) to provide compounds A10-5A and A10-5B.
[1107]
Step F: (5aR, 6S, 6aS) -3- ( (6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H- inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylicacid (A10-6A and A10-6B) To a mixture of compound A10-5A (50 mg, 0.093 mmol) in THF (1 mL) , MeOH (1 mL) and water (1 mL) was added LiOH·H 2O (38 mg, 0.93 mmol) , and the resulting mixture was stirred at room temperature for 2 hrs. The final mixture was acidified with HCl (2 N) to pH=7 and extracted with EtOAc (20 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated to give a residue, which was purified by reverse preparative HPLC (preparative HPLC on a GILSON 281 instrument fitted with a Waters XSELECT C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 68-88%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to give compound A10-6A. 1H NMR (400 MHz, MeOD-d 4) δ: 8.07 (s, 1 H) , 7.68 (d, J=7.83 Hz, 1 H) , 7.44-7.52 (m, 1 H) , 7.34-7.42 (m, 1 H) , 7.12 (d, J=7.83 Hz, 1 H) , 7.04 (d, J=10.17 Hz, 1 H) , 6.99 (s, 1 H) , 6.83 (d, J=6.65 Hz, 1 H) , 5.30 (s, 2 H) , 4.76 (t, J=8.61 Hz, 1 H) , 3.31-3.39 (m, 1 H) , 3.07-3.20 (m, 1 H) , 2.97 (d, J=7.04 Hz, 1 H) , 2.42-2.55 (m, 2 H) , 1.95 (t, J=11.35 Hz, 1 H) , 1.42 (s, 3 H) , 1.25 (s, 3 H) , 1.22 (d, J=2.35 Hz, 1 H) . MS (ESI) m /e (M+H +) : 512.2.
[1108]
In a similar manner, compound A10-5B was treated with LiOH to afford, after purification by reverse preparative HPLC (preparative HPLC on a GILSON 281 instrument fitted with a Phenomenex Synergi C18 150*30mm*4um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 62-92%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) , compound A10-6B. 1H NMR (400 MHz, MeOD-d 4) δ: 8.10 (s, 1 H) , 7.70 (d, J=7.83 Hz, 1 H) , 7.46-7.57 (m, 1 H) , 7.35-7.43 (m, 1 H) , 7.14 (d, J=7.83 Hz, 1 H) , 7.04-7.09 (m, 2 H) , 6.87 (d, J=6.65 Hz, 1 H) , 5.32 (s, 2 H) , 4.78 (t, J=8.61 Hz, 1 H) , 3.32-3.40 (m, 1 H) , 3.11-3.24 (m, 1 H) , 3.00 (d, J=7.04 Hz, 1 H) , 2.43-2.57 (m, 2 H) , 1.97 (t, J=11.35 Hz, 1 H) , 1.44 (s, 3 H) , 1.27 (s, 4 H) . MS (ESI) m /e (M+H +) : 512.2.
[1109]
EXAMPLE 24
[1110]
(5aR, 6R, 6aR) -5, 5-difluoro-3- ( (6-fluoro-1, 1-dimethyl-3- (2- (trifl uoromethyl) phenyl) -2, 3-dihydro-1 H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A11-3)
[1111]


[1112]
Step A: (5aR, 6R, 6aR) -tert-butyl 5, 5-difluoro-3- ( (6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) ph enyl) -2, 3-di hydro-1H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2- c] pyridine-6-carboxylate (A11-2) To a solution of compound A10-3 (50 mg, 0.166 mmol) in toluene (10 ml) was added intermediate 1-12 (67.3 mg, 0.199 mmol) , Cs 2CO 3 (162 mg, 0.497 mmol) and Bret-Phos Palladacycle (13.24 mg, 0.017 mmol) . The mixture was stirred at 120 ℃ under N 2 overnight . After cooling to room temperature, the mixture was filtered and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, and concentrated in vacuo to give crude compound A11-2, which was used in the step without purification. MS (ESI) m /e (M+H +) : 604.2.
[1113]
Step B: (5aR, 6R, 6aR) -5, 5-difluoro-3- ( (6-fluoro-1, 1-dimethyl-3- (2- (trifl uoromethyl) phenyl) -2, 3- dihydro-1 H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylic acid (A11-3) To a mixture of compound A11-2 (crude, 65 mg) in MeOH (1.00 mL) , THF (1.00 mL) and water (1.00 mL) was added LiOH (120 mg, 5.01 mmol) and the resulting mixture was stirred at room temperature for 2 h. The reaction mixture was acidified with HCl (2 N) to pH=7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to obtain a residue, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a YMC-Actus Triart C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.05%Ammonia, v/v) , mobile phase B: acetonitrile. Gradient: 51-81%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to give compound A11-3. 1H NMR (400 MHz, MeOD-d 4) δ: 8.17 (br. s., 1H) , 7.71 (d, J=7.83 Hz, 1H) , 7.48 (d, J=7.43 Hz, 1H) , 7.40 (d, J=6.65 Hz, 1H) , 7.12 (d, J=7.43 Hz, 1H) , 7.02 (d, J=10.17 Hz, 1H) , 6.77-6.84 (m, 2H) , 5.32 (s, 2H) , 4.73-4.81 (m, 1H) , 3.17 (br. s., 1H) , 2.83 (br. s., 1H) , 2.49 (dd, J=7.43, 12.52 Hz, 1H) , 1.95 (t, J=11.35 Hz, 1H) , 1.88 (br. s., 1H) , 1.44 (s, 3H) , 1.27 (s, 3H) . MS (ESI) m /e (M+H +) : 548.1.
[1114]
EXAMPLE 25
[1115]
(5aR, 6S, 6aS) -3- ( (6-fluoro-1, 1-dimethyl-3- (3- (trifluoromethyl) pyridin-4-yl) -2, 3-dihydro-1H-inden- 5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A12-8)
[1116]


[1117]
Step A: ethyl 6-fluoro-1, 1-dimethyl-3- ( ( (trifluoromethyl) sulfonyl) oxy) -1H-indene-5-carboxylate (A12-1) To a solution of intermediate 2-7 (3.50 g, 13.99 mmol) in dry DCM (40 mL) at 0 ℃ was added trifluoromethanesulfonic anhydride (7.89 g, 28.0 mmol) dropwise. The mixture was stirred for 2 h at room temperature, and then quenched with saturated aqueous NaHCO 3 (30 mL) and extracted with DCM (50 mL) three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to give a residue which was purified by column chromatography over silica gel (eluting with PE: EA=100: 0 to 90: 10) to give compound A12-8. MS (ESI) m /e (M+H +) : 254.2.
[1118]
Step B: ethyl 6-fluoro-1, 1-dimethyl-3- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indene-5- carboxylate (A12-2) To a solution of compound A12-1 (1.50 g, 1.962 mmol) in 1, 4-dioxane (15 mL) was added 4, 4, 4' , 4' , 5, 5, 5' , 5' -octamethyl-2, 2' -bi (1, 3, 2-dioxaborolane) (598 mg, 2.354 mmol) , potassium acetate (0.578 g, 5.89 mmol) and PdCl 2 (dppf) (144 mg, 0.196 mmol) . The reaction mixture was heated at 90 ℃ under an atmosphere of N 2 for 12 hours. After cooling, the mixture was filtered over Celite then concentrated in vacuo to provide a residue, which was purified by column chromatography over silica gel (eluting with PE: EA=100: 0 to 90: 10) to give compound A12-2.
[1119]
Step C: ethyl 6-fluoro-1, 1-dimethyl-3- (3- (trifluoromethyl) pyridin-4-yl) -1H-indene-5-carboxylate (A12-3) A mixture of compound A12-2 (200 mg, 0.555 mmol) , 4-bromo-3- (trifluoromethyl) pyridine (125 mg, 0.555 mmol) , K 3PO 4 (354 mg, 1.666 mmol) and Pd (dtbpf) Cl 2 (36 mg, 0.056 mmol) in THF (6 mL) and water (2 mL) was microwaved to 100 ℃ for 30 mins under nitrogen atmosphere. After cooling to room temperature, the reaction was filtered and the filtrate was extracted with EtOAc. The combined organic layers were washed with water, dried over Na 2SO 4 and concentrated in vacuo to obtain a residue, which was purified by flash chromatography over silica gel (eluting with PE: EA=5: 1) to give compound A12-3.
[1120]
Step D: ethyl 6-fluoro-1, 1-dimethyl-3- (3- (trifluoromethyl) pyridin-4-yl) -2, 3-dihydro-1H-indene-5- carboxylate (A12-4) To a stirred solution of compound A12-3 (165 mg, 0.435 mmol) in MeOH (15 mL) and THF (5 mL) was added 10%Pd/C (9 mg, 0.087 mmol) and the reaction was stirred at 25 ℃ under H 2 (1 atm) for 16 hrs. The mixture was filtered and the filtrate was concentrated in vacuo to afford crude compound A12-4, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 382.2.
[1121]
Step E: (6-fluoro-1, 1-dimethyl-3- (3- (trifluoromethyl) pyridin-4-yl) -2, 3-dihydro-1H-inden-5-yl) methanol (A12-5) To a stirred solution of A12-4 (156 mg, 0.409 mmol) in THF (5 mL) was added lithium aluminum (III) hydride (39 mg, 1.023 mmol) at 0 ℃ and the mixture was stirred for 1 h. The mixture was quenched with water (0.03 mL) and NaOH (0.03mL, 15%) carefully and stirred for 15 mins. The reaction was then filtered, and the filtrate was concentrated in vacuo to give crude compound A12-5, which was used in the next step directly.
[1122]
Step F: (6- (bromomethyl) -5-fluoro-3, 3-dimethyl-2, 3-dihydro-1H-inden-1-yl) -3- (trifluoromethyl) pyridine (A12-6) To a solution of crude compound A12-5 (110 mg, 0.324 mmol) in dry DCM (5.00 mL) at 0 ℃ was added PBr 3 (43.9 mg, 0.162 mmol) dropwise. The reaction was stirred for 3 h at 0 ℃ then warmed to 20 ℃ and stirred for 2 h. The reaction mixture was quenched with water, neutralized with saturated aqueous NaHCO 3 to pH = 7, and extracted with EtOAc three times. The combined organic layers were dried over Na 2SO 4 and concentrated in vacuo to afford crude compound A12-6, which was used in the next step without purification.
[1123]
Step G: (5aR, 6S, 6aS) -ethyl 3- ( (6-fluoro-1, 1-dimethyl-3- (3- (trifluoromethyl) pyridin-4-yl) -2, 3- dihydro-1H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylate (A12-7) A mixture of crude compound A12-6 (90 mg, 0.224 mmol) , intermediate 1-9 (49.1 mg, 0.224 mmol) and Ag 2CO 3 (154 mg, 0.559 mmol) in toluene (5.00 mL) was heated at 120 ℃ for 2 hrs. The reaction was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by column chromatography over silica gel (eluting with PE: EA=100: 0 to 70: 30) to provide compound A12-7. MS (ESI) m /e (M+H +) : 541.3.
[1124]
Step H: (5aR, 6S, 6aS) -3- ( (6-fluoro-1, 1-dimethyl-3- (3- (trifluoromethyl) pyridin-4-yl) -2, 3-dihydro- 1H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylic acid (A12-8) To a mixture of compound A12-7 (80 mg, 0.148 mmol) in THF (2 mL) , MeOH (2 mL) and water (2 mL) was added lithium hydroxide (35 mg, 1.480 mmol) and the resulting mixture was stirred at room temperature for 2hrs. The final mixture was acidified with HCl (2 N) to pH=4, and extracted with EtOAc (30 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a Waters XSELECT C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 51-70%B, 0-9 min; 100%B, 9-11 min) to give compound A12-8. 1H NMR (400 MHz, MeOD-d 4) δ: 8.89 (br. s., 1 H) , 8.66 (br. s., 1 H) , 8.10 (s, 1 H) , 7.24 (d, J=6.26 Hz, 1 H) , 7.10 (d, J=10.17 Hz, 1 H) , 7.00 (br. s., 1 H) , 6.92 (d, J=3.91 Hz, 1 H) , 5.32 (s, 2 H) , 3.32 -3.41 (m, 1 H) , 3.15 (d, J=19.17 Hz, 1 H) , 2.99 (d, J=5.48 Hz, 1 H) , 2.48-2.59 (m, 2 H) , 1.99 (br. s., 1 H) , 1.45 (s, 3 H) , 1.28 (s, 3 H) , 1.21 (s, 1 H) . MS (ESI) m /e (M+H +) : 513.2.
[1125]
Table 4. Example 26 and 27 (Compounds A12-9 and A12-10) was prepared in a similar manner to Example 25 (Compound A12-8) using the appropriate intermediates and commercially available materials, and including procedures described across this application when necessary.
[1126]


[1127]


[1128]
EXAMPLE 28
[1129]
(6S) -3- ( (6-fluoro-1, 1-dimethyl-3- (4- (3- (methylsulfonyl) propoxy) -2- (trifluoromethyl) phenyl) -2, 3- dihydro-1H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylic acid (Compound A13-6)
[1130]


[1131]
Step A: ethyl 6-fluoro-1, 1-dimethyl-3- (4- (3- (methylsulfonyl) propoxy) -2- (trifluoromethyl) phenyl) -1H-indene-5-carboxylate (A13-1) A mixture of compound A12-2 (130 mg, 0.36 mmol) , 1-bromo-4- (3- (methylsulfonyl) propoxy) -2- (trifluoromethyl) benzene (143 mg, 0.39 mmol; prepared according to WO2014/022528) , K 2CO 3 (99 mg, 0.72 mmol) and Pd (dppf) Cl 2 (15 mg) in THF/H 2O (2 mL/0.5 mL) was microwaved at 100 ℃ for 30 min. The reaction mixture was cooled, diluted with H 2O (10 mL) then extracted with EtOAc (20 mL) twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, and concentrated in vacuo. The resulting residue was purified by column chromatography over silica gel (eluting with PE: EA=1: 1) to afford compound A13-1.
[1132]
Step B: ethyl 6-fluoro-1, 1-dimethyl-3- (4- (3- (methylsulfonyl) propoxy) -2- (trifluoromethyl) phenyl) - 2, 3-dihydro-1H-indene-5-carboxylate (A13-2) A mixture of compound A13-1 (130 mg, 0.25 mmol) and 10%Pd/C (20 mg) in MeOH (5 mL) was hydrogenated (1 atm) at room temperature overnight. The reaction was then filtered; and the filtrate was concentrated to give crude compound A13-2. Step C: (6-fluoro-1, 1-dimethyl-3- (4- (3- (methylsulfonyl) propoxy) -2- (trifluoromethyl) phenyl) -2, 3- dihydro-1H-inden-5-yl) methanol (A13-3) To a stirred solution of LiAlH 4 (14 mg, 0.37 mmol) in dry THF (5 mL) was added compound A13-2 (132 mg, 0.25 mmol) at room temperature and the reaction was stirred for 2 hours. The reaction mixture was quenched with water and NaOH carefully, and stirred for 15 min. The reaction was then filtered, and the filtrate was concentrated in vacuo to give crude compound A13-3, which was used in the next step directly.
[1133]
Step D: 5- (bromomethyl) -6-fluoro-1, 1-dimethyl-3- (4- (3- (methylsulfonyl) propoxy) -2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene (A13-4) To a stirred solution of crude compound A13-3 (45 mg, 0.095 mmol) in dry DCM (5 mL) at room temperature was added PBr 3 (27 mg, 0.1 mmol) . The reaction mixture was stirred for 2 hours, and then concentrated to give crude compound A13-4, which was used in the next step directly.
[1134]
Step E: (6S) -ethyl 3- ( (6-fluoro-1, 1-dimethyl-3- (4- (3- (methylsulfonyl) propoxy) -2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methoxy) -5, 5a, 6, 6a- tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A13-5) A mixture of crude compound A13-4 (22 mg, 0.041 mmol) , intermediate 1-9 (8 mg, 0.037 mmol) and Ag 2CO 3 (20 mg, 0.074 mmol) in toluene (2 mL) was heated at reflux overnight. The cooled mixture was dissolved in H 2O (10 mL) and extracted with EtOAc (20 mL) twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by column chromatography over silica gel (eluting with PE: EA=1: 1) to afford compound A13-5.
[1135]
Step F: (6S) -3- ( (6-fluoro-1, 1-dimethyl-3- (4- (3- (methylsulfonyl) propoxy) -2- (trifluoro- methyl) phenyl) -2, 3-dihydro-1H-inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] - cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A13-6) A solution of compound A13-5 (10 mg, 0.014 mmol) and LiOH (4 mg, 0.14 mmol) in THF/MeOH/H 2O (3 mL/0.5 mL/0.5 mL) was stirred at room temperature overnight. The final mixture was acidified with HCl (2 N) to pH=7 and extracted with EtOAc (20 mL) twice. The combined organic layers were washed with brine, dried over Na 2SO 4, concentrated in vacuo and the residue was purified by preparative HPLC (on a GILSON 281 instrument fitted with a Phenomenex Gemini C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 70-9%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to give compound A13-6. 1H NMR (400 MHz, MeOD-d 4) δ: 7.96 (d, J=9.59 Hz, 1H) , 7.23 (br. s., 1H) , 7.00-7.10 (m, 2H) , 6.98 (d, J=9.59 Hz, 1H) , 6.80 (d, J=3.72 Hz, 1H) , 6.58 (br. s., 1H) , 5.23 (d, J=5.09 Hz, 2H) , 4.67 (br. s., 1H) , 4.17 (t, J=5.77 Hz, 2H) , 3.35 (br. s., 2H) , 3.19 (br. s., 1H) , 2.94-3.10 (m, 4H) , 2.89 (br. s., 1H) , 2.38-2.47 (m, 2H) , 2.26-2.34 (m, 2H) , 1.89 (d, J=6.65 Hz, 1H) , 1.42 (br. s., 3H) , 1.28 (br. s., 3H) , 1.12 (br. s., 1H) . MS (ESI) m /e (M+H +) : 648.6.
[1136]
Table 5. Examples 29 to 31 (compounds A13-7 to A13-9) were prepared in a similar manner to Example 28 (Compound A13-6) using the appropriate intermediates and commercially available materials, and including procedures described across this application when necessary.
[1137]


[1138]


[1139]
EXAMPLE 32
[1140]
(5aR, 6S, 6aS) -3- ( (5-fluoro-3, 3-dimethyl-1- (2- (trifluoromethyl) phenyl) indolin-6-yl) methoxy) - 5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylicacid (Compound A14-7)
[1141]


[1142]
Step A: 5-fluoro-3, 3-dimethylindoline (A14-1) 4-fluorophenylhydrazine hydrochloride (10.00 g, 61.50 mmol) was added to a stirred solution of isobutyraldehyde (4.43 g, 61.50 mmol) in AcOH (180 mL) and the mixture was stirred at 60 ℃ for 3 h. The mixture was then cooled to room temperature and 1, 2-dichloroethane (180 mL) was added, followed by sodium triacetoxyhydro-borate (13.04 g, 61.50 mmol) in several portions over 30 min at 0 ℃. After completion of the addition, the mixture was allowed to warm to room temperature and stirred for one hour. The reaction mixture was concentrated, washed with saturated aqueous Na 2CO 3, and extracted with EtOAc (300 mL) three times. The combined organic layers were washed with saturated aqueous sodium hydroxide (150 mL) , dried over Na 2SO 4 and the solvent was evaporated under reduced pressure. The resulting residue was purified by column chromatography over silica gel (eluting with PE: EA=50: 1 to 10: 1) to give compound A14-1. MS (ESI) m /e (M+H +) : 166.1.
[1143]
Step B: 6-bromo-5-fluoro-3, 3-dimethylindoline (A14-2) To a solution of compound A14-1 (400 mg, 2.42 mmol) in 98%H 2SO 4 (5 mL) was added Ag 2SO 4 (400 mg, 1.28 mmol) and the suspension was stirred under N 2 atmosphere for 30 min. The mixture was then cooled to -5 ℃, and Br 2 (0.125 mL, 2.42 mmol) was slowly added over 5 min while maintaining the temperature for one hour. The reaction mixture was then slowly poured into 50 mL water/ice and filtered over Celite TM. The filtrate was treated with 50%aqueous NaOH until pH=9-10 and extracted with EtOAc (30 mL) three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography over silica gel (eluting with PE: EA=50: 1 to 10: 1) to give compound A14-2.
[1144]
Step C: 6-bromo-5-fluoro-3, 3-dimethyl-1- (2- (trifluoromethyl) phenyl) indoline (A14-3) To a suspension of compound A14-2 (600 mg, 2.46 mmol) and 1-fluoro-2- (trifluoromethyl) benzene (1210 mg, 7.37 mmol) in dry NMP (10 mL) at 0 ℃ under a N 2 atmosphere was added sodium hydride (177 mg, 7.37 mmol) . The reaction mixture was warmed gradually to 80 ℃ over 3 hours. Then the reaction mixture was cooled to room temperature, poured into water (20 mL) and extracted with EtOAc (20 mL) twice. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to give a residue, which was purified by column chromatography over silica gel (eluting with PE 100%) to give compound A14-3. MS (ESI) m /e (M+H +) : 388.0, 390.0.
[1145]
Step D: 6-bromo-5-fluoro-3, 3-dimethyl-1- (2- (trifluoromethyl) phenyl) indoline (A14-4) A mixture of compound A14-3 (650 mg, 1.67 mmol) , and Pd (dppf) Cl 2 (61 mg, 0.084 mmol) in MeOH (60 mL) , DMF (20 mL) and Et 3N (20 mL) was heated at 80 ℃ for 24 hours under CO atmosphere (50 psi) . The reaction mixture was then washed with saturated aqueous NH 4Cl, extracted with EtOAc (50 mL) twice and concentrated. The resulting residue was purified by column chromatography over silica gel (eluting with PE: EA=10: 1) to give compound A14-4. MS (ESI) m /e (M+H +) : 368.1.
[1146]
Step E: methyl 5-fluoro-3, 3-dimethyl-1- (2- (trifluoromethyl) phenyl) indoline-6-carboxylate (A14-5) To a solution of compound A14-4 (110 mg, 0.29 mmol) in dry THF (3 mL) at 0 ℃ was added lithium aluminum (III) hydride (13 mg, 0.35 mmol) . After completion of the addition, the mixture was stirred at this temperature for 1h. Then the reaction was quenched with anhydrous Na 2SO 4 (2 g) and water (1 mL) and the resulting mixture was filtered over Celite TM, rinsing with EtOAc (20 mL) . The filtrate was concentrated in vacuo to give compound A14-5, which was used in the next step directly.
[1147]
Step F: (5aR, 6S, 6aS) -ethyl3- ( (5-fluoro-3, 3-dimethyl-1- (2- (trifluoromethyl) phenyl) indolin-6-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A14-6) A mixture of compound A14-5 (60 mg, 0.25 mmol) , intermediate 1-10 (85 mg, 0.25 mmol) , Brett-Phos palladacycle (10 mg, 0.013 mmol) and Cs 2CO 3 (204 mg, 0.63 mmol) in toluene (10 mL) was heated at 110 ℃ for 10 hours. The mixture was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified with preparative TLC over silica gel (eluting with PE: EA=5: 1) to give compound A14-6. MS (ESI) m /e (M+H +) : 541.2.
[1148]
Step G: (5aR, 6S, 6aS) -3- ( (5-fluoro-3, 3-dimethyl-1- (2- (trifluoromethyl) phenyl) indolin-6-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylicacid (A14-7) To a mixture of compound A14-6 (80 mg, 0.15 mmol) in THF (1 mL) , MeOH (1 mL) and H 2O (1 mL) was added lithium hydroxide monohydrate (62 mg, 1.48 mmol) and the resulting mixture was stirred at room temperature for 5 hours. The reaction mixture was acidified with HCl (2 N) to pH=7 and extracted with EtOAc (20 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to give a residue, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a Waters XSELECT C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 58-88%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to give compound A14-7. 1H NMR (400 MHz, MeOD-d 4) δ: 1.21 (br. s., 1 H) 1.37 (br. s., 6 H) 2.42-2.54 (m, 1 H) 2.96 (d, J=5.09 Hz, 1 H) 3.06-3.16 (m, 1 H) 3.39-3.66 (m, 2 H) 5.21 (s, 2 H) 6.12 (d, J=5.87 Hz, 1 H) 6.85-6.99 (m, 2 H) 7.39-7.52 (m, 2 H) 7.67 (t, J=7.63 Hz, 1 H) 7.78 (d, J=7.43 Hz, 1 H) 8.06 (s, 1 H) . MS (ESI) m /e (M+H +) : 513.2.
[1149]
EXAMPLE 33
[1150]
(5aR, 6S, 6aS) -3- ( (1- (2- (trifluoromethyl) phenyl) indolin-6-yl) methoxy) -5, 5a, 6, 6a-tetra hydro cyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A15-6)
[1151]


[1152]
Step A: 1- (2-Trifluoromethyl-phenyl) -1H-indole-6-carboxylic acid methyl ester (A15-1) To a suspension of 1H-Indole-6-carboxylic acid methyl ester (600 mg, 2.46 mmol) and 1-fluoro-2-(trifluoromethyl) benzene (1210 mg, 7.37 mmol) in dry NMP (10 mL) at 0 ℃ was added sodium hydride (177 mg, 7.37 mmol) under N 2. After completion of the addition, the reaction was warmed gradually to 80 ℃ for 3 hours. The reaction mixture was then cooled to room temperature, poured into water (20 mL) and extracted with EtOAc (20 mL) twice. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to give a residue, which was purified by column chromatography over silica gel (eluting with PE) to give compound A15-1 which was used in the next step without purification.
[1153]
StepB: methyl 1- (2- (trifluoromethyl) phenyl) indoline-6-carboxylate (A15-1) To a mixture of compound A15-1 (300 mg, 0.94 mmol) in TFA (10 mL) was added NaCNBH 3 (975 mg, 14.1 mmol) portionwise at 0 ℃ under N 2 atmosphere. After the addition was complete, the reaction mixture was stirred at room temperature for 24 hours. The whole reaction was poured into aqueous Na 2CO 3 (4M, 150 mL) and the product was extracted with EtOAc. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to give compound A15-2, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 322.1.
[1154]
Step C: (1- (2- (trifluoromethyl) phenyl) indolin-6-yl) methanol (A15-3) To a suspension of LiAlH 4 (63 mg, 1.66 mmol) in dry THF (15 mL) at 0 ℃ was added a solution of compound A15-2 (266 mg, 0.83 mmol) in THF (2 mL) dropwise. After completion of the addition, the mixture was stirred at 0 ℃ for 1 h. The mixture was quenched with saturated aqueous NH 4Cl and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, filtered and concentrated in vacuo to afford crude compound A15-3, which was used in the next step without purification. MS (ESI) m /e (M+H +) : 294.1.
[1155]
Step D: 6- (bromomethyl) -1- (2- (trifluoromethyl) phenyl) indoline (A15-4) To a solution of crude compound A15-3 (190 mg, 0.65 mmol) in dry DCM (8 mL) at 0 ℃ was added PBr 3 (193 mg, 0.71 mmol) dropwise. The reaction solution was stirred at 0 ℃ for 1h, then warmed to 20 ℃ and stirred for another 3 hrs. The reaction mixture was quenched with water, neutralized with saturated aqueous NaHCO 3 to pH=7, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, filtered and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel (PE: EA=10: 1) to afford compound A15-4. MS (ESI) m /e (M+H +) : 356.0, 358.0.
[1156]
Step E: (5aR, 6S, 6aS) -ethyl 3- ( (1- (2- (trifluoromethyl) phenyl) indolin-6-yl) methoxy) -5, 5a, 6, 6a- tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A15-5) A mixture of compound A15-4 (139 mg, 0.39 mmol) , intermediate 1-9 (85 mg, 0.39 mmol) and Ag 2CO 3 (322 mg, 1.17 mmol) in toluene (3 mL) was heated at 100 ℃ for 2 hrs. The mixture was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=3: 1) to afford compound A15-5. MS (ESI) m /e (M+H +) : 495.2.
[1157]
Step F: (5aR, 6S, 6aS) -3- ( (1- (2- (trifluoromethyl) phenyl) indolin-6-yl) methoxy) -5, 5a, 6, 6a-tetra hydro cyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A15-6) To a mixture of A15-5 (96 mg, 0.195 mmol) in THF (2 mL) , MeOH (2 mL) and H 2O (2 mL) was added LiOH·H 2O (80 mg, 1.95 mmol) , and the resulting solution was stirred at room temperature for 5 h. The reaction mixture was acidified with HCl (2 N) to pH=7 in an ice-water bath and then filtered, washed with water (5 mL) and dried in vacuo to give compound A15-6. 1H NMR (400 MHz, MeOD-d 4) δ: 7.99 (s, 1 H) , 7.79 (d, J=7.83 Hz, 1 H) , 7.64-7.72 (m, 1 H) , 7.40-7.52 (m, 2 H) , 7.12 (d, J=7.43 Hz, 1 H) , 6.76 (d, J=7.04 Hz, 1 H) , 6.60 (s, 1 H) , 6.09 (s, 1 H) , 5.08 (s, 2 H) , 3.18-3.26 (m, 1 H) , 3.12 (br. s., 2 H) , 2.97-3.04 (m, 1 H) , 2.90 (d, J=5.09 Hz, 1 H) , 2.37-2.45 (m, 1 H) , 1.12 (br. s., 1 H) . MS (ESI) m /e (M+H +) : 467.2.
[1158]
Table 6. Examples 34 to 37 (Compounds A15-7 to A15-10) were prepared in a similar manner to Example 33 (Compound A15-6) using the appropriate intermediates and commercially available materials, and including procedures described across this application when necessary.
[1159]


[1160]


[1161]
EXAMPLES 38 and 39
[1162]
(Compounds A16-8 and A16-9)
[1163]


[1164]
Step A: 2- (4- (ethoxycarbonyl) -2- (2- (trifluoromethyl) benzoyl) phenyl) -2-methylpropanoic acid (A16-1) To a biphasic system of compound 3-5 (1.50 g, 4.16 mmol) and sodium periodate (7.12 g, 33.30 mmol) in CCl 4 (10 mL) , acetonitrile (10 mL) and water (15 mL) was added ruthenium (III) chloride (0.432 g, 2.08 mmol) . The reaction mixture was stirred vigorously overnight, then 10 mL of DCM and 5 mL of H 2O were added, and the organic layer was separated. The aqueous layer was further extracted with DCM (35 mL) , and the combined organic layers were dried over MgSO 4 and concentrated in vacuo. The resulting residue was purified by column chromatography over silica gel (eluting with PE: EA=1: 1) to give compound A16-1. MS (ESI) m /e (M+H +) : 409.1.
[1165]
Step B: ethyl 1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -1H-isoindole-5-carboxylate (A16-2) To a solution of compound A16-1 (900 mg, 2.20 mmol) in 1, 4-dioxane (20 mL) was added diphenyl phosphorazidate (607 mg, 2.20 mmol) , followed by triethylamine (223 mg, 2.20 mmol) . The reaction was stirred at room temperature for 12 h, then 6 mL of 1 M HCl was added and the mixture was refluxed for 1 hr. Then the reaction mixture was cooled, concentrated, treated with saturated aqueous Na 2CO 3 until pH=10, and then extracted with EtOAc. The combined organic layers were combined and concentrated to give a residue, which was purified by chromatography over silica gel (eluting with PE: EA=2: 1) to provide compound A16-2. MS (ESI) m /e (M+H +) : 362.2.
[1166]
Step C: ethyl 1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) isoindoline-5-carboxylate (A16-3) 10%Pd/C (88. mg, 0.83 mmol) ) was added to a solution of compound A16-2 (300 mg, 0.83 mmol) in 2-propanol (50 mL) and the resulting mixture was stirred at 50 ℃ under H 2 (50 psi) for 12 h. The mixture was filtered over Celite TM and the filtrate was concentrated in vacuo to give compound A16-3, which was used directly in the next step. MS (ESI) m /e (M+H +) : 364.1.
[1167]
Step D: (1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) isoindolin-5-yl) methanol (A16-4) To a suspension of LiAlH 4 (75 mg, 1.97 mmol) in dry THF (2 mL) at 0 ℃ was added a solution of compound A16-3 (143 mg, 0.39 mmol) in THF (2 mL) dropwise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 12 h. The reaction was then carefully quenched with water and 10%aq. NaOH and diluted with another 10 mL of THF. The resulting precipitate was removed by filtration and the filtrate was concentrated to provide crude compound A16-4, which was used in the next step directly. MS (ESI) m /e (M+H +) : 322.1.
[1168]
Step E: 5- (bromomethyl) -1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) isoindoline (A16-5) To a solution of crude compound A16-4 (45.0 mg, 0.14 mmol) in dry CH 2Cl 2 (15 mL) at 0 ℃ was added PBr 3 (30.3 mg, 0.11 mmol) dropwise. The reaction was stirred at 0 ℃ for 1 h, then warmed to 20 ℃ and stirred for another 3 h. The reaction was then quenched with water, neutralized with saturated aqueous NaHCO 3 until pH=7, and then extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4 and concentrated in vacuo to afford crude compound A16-5, which was used in the next step directly.
[1169]
Step F: 5- (bromomethyl) -1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) isoindoline (A16-6) A mixture of crude compound A16-5 (88 mg, 0.23 mmol) , intermediate 1-9 (50 mg, 0.23 mmol) and Ag 2CO 3 (189 mg, 0.68 mmol) in toluene (20 mL) was heated to 100 ℃ for 2 h. Then the reaction was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by preparative TLC over silica gel to afford compound A16-6. MS (ESI) m /e (M+H +) : 523.3.
[1170]
Step G: (5aR, 6S, 6aS) -ethyl 3- ( (1, 1, 2-trimethyl-3- (2- (trifluoromethyl) phenyl) isoindolin-5- yl) methoxy-5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A16-7) A mixture of compound A16-6 (40 mg, 0.08 mmol) , iodomethane (22 mg, 0.15 mmol) and K 2CO 3 (32 mg, 0.23 mmol) in DMF (10 mL) was heated at 100 ℃ for 12 h. The reaction was cooled and concentrated, and the resulting residue was diluted with EtOAc (50 mL) and washed with aqueous saturated NaHCO 3 (30 mL) , and then brine (30 mL) . The organic layer was dried over Na 2SO 4, and concentrated under reduced pressure. The resulting residue was purified by preparative TLC over silica gel (eluting with PE: EA=3: 1) to give compound A16-7. MS (ESI) m /e (M+H +) : 537.3.
[1171]
Step H: (5aR, 6S, 6aS) -3- ( (1, 1, 2-trimethyl-3- (2- (trifluoromethyl) phenyl) isoindolin-5-yl) methoxy) - 5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A16-8) To a mixture of compound A16-7 (40 mg, 0.08 mmol) in THF (1mL) , MeOH (1 mL) and H 2O (1mL) was added LiOH (37 mg, 1.53 mmol) , and the resulting mixture was stirred at room temperature for 12 h. The reaction mixture was acidified with HCl (1 N) to pH=6, and extracted with EtOAc (20 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by reverse preparative HPLC (on a GILSON 281 instrument fitted with a Phenomenex Gemini C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 23-43%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to give compound A16-8. 1H NMR (400 MHz, MeOD-d 4) δ: 8.01 (s, 2 H) , 7.77-7.82 (m, 2 H) , 7.61-7.67 (m, 1 H) , 7.55 (d, J=7.53 Hz, 1 H) , 7.42 (br. s., 1 H) , 6.88 (br. s., 1 H) , 6.71 (s, 1 H) , 6.08 (br. s., 1 H) , 5.26-5.36 (m, 2 H) , 3.24 (br. s., 1 H) , 3.02-3.12 (m, 1 H) , 2.89-2.97 (m, 4 H) , 2.47 (br. s., 1 H) , 1.96 (s, 3 H) , 1.70 (s, 3 H) , 1.12-1.18 (m, 1 H) . MS (ESI) m /e (M+H +) : 509.2.
[1172]
Step I: (5aR, 6S, 6aS) -3- ( (1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) isoindolin-5-yl) methoxy) - 5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A16-9) To a mixture of compound A16-6 (40 mg, 0.08 mmol) in THF (2 mL) , MeOH (2 mL) and H 2O (2 mL) was added LiOH (37 mg, 1.53 mmol) , and the resulting mixture was stirred at room temperature for 12 hrs. Then the reaction mixture was acidified with HCl (1 N) to pH=6, and extracted with EtOAc (30 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by reverse preparative HPLC (preparative HPLC on a GILSON 281 instrument fitted with a YMC-pack ODS-AQ 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 25-55%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to give compound A16-9. 1H NMR (400 MHz, MeOD-d 4) δ: 8.02 (s, 1 H) , 7.94 (d, J=7.53 Hz, 1 H) , 7.61-7.75 (m, 3 H) , 7.51 (d, J=8.03 Hz, 1 H) , 7.11-7.18 (m, 2 H) , 6.71 (s, 1 H) , 6.42 (s, 1 H) , 5.30-5.40 (m, 2 H) , 3.20-3.29 (m, 1 H) , 2.99-3.10 (m, 1 H) , 2.93 (d, J=4.77 Hz, 1 H) , 2.38-2.49 (m, 1 H) , 1.80 (s, 6 H) , 1.13 (dt, J=6.09, 2.85 Hz, 1 H) . MS (ESI) m /e (M+H +) : 495.2.
[1173]
EXAMPLE 40
[1174]
(5aR, 6S, 6aS) -3- ( (3-methyl-3- (2- (trifluoromethyl) phenyl) -1, 3-dihydroisobenzofuran-5-yl) methoxy) - 5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A17-4)
[1175]


[1176]
Step A: 1- (2, 5-bis ( (methoxymethoxy) methyl) phenyl) -1- (2- (trifluoromethyl) phenyl) ethanol (A17-1) To a solution of intermediate 5-5 (300 mg, 0.76 mmol) in anhydrous DCM (3 mL) , was added MeMgBr (0.75 ml, 3.0 eq) at 0 ℃ under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature overnight, and then quenched with saturated aqueous NH 4Cl, diluted with DCM and H 2O, then extracted with DCM twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to obtain compound A17-1, which was used in the next step without further purification.
[1177]
Step B: 6- (chloromethyl) -1-methyl-1- (2- (trifluoromethyl) phenyl) -1, 3-dihydroisobenzofuran (A17-2) A solution of compound A17-1 (230 mg, 0.555 mmol) in 1, 4-dioxane (5.0 mL) and concentrated HCl (5.0 mL) was heated under refluxed overnight. Then the reaction mixture was concentrated in vacuo to obtain a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=3: 1) to afford compound A17-2. MS (ESI) m /e (M+H +) : 327.2.
[1178]
Step C: (5aR, 6S, 6aS) -ethyl 3- ( (3-methyl-3- (2- (trifluoromethyl) phenyl) -1, 3-dihydroisobenzofuran-5- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A17-3) To a solution of compound A17-2 (20 mg, 0.06 mmol) in toluene (2 mL) were added Ag 2CO 3 (25.3 mg, 1.5eq) and intermediate 1-9 (13.2 mg, 0.06 mmol) . The reaction mixture was stirred at 120 ℃ for 18 hours, then cooled, filtered through Celite TM and concentrated in vacuo. The resulting residue was purified by preparative TLC over silica gel to afford compound A17-3. MS (ESI) m /e (M+H +) : 524.4
[1179]
Step D: (5aR, 6S, 6aS) -3- ( (3-methyl-3- (2- (trifluoromethyl) phenyl) -1, 3-dihydroisobenzofuran-5- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A17- 4) To a mixture of compound A17-3 (10.0 mg, 0.019 mmol) in THF (0.5 mL) , MeOH (0.5 mL) and H 2O (0.5 mL) was added LiOH (5.0 mg, 10.0 eq) . The reaction mixture was stirred at room temperature for 3 h, then acidified with HCl (2 N) to pH=6 and extracted with EtOAc (5 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A17-4. 1H NMR (400 MHz, MeOD-d 4) δ: 8.07 (s, 1H) , 7.76 (d, J=8.8HZ, 1H) , 7.60 (d, J=8HZ, 1H) , 7.51-7.43 (m, 2H) , 7.42-7.33 (m, 2H) , 7.25 (d, J=8HZ, 1H) , 6.67 (s, 1H) , 5.34 (s, 2H) , 5.00 (d, J=12HZ, 1H) , 4.88-4.84 (m, 1H) , 3.29-3.21 (m, 1H) , 3.04 (d, J=16HZ, 1H) , 2.93 (d, J=8HZ, 1H) , 2.47-2.40 (m, 1H) , 1.87 (s, 3H) , 1.14 (s, 1H) . MS (ESI) m /e (M+H +) : 496.2.
[1180]
EXAMPLE 41
[1181]
(5aR, 6S, 6aS) -3- ( (6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -1, 3-dihydroisobenzofuran-5- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A18-9)
[1182]


[1183]
Step A: (2-bromo-5-fluoro-1, 4-phenylene) dimethanol (A18-2) A mixture of methyl 5-bromo-2-fluoro-4-formylbenzoate A18-1 (1.0 g, 3.83 mmol) in THF (10 ml) at 0 ℃ under nitrogen was treated with LiAlH 4 (0.363 g, 9.58 mmol) . The reaction mixture was stirred at that temperature for 12 hours, then Na 2SO 4 (6.0 g) was added. The resulting mixture was quenched with water slowly, then filtered and concentrated in vacuo. The resulting residue was purified by column chromatography over silica gel (eluting with PE: EA=3: 1) to give compound A18-2. MS (ESI) m /e (M-OH -) : 216.3/218.3.
[1184]
Step B: 1-bromo-4-fluoro-2, 5-bis ( (methoxymethoxy) methyl) benzene (A18-3) A solution of compound A18-2 (0.5 g, 2.127 mmol) in DMF (5.0 ml) at 0 ℃ was treated with N-ethyl-N-isopropylpropan-2-amine (0.412 g, 3.19 mmol) , followed by the dropwise addition of chloro (methoxy) methane (0.685 g, 8.51 mmol) . The reaction was allowed to warm to room temperature and stirred for 18 hrs. The reaction mixture was then filtered and extracted with EtOAc (10 ml) three times. The combined organic layers were washed with water and brine, dried over Na 2SO 4, filtered and concentrated in vacuo to give a residue, which was purified by flash chromatography over silica gel (eluting with PE: EA=8: 1) to give compound A18-3.
[1185]
Step C: (4-fluoro-2, 5-bis ( (methoxymethoxy) methyl) phenyl) (2- (trifluoromethyl) phenyl) methanol (A18-4) To a solution of compound A18-3 (0.4 g, 1.238 mmol) in THF (5.0 ml) at -78 ℃ was added n-BuLi (2.5N in hexanes, 0.743 ml, 1.857 mmol) and the resulting solution was stirred at that temperature for 30 min. Then, 2- (trifluoromethyl) benzaldehyde (0.323 g, 1.857 mmol) in 0.5 ml of THF was added dropwise to the reaction and the reaction mixture was stirred at -78 ℃ for 30 min. Then the reaction was quenched with 1N HCl, and extracted with EtOAc. The combined EtOAc layers were washed with brine, dried over Na 2SO 4, and concentrated in vacuo to give a residue, which was purified by flash chromatography over silica gel (eluting with PE: EA=3: 1) to afford compound A18-4. MS (ESI) m /e (M+Na +) : 441.4.
[1186]
Step D: 6- (chloromethyl) -5-fluoro-1- (2- (trifluoromethyl) phenyl) -1, 3-dihydroisobenzofuran (A18-5) A solution of compound A18-4 (100 mg, 0.239 mmol) in 1, 4-dioxane (4 ml) and concentrated HCl (4.00 ml) was stirred at 100 ℃ overnight. The reaction mixture was extracted with DCM (5 ml) , and the DCM layer was washed with water, brine, dried over Na 2SO 4, and concentrated in vacuo to provide compound A18-5, which was used in the next step without purification. MS (ESI) m /e (M+H ++ACN) : 394.2.
[1187]
Step E: 5- (chloromethyl) -6-fluoro-3- (2- (trifluoromethyl) phenyl) isobenzofuran-1 (3H) -one (A18-6) A mixture of compound A18-5 (60.0 mg, 0.181 mmol) and PCC (78 mg, 0.363 mmol) in anhydrous DCM (3 ml) was stirred at 50 ℃ overnight. The reaction mixture was filtered through a Celite TM pad and the residue was washed with DCM. The filtrate was concentrated and purified by preparative TLC over silica gel to give compound A18-6. MS (ESI) m /e (M+H+) : 345.2.
[1188]
Step F: 2- (4- (chloromethyl) -5-fluoro-2- (hydroxy (2- (trifluoromethyl) phenyl) methyl) -phenyl) propan- 2-ol (A18-7) To a solution of compound A18-6 (35 mg, 0.102 mmol) in THF (2.0 ml) at 0 ℃ was added methylmagnesium bromide (0.085 ml, 0.254 mmol) dropwise. The resulting solution was allowed to warm to room temperature and stirred for 2 h. Then the reaction was quenched with saturated aqueous NH 4Cl, and extracted with EtOAc. The organic layer washed with brine, dried over Na 2SO 4, and concentrated in vacuo to give crude product A18-7, which was used in the next step without purification.
[1189]
Step G: (5aR, 6S, 6aS) -ethyl 3- ( (6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -1, 3– dihydroisobenzofuran-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2- c] pyridine-6-carboxylate (A18-8) To a solution of compound A18-7 (30 mg, 0.064 mmol) in toluene (3 ml) was added Ag 2CO 3 (26.3 mg, 0.096 mmol) and intermediate 1-9 (16.76 mg, 0.076 mmol) . The mixture was stirred at 120 ℃ for 4 hours. Then the reaction mixture was filtered through Celite TM and washed with DCM, The filtrate was concentrated in vacuo to obtain a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=5: 1) to give compound A18-8. MS (ESI) m /e (M+H +) : 541.2.
[1190]
Step H: (5aR, 6S, 6aS) -3- ( (6-fluoro-1, 1-dimethyl-3- (2- (trifluoromethyl) phenyl) -1, 3- dihydroisobenzofuran-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2- c] pyridine-6-carboxylic acid (A18-9) To a mixture of compound A18-8 (15 mg, 0.028 mmol) in THF (1 mL) , MeOH (1 mL) and H 2O (1 mL) was added LiOH (3.32 mg, 0.138 mmol) . The mixture was stirred at room temperature for 3 h, then acidified with HCl (2 N) to pH=6, and extracted with EtOAc (8 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a Phenomenex Synergi C18 100*21.2 mm*4um) using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 66-86%B, 0-10 min; 100%B, 10.5-12.5min; 5%B, 13-15min) to afford compound A18-9. 1H NMR (400 MHz, MeOD-d 4) δ: 8.02 (d, J=3.6 HZ, 1H) , 7.77 (d, J=8.0 HZ, 1H) , 7.64 (t, J=8.0 HZ, 1H) , 7.50 (t, J=8.0 HZ, 1H) , 7.37 (d, J=7.2HZ, 1H) , 7.13 (d, J=9.6 HZ, 1H) , 6.92 (t, J=8.0 HZ, 1H) , 6.74 (s, 1H) , 6.49 (s, 1H) , 5.31 (br. s., 2H) , 3.30-3.22 (m, 1H) , 3.10-3.03 (m, 1H) , 2.94 (d, J=5.6 HZ, 1H) , 2.50-2.44 (m, 1H) , 1.73 (s, 3H) , 1.55 (s, 3H) , 1.16 (s, 1H) . MS (ESI) m /e (M+H +) : 513.2.
[1191]
EXAMPLE 42
[1192]
(5aR, 6S, 6aS) -3- ( (8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl) methoxy) - 5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A19- 9A)
[1193]


[1194]
Step A: methyl 8-oxo-5, 6, 7, 8-tetrahydronaphthalene-2-carboxylate (A19-2) To a mixture of 7-bromo-3, 4-dihydronaphthalen-1 (2H) -one A19-1 (15 g, 67 mmol) and Pd (OAc) 2 (0.75 g, 3.4 mmol) in DMF (20mL) and MeOH (300 mL) were added Xant-Phos (3.9 mg, 4.7 mmol) and Et 3N (34 g, 0.33 mmol) . Then the mixture was heated to 70 ℃ for 48 h under a CO atmosphere (55 psi) . After cooling to room temperature, the reaction was filtered and the filtrate was concentrated in vacuo to afford a residue, which was partitioned between EA and water. The organic layer was separated and the aqueous layer was extracted with EA twice. The combined organic layers were washed with water, dried and concentrated in vacuo to obtain a residue, which was purified by column chromatography over silica gel to afford A19-2. MS (ESI) m /e (M+H +) : 204.1/205.1.
[1195]
Step B: methyl 8- ( ( (trifluoromethyl) sulfonyl) oxy) -5, 6-dihydronaphthalene-2-carboxylate (A19-3) To a solution of compound A19-2 (3 g, 15 mmol) in dry THF (60 mL) at -78 ℃ was added KHMDS (1 M in THF, 20 mL, 20 mmol) dropwise, followed by Tf 2NPh (6.43 g, 18 mmol) . The reaction mixture was allowed to warm to room temperature and stirred for 16 hrs. Then the reaction was quenched with water, and neutralized with aqueous HCl (2N) to pH=7. The organic layer was separated and the aqueous solution was extracted with EtOAc two times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by column chromatography over silica gel to obtain compound A19-3. MS (ESI) m /e (M+H +) : 336.0/337.1.
[1196]
Step C: methyl 8- (2- (trifluoromethyl) phenyl) -5, 6-dihydronaphthalene-2-carboxylate (A19-5) A mixture of compound A19-3 (300 mg, 0.89 mmol) , 2-CF3-phenyl boronic acid (204 mg, 1.07 mmol) ) , K 2CO 3 (308 mg, 2.23 mmol) , and Pd (dppf) Cl 2 (33 mg, 0.04 mmol) in 1, 4-dioxane (5mL) and H 2O (1 mL) was microwaved to 100 ℃ for 30 min under a nitrogen atmosphere. After cooling to room temperature, the reaction was filtered, and the filtrate was extracted with EtOAc. The combined organic layers were washed with water, dried over Na 2SO 4, and concentrated in vacuo to obtain a residue, which was purified by preparative TLC over silica gel to give compound A19-4. MS (ESI) m /e (M+H +) : 332.1/333.0.
[1197]
Step D: methyl 8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalene-2-carboxylate (A19-5) To a solution of compound A19-4 (200 mg, 0.6 mmol) in MeOH (10 mL) and THF (5 mL) was added 10%Pd/C (10 mg) . The reaction was stirred at 25 ℃ under H 2 (1 atm) for 16 hrs. Then the mixture was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by preparative TLC over silica gel to afford compound A19-5. MS (ESI) m /e (M+H +) : 334.1/335.2.
[1198]
Step E: (8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl) methanol (A19-6) To a mixture of LiAlH 4 (137 mg, 3.6 mmol) in dry THF (6 mL) at 0 ℃ was added a solution of compound A19-5 (120 mg, 0.36 mmol) in THF (4 mL) dropwise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 4 hrs. The mixture was then quenched with saturated aqueous NH 4Cl, and extracted with EtOAc twice. The organic layers were combined and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A19-6. MS (ESI) m /e (M+H +) : 306.2/307.1.
[1199]
Step F: 7- (bromomethyl) -1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4-tetrahydronaphthalene (A19-8) To a solution of compound A19-6 (80 mg, 0.26 mmol) in dry THF (2 mL) at 0 ℃ was added PBr 3 (57 mg, 021 mmol) dropwise. The reaction was stirred at 0 ℃ for 1 h, then warmed to 20 ℃ and stirred for 2 hrs. The reaction was quenched with water, and neutralized with saturated aqueous NaHCO 3 to pH=7. The organic layer was separated and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A19-7.
[1200]
Step G: (5aR, 6S, 6aS) -ethyl 3- ( (8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalen-2- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A19-10) A mixture of compound A19-7 (100 mg, 0.27 mmol) , intermediate 1-9 (54 mg, 0.24 mmol) and Ag 2CO 3 (186 mg, 0.68 mmol) in toluene (3 mL) was heated to 120 ℃ for 3 hrs. The reaction was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by Preparative TLC over silica gel to give compound A19-8. MS (ESI) m/e (M+H +) : 507.2/507.5.
[1201]
Step H: (5aR, 6S, 6aS) -3- ( (8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalen-2- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A19- 9) To a solution of compound A19-8 (80 mg) in THF (2 mL) , MeOH (2 mL) and H 2O (2 mL) was added NaOH (32 mg) and the reaction was stirred at room temperature for 5 hrs. The reaction mixture was acidified with HCl (2 N) to pH=5 and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=1: 1) to obtain compound A19-9. 1H NMR (400 MHz, MeOD-d 4) δ: 8.12 (s, 1H), 7.67 (d, J=8 Hz, 1H) , 7.41 (t, J=7.6 Hz, 1H) , 7.34 (t, J=7.6 Hz, 1H) , 7.22-6.99 (m, 3H) , 7.00 (d, J=7.6 Hz, 1H) , 6.68 (d, J=4.8 Hz, 1H) , 5.21 (s, 2H) , 4.50-4.47 (m, 1H) , 3.43-3.35 (m, 1H) , 3.32-3.17 (m, 1H) , 3.03-2.97 (m, 1H) , 2.94-2.88 (m, 1H) , 2.84 (s, 1H) , 2.56-2.51 (m, 1H) , 2.22-2.16 (m, 1H) , 2.03-1.99 (m, 1H) , 1.80-1.76 (m, 1H) , 1.30 (d, J=2.8 Hz, 1H) . MS (ESI) m/e (M+H +) : 480.5.
[1202]
Chiral SFC resolution of compound A19-9 (compound A19-9A) Compound A19-9 was purified by chiral preparative SFC (Column: Chiralcel OD-3 150×4.6 mm I.D., 3um; Mobile phase: iso-propanol in CO 2 from 10% to 50%; Flow rate: 2.5 mL/min; Wavelength: 220nm) . The first peak with shorter retention time is the isomer A19-9A. 1H NMR (400 MHz, MeOD-d 4) δ: 8.12 (s, 1H) , 7.67 (d, J=8 Hz, 1H) , 7.41 (t, J=7.6 Hz, 1H) , 7.34 (t, J=7.6 Hz, 1H) , 7.22-6.99 (m, 3H) , 7.00 (d, J=7.6 Hz, 1H) , 6.68 (d, J=4.8 Hz, 1H) , 5.21 (s, 2H) , 4.50-4.47 (m, 1H) , 3.43-3.35 (m, 1H) , 3.32-3.17 (m, 1H) , 3.03-2.97 (m, 1H) , 2.94-2.88 (m, 1H) , 2.84 (s, 1H) , 2.56-2.51 (m, 1H) , 2.22-2.16 (m, 1H) , 2.03-1.99 (m, 1H) , 1.80-1.76 (m, 1H) , 1.30 (d, J=2.8 Hz, 1H) . MS (ESI) m/e (M+H +) : 480.5.
[1203]
Table 7. Examples 43 to 45 (Compounds A19-10 to A19-12) were prepared in a similar manner to Example 42 (Compound A19-9) using the appropriate intermediates and commercially available materials, and including procedures described across this application when necessary.
[1204]


[1205]
EXAMPLE 46
[1206]
(5aR, 6S, 6aS) -3- ( (7-methyl-8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A20-9)
[1207]


[1208]
Step A: methyl 7-methyl-8-oxo-5, 6, 7, 8-tetrahydronaphthalene-2-carboxylate (A20-2) To a solution of DIPEA (1.11 g, 0.011 mmol) in THF (8 mL) at -78 ℃ under N 2 was added n-BuLi (2.5 N in hexanes, 4.2 mL, 0.011 mmol) dropwise and the mixture was stirred for 30 min. Then the resulting solution was added to a mixture of compound A19-2 (2.04 g, 0.01 mol) and HMPA (18 g, 0.1 mmol) in THF (50 mL) at -78 ℃ over 2 hrs. To the resulting solution was added a solution of MeI (1.7 g, 0.012 mol) in THF (5 mL) dropwise via syringe at -78 ℃. The reaction was quenched by addition of saturated aqueous NH 4Cl and water and the resulting mixture was filtered. The filtrate was concentrated in vacuo to give a residue, which was purified by flash chromatography over silica gel (eluting with PE: EA=4: 1) to afford compound A20-2. MS (ESI) m/e (M+H +) : 218.3.
[1209]
Step B: methyl 7-methyl-8- ( ( (trifluoromethyl) sulfonyl) oxy) -5, 6-dihydronaphthalene-2-carboxylate (A20-3) A mixture of compound A20-2 (1.0 g, 4.59 mmol) in THF (20 mL) at -78 ℃ under N 2 was treated with KHMDS (1 N in THF, 9.2 mL, 9.17 mmol) slowly, followed by stirring for one hour at -78 ℃. Then the reaction mixture was treated with PhN (Tf) 2 (2.10 g, 5.86 mmol) slowly. The reaction was stirred 6 h, then acidified with diluted hydrochloric acid. The reaction was further quenched by the addition of saturated aqueous NH 4Cl and water. The organic layer was separated and concentrated in vacuo. The resulting residue was purified by flash chromatography over silica gel (eluting with PE: EA=4: 1) to afford compound A20-3. MS (ESI) m/e (M+H +) : 350.1
[1210]
Step C: methyl 7-methyl-8- (2- (trifluoromethyl) phenyl) -5, 6-dihydronaphthalene-2-carboxylate (A20-4) To a solution of compound A20-3 (600 mg, 1.7 mmol) , K 3PO 4 (600 mg, 2.9 mmol) and (2- (trifluoromethyl) phenyl) boronic acid (423 mg, 2.2 mmol) in THF (30 mL) and H 2O (10 mL) was added DTBPF-PdCl 2 (80 mg) . The reaction was heated at 100 ℃ for 30 minutes, then cooled. The cooled mixture was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by flash chromatography over silica gel (eluting with PE: EA=4: 1) to give compound A20-4. MS (ESI) m/e (M+H +) : 346.2.
[1211]
Step D: methyl 7-methyl-8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalene-2-carboxylate (A20-5) To a mixture of compound A20-4 (500 mg, 1.445 mmol) in MeOH/THF (25 mL/5 mL) was added 10%Pd/C (50 mg) . The reaction was stirred at room temperature under H 2 (50 psi) for 6 hrs. The reaction was filtered and concentrated in vacuo, and the resulting residue was purified by preparative HPLC to obtain compound A20-5. MS (ESI) m/e (M+H +) : 348.4.
[1212]
Step E: (7-methyl-8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl) methanol (A20- 6) To a solution of compound A20-5 (150 mg, 0.431 mmol) in THF (15 mL) at 0 ℃ under N 2 was added LiAlH 4 (150 mg, 3.95 mmol) slowly. The mixture was stirred for 3 h, then quenched with NaOH and water slowly, and filtered. The organic layer was separated, and concentrated in vacuo. The resulting residue was purified by flash chromatography over silica gel (eluting with PE: EA=4: 1) to give compound A20-6. MS (ESI) m/e (M+H +) : 320.1 (-17) .
[1213]
Step F: 7- (bromomethyl) -2-methyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4-tetrahydronaphthalene (A20-7) To a stirred solution of compound A20-6 (50 mg, 0.156 mmol) in THF (5 mL) at 0 ℃ was added PBr 3 (42 mg, 0.156 mmol) dropwise and the resulting mixture was stirred at at 0 ℃ for 3 h. Then water (5 mL) was added to the mixture, and the mixture was extracted with EtOAc (5 mL) three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by flash chromatography over silica gel (eluting with PE: EA=4: 1) to give compound A20-7. MS (ESI) m/e (M+H +) : 382.3.
[1214]
Step G: (5aR, 6S, 6aS) -ethyl 3- ( (7-methyl-8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydro- naphthalen-2-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylate (A20-8) To a stirred solution of compound A20-7 (50 mg, 0.1309 mmol) and intermediate 1-9 (23.8 mg, 0.109 mmol) in toluene (10 mL) , was added Ag 2CO 3 (72 mg, 0.26 mmol) in one portion. The resulting mixture was heated to 120 ℃ under N 2 overnight. The mixture was then filtered and the filtrate was concentrated to afford crude compound A20-8, which was used in the next step without further purification. MS (ESI) m/e (M+H +) : 521.2.
[1215]
Step H: (5aR, 6S, 6aS) -3- ( (7-methyl-8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalen-2-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A20-9) To a mixture of compound A20-8 (60 mg, crude) in THF (2 mL) , MeOH (2 mL) and H 2O (2 mL) was added NaOH (46 mg, 1.15 mmol) . The reaction was stirred at room temperature for 2 h, then acidified with HCl (2 N) to pH=2, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a YMC-Actus Triart C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 49-79%B, 0-11min; 100%B, 10.5-12.5min; 5%B, 13-15min) . to obtain compound A20-9. 1H NMR (400 MHz, MeOD-d 4) δ: 8.05 (s, 1H) , 7.65 (dd, J=8.0 Hz , 1H) , 7.33-7.30 (m, 1H) , 7.27-7.24 (m, 1H) , 7.14 (s, 2H) , 7.00 (dd, J=8.0 Hz , 1H) , 6.82 (s, 1H) , 6.60 (s, 1H) , 5.09 (s, 2H) , 4.64 (dd, J=8.0 Hz , 1H) , 3.23-3.17 (m, 1H) , 3.03-2.96 (m, 1H) , 2.92-2.91 (m, 1H) , 2.87-2.85 (m, 1H) , 2.84-2.80 (m, 1H) , 2.47-2.43 (m, 1H) , 2.26-2.25 (m, 1H) , 1.88-1.75 (m, 2H) , 1.15 (s, 1H) . MS (ESI) m/e (M+H +) : 493.2.
[1216]
Table 8. Example 47 (compound A20-10) was prepared in a similar manner to Example 46 (Compound A20-9) using the appropriate intermediates and commercially available materials, but without Step D, and including procedures described across this application when necessary.
[1217]


[1218]


[1219]
EXAMPLE 48
[1220]
(5aR, 6S, 6aS) -3- ( (4- (2- (trifluoromethyl) phenyl) chroman-6-yl) methoxy) -5, 5a, 6, 6a-tetrahy drocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A21-10)
[1221]


[1222]
Step A: 6-bromo-4- (2- (trifluoromethyl) phenyl) chroman-4-ol (A21-2) To a solution of 1-bromo-2- (trifluoromethyl) benzene (4.5 g, 0.02 mol) in dry THF (50 mL) at -78 ℃ under N 2 was added n-BuLi (2.5 M in hexanes, 8 mL, 0.02 mol) dropwise. After completion of the addition, the mixture was stirred at -78 ℃ for an hour. Then a solution of 6-bromochroman-4-one A21-1 (2.27 g, 0.01 mol) in dry THF (20 mL) was added dropwise. The reaction mixture was stirred 3 h at -78 ℃, then quenched with saturated aqueous NH 4Cl, and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by chromatography over silica gel to give compound A21-2. MS (ESI) m/e (M+H +-18) : 372.0 (-17) .
[1223]
Step B: 4-hydroxy-4- (2- (trifluoromethyl) phenyl) chroman-6-carboxylic acid (A21-3) To a stirred solution of compound A21-2 (1.2 g, 3.22 mmol) in dry THF (20 mL) at -78 ℃ under N 2 was added n-BuLi (2.5 M in hexanes, 3.86 mL, 9.66 mmol) dropwise. After completion of the addition, the mixture was stirred for 2 hours, then carbon dioxide was bubbled into the mixture for 30 min. The reaction was stirred at -78 ℃ for 1h, and then warmed to -20 ℃ slowly. The reaction was quenched with water, then acidified with dilute HCl (1N) to pH=2 and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford crude compound A21-3 which was used in the next step directly.
[1224]
Step C: methyl 4-hydroxy-4- (2- (trifluoromethyl) phenyl) chroman-6-carboxylate (A21-4) To a mixture of crude compound A21-3 (1.247 mg , 3.69 mmol) in DMF (20 mL) at 0 ℃ was added K 2CO 3 (764 mg, 5.54 mmol) in one portion, followed by MeI (1.048 g, 7.38 mmol) . The resulting mixture was stirred at at 0 ℃ for 1 h, then warmed to room temperature for 2 hrs. The mixture was then poured into water, and extracted with EtOAc (15 mL) three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated to afford a residue, which was purified by chromatography over silica gel to obtain compound A21-4. MS (ESI) m/e (M+H +-18) : 352.1 (-17) .
[1225]
Step D: methyl 4- (2- (trifluoromethyl) phenyl) -2H-chromene-6-carboxylate (A21-5) A solution of compound A21-4 (400 mg, 1.136 mmol) and Et 3SiH (264 mg, 2.276 mmol) in dry DCM (20 mL) was stirred at room temperature for 30 min, and then cooled to 0 ℃. Then TFA (1.2 mL) was added in one portion and the resulting mixture was stirred for one hour. The reaction was neutralized with NaHCO 3, and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford crude compound A21-5, which was used in the next step without purification. MS (ESI) m/e (M+H +) : 334.1.
[1226]
Step E: methyl 4- (2- (trifluoromethyl) phenyl) chroman-6-carboxylate (A21-6) Palladium (10%) on carbon (60 mg) was added to a solution of compound A21-5 (500 mg, crude) in MeOH (30 mL) and THF (30 mL) . The resulting mixture was stirred at 25 ℃ under H 2 (1 atm) for 16 hrs. The mixture was then filtered over Celite TM and the filtrate was concentrated in vacuo to afford crude compound A21-6, which was used in the next step without purification. MS (ESI) m/e (M+H +) : 336.1.
[1227]
Step F: (4- (2- (trifluoromethyl) phenyl) chroman-6-yl) methanol (A21-7) To a suspension of LiAlH 4 (400 mg, 10.53 mmol) in dry THF (10 mL) at 0 ℃ was added a solution of crude compound A21-6 (600 mg, crude) in THF (20 mL) dropwise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 1h. The reaction was then quenched with saturated aqueous NH 4Cl and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A21-7. MS (ESI) m/e (M+H +-18) : 308.1 (-17) .
[1228]
Step G: 6- (chloromethyl) -4- (2- (trifluoromethyl) phenyl) chroman (A21-8) To a solution of compound A21-7 (60 mg, 0.19 mmol) in dry DCM (5 mL) at 0 ℃ was added SOCl 2 (23 mg, 0.19 mmol) dropwise. The reaction solution was stirred at 0 ℃ for 1h, then warmed to 20 ℃ and stirred for 2 h. The reaction was quenched with water, neutralized with aqueous saturated NaHCO 3 to pH=7, and the mixture was extracted with DCM twice. The combined organic layers were washed with brine, dried over Na 2SO 4, filtered and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A21-8. MS (ESI) m/e (M+H +) : 327.1.
[1229]
Step H: (5aR, 6S, 6aS) -ethyl 3- ( (4- (2- (trifluoromethyl) phenyl) chroman-6-yl) methoxy) -5, 5a, 6, 6a- tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A21-9) A mixture of compound A21-8 (30 mg, 0.092 mmol) , intermediate 1-9 (16.8 mg, 0.077 mmol) and Ag 2CO 3 (275 mg, 0.184 mmol) in toluene (1 mL) was heated at 100 ℃ for 2 h. Then the reaction was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by preparative TLC over silica gel to obtain compound A21-9. MS (ESI) m/e (M+H +) : 510.2.
[1230]
Step I: (5aR, 6S, 6aS) -3- ( (4- (2- (trifluoromethyl) phenyl) chroman-6-yl) methoxy) -5, 5a, 6, 6a-tetrahy drocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A21-10) To a mixture of compound A21-9 (25 mg, 0.049 mmol) in THF (1 mL) , MeOH (1 mL) and H 2O (1 mL) was added NaOH (20 mg, 0.49 mmol) , and the resulting mixture was stirred at room temperature for 2 h. The mixture was acidified with HCl (2 N) to pH=7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A21-10. 1H NMR (400 MHz, MeOD-d 4) δ: 7.76 (d, J=7.83 Hz, 1 H) 7.63 (d, J=7.83 Hz, 1 H) 7.35-7.41 (m, 1 H) 7.28-7.34 (m, 1 H) 7.07 (d, J=8.22 Hz, 1 H) 6.99 (dd, J=7.24, 3.72 Hz, 1 H) 6.73 (d, J=8.22 Hz, 1 H) 6.57 (s, 1 H) 6.40 (s, 1 H) 4.88-4.97 (m, 2 H) 4.49 (t, J=7.24 Hz, 1 H) 4.18-4.26 (m, 1 H) 4.04-4.10 (m, 1 H) 3.05 (dd, J=18.39, 4.30 Hz, 1 H) 2.80-2.88 (m, 1 H) 2.64 (d, J=5.09 Hz, 1 H) 2.15-2.24 (m, 2 H) 1.95-2.03 (m, 1 H) 0.92 (br. s., 1 H) . MS (ESI) m/e (M+H +) : 482.2.
[1231]
Table 9. Example 49 (compound A21-11) was prepared in a similar manner to Example 48 (Compound A21-10) using the appropriate intermediates and commercially available materials, but without Steps D and E, and including procedures described across this application when necessary.
[1232]


[1233]
EXAMPLE 50
[1234]
(5aR, 6S, 6aS) -3- ( (1- (2- (trifluoromethyl) phenyl) isochroman-7-yl) methoxy) -5, 5a, 6, 6a- tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A22-8)
[1235]


[1236]
Step A: methyl 4- (2-oxoethyl) -3- (2- (trifluoromethyl) benzoyl) benzoate (A22-2) To a stirring mixture of intermediate 3-5 (1.2 g, 3.77 mmol) in DCM (50 mL) at -78 ℃ was bubbled ozone for 20 min, then the solution was quenched with Me 2S (0.93 g, 15 mmol) dropwise. The resulting mixture was stirred at -78 ℃ for 1h, then warmed to 0 ℃ slowly and stirred overnight. The reaction was filtered through Celite TM and the filtrate was concentrated in vacuo to afford crude compound A22-2, which was used in the next step without purification. MS (ESI) m/e (M+H +) : 351.3.
[1237]
Step B: methyl 3- (hydroxy (2- (trifluoromethyl) phenyl) methyl) -4- (2-hydroxyethyl) benzoate (A22-3) To a solution of compound A22-2 (1.5 g, crude) in MeOH (50 mL) at 0 ℃ was added NaBH 4 (750 mg, 23 mmol) in one portion. After stirring at 0 ℃ for 4 hours, the reaction was quenched with saturated aqueous NH 4Cl, and extracted with EtOAc twice. The combined organic layers were concentrated in vacuo to afford crude compound A22-3, which was used in the next step without purification. MS (ESI) m/e (M+H +-18) : 354.1 (-17) .
[1238]
Step C: methyl 1- (2- (trifluoromethyl) phenyl) isochroman-7-carboxylate (A22-4) A mixture of compound A22-3 (1.5 g, crude) and H 3PO 4 (4 mL) in toluene (40 mL) was heated at reflux overnight. After cooling to room temperature, the reaction mixture was acidified with HCl (1 N) to pH=7, and extracted with EtOAc (40 mL) twice. The combined organic layers were concentrated in vacuo to give a residue, which was purified by flash chromatography over silica gel to afford compound A22-4. MS (ESI) m/e (M+H +) : 337.1.
[1239]
Step D: (1- (2- (trifluoromethyl) phenyl) isochroman-7-yl) methanol (A22-5) To a suspension of LiAlH 4 (115 mg, 2.97 mmol) in dry THF (10 mL) at 0 ℃ was added a solution of compound A22-4 (200 mg, 0.59 mmol) in THF (20 mL) dropwise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 4 h. Then the reaction was quenched with saturated aqueous NH 4Cl and extracted with EtOAc twice. The combined organic layers were washed with brine and concentrated to afford a residue, which was purified by flash chromatography over silica gel to obtain compound A22-5. MS (ESI) m/e (M+H +) : 308.1 (-17) .
[1240]
Step E: 7- (bromomethyl) -1- (2- (trifluoromethyl) phenyl) isochroman (A22-6) To a solution of compound A22-5 (100 mg, 0.32 mmol) in dry DCM (10 mL) at 0 ℃ was added PBr 3 (87 mg, 0.32 mmol) dropwise. The resulting reaction solution was stirred at 0 ℃ for an hour, then warmed to 20 ℃ and stirred for 2 h. The reaction was quenched with water, and neutralized with saturated aqueous NaHCO 3 to pH=7. The organic layer was separated, dried and concentrated in vacuo to afford a residue, which was purified by flash chromatography over silica gel to obtain compound A22-6. MS (ESI) m/e (M+H +) : 372.0/374.0.
[1241]
Step F: (5aR, 6S, 6aS) -ethyl 3- ( (1- (2- (trifluoromethyl) phenyl) isochroman-7-yl) methoxy) -5, 5a, 6, 6a- tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A22-7) A mixture of compound A22-6 (60 mg, 0.16 mmol) , intermediate 1-9 (29 mg, 0.13 mmol) and Ag 2CO 3 (90 mg, 0.32 mmol) in toluene (5 mL) was heated at 110 ℃ for 2 h. The reaction was filtered and the filtrate was concentrated in vacuo to afford a residue, which was purified by flash chromatography over silica gel to give compound A22-7. MS (ESI) m/e (M+H +) : 510.2.
[1242]
Step G: (5aR, 6S, 6aS) -3- ( (1- (2- (trifluoromethyl) phenyl) isochroman-7-yl) methoxy) -5, 5a, 6, 6a- tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A22-8) To a mixture of compound A22-7 (40 mg, 0.079 mmol) in THF (2 mL) , MeOH (2 mL) and H 2O (2 mL) was added NaOH (32 mg, 0.8 mmol) . The resulting mixture was stirred at room temperature for 2 h. Then the mixture was acidified with HCl (2 N) to pH=7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A22-8. 1H NMR (400 MHz, MeOD-d 4) δ: 7.90 (d, J=9.00 Hz, 1 H) 7.74 (d, J=6.26 Hz, 1 H) 7.45-7.52 (m, 2 H) 7.20 (q, J=7.83 Hz, 3 H) 6.56 (s, 1 H) 6.51 (s, 1 H) 6.06 (s, 1 H) 5.07-5.14 (m, 2 H) 4.18-4.26 (m, 1 H) 3.92 (td, J=11.05, 3.33 Hz, 1 H) 3.14-3.24 (m, 2 H) 2.94-3.02 (m, 1 H) 2.88 (d, J=5.48 Hz, 1 H) 2.78 (d, J=16.43 Hz, 1 H) 2.41 (br. s., 1 H) 1.10 (br. s., 1 H) . MS (ESI) m/e (M+H +) : 482.2.
[1243]
EXAMPLE 51
[1244]
(5aR, 6S, 6aS) -3- ( (8-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4-tetrahy- droisoquinolin-7-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylic acid (Compound C6-6)
[1245]


[1246]
Step A: ethyl 8-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4-tetrahydroisoquinoline-7- carboxylate (C6-2) To a stirred solution of compound C4-9B (350 mg, 0.890 mmol, 1.0 eq) in MeOH (7.0 mL) was added 10%Pd/C (35 mg) , and the mixture was stirred at room temperature under a H 2 (1 atm) for 3 h. Then the reaction mixture was filtered and the filtrate was concentrated in vacuo to afford crude compound C6-2, which was used in the next step without purification. MS (ESI) m/e (M+H +) : 396.2.
[1247]
Step B: (8-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4-tetrahydroisoquinolin-7- yl)methanol (C6-3) To a mixture of LAH (144 mg, 3.79 mmol, 5.0 eq) in dry THF (10.0 mL) at 0 ℃ under N 2 was added dropwise a solution of crude compound C6-2 (300 mg, 0.759 mmol, 1.0 eq) in THF (5.0 mL) . After addition, the reaction mixture was stirred at room temperature for 2 h. Then the reaction was quenched with 0.2 mL H 2O, 0.2 mL NaOH (15 %) and 0.2 mL H 2O. Then the reaction mixture was filtered, and the filtrate was concentrated in vacuo to afford crude compound C6-3, which was used in the next step without purification. MS (ESI) m/e (M+H +) : 354.2.
[1248]
Step C: 7- (bromomethyl) -8-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4- tetrahydroisoquinoline (C6-4) To a solution of crude compound C6-3 (100 mg, 283 mmol, 1.0 eq) in DCM (5.0 mL) at 0 ℃ under N 2 was added PBr 3 (76.6 mg, 0.283 mmol, 1.0 eq) dropwise and the reaction mixture was stirred for 1h. A solution of saturated aqueous NaHCO 3 was added to adjust the reaction mixture to pH = 7, then the reaction mixture was extracted with EtOAc (5.0 mL) three times. The combined organic layers were washed with brine, dried over MgSO 4, and concentrated in vacuo to give compound C6-4.
[1249]
Step D: (5aR, 6S, 6aS) -ethyl 3- ( (8-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4- tetrahydroisoquinolin-7-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine- 6-carboxylate (C6-5) To a solution of compound C6-4 (22.8 mg, 0.0548 mmol, 1.2 eq) and intermediate 1-9 (10 mg, 0.0457 mmol, 1.0 eq) in toluene (2.0 mL) was added Ag 2CO 3 (37.8 mg, 0.137 mmol, 3.0 eq) in one portion. The reaction mixture was heated at 110 ℃ for 5 h. Then the reaction was cooled to room temperature and filtered. The filtrate was concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=5: 1) to give compound C6-5. MS (ESI) m/e (M+H +) : 555.2.
[1250]
Step E: (5aR, 6S, 6aS) -3- ( (8-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4-tetrahy- droisoquinolin-7-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylic acid (C6-6) To a solution of compound C6-5 (12.0 mg, 0.0222 mmol, 1.0 eq) in THF (0.5 mL) , MeOH (0.5 mL) and H 2O (0.5 mL) was added LiOH.H 2O (9.31 mg, 0.222 mmol, 10.0 eq) and the reaction was stirred at room temperature for 1 h. Then the reaction mixture was acidified with HCl (1 N) to pH = 2, and extracted with EtOAc (5.00 mL) three times. The combined organic layers were washed with brine, dried over MgSO 4, and concentrated in vacuo to afford a residue, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a Diamonsil (150*20mm*5um) using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 10-40%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to give compound C6-6. 1H NMR (400 MHz, MeOD-d 4) δ: 8.00 (s, 1H) , 7.98 (d, J=7.2 Hz, 1H) , 7.73~7.61 (m, 3H) , 7.52 (d, J = 8.4 Hz, 1H) , 7.16 (d, J = 7.6 Hz, 1H) , 6.64 (s, 1H) , 6.22 (s, 1H) , 5.26 (s, 2H) , 3.28~3.21 (m, 3H) , 3.05 (d, J = 18.8 Hz, 1H) , 2.92 (d, J = 4.8 Hz, 1H) , 2.45~2.42 (m, 1H) , 1.60 (s, 3H) , 1.49 (s, 3H) , 1.13 (t, J = 2.8 Hz, 1H) . MS (ESI) m /e (M+H +) : 527.3.
[1251]
EXAMPLE 52
[1252]
(5aR, 6S, 6aS) -3- ( (8-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4-tetrahydroquinolin- 7-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A24-8)
[1253]


[1254]
Step A: 2-fluoro-3-methyl-N- (2- (trifluoromethyl) phenyl) aniline (A24-2) A mixture of 2- (dicyclohexylphosphino) -2’, 4’, 6’-triisopropylbiphenyl (133 mg, 0.28 mmol) , Cs 2CO 3 (19.53 g, 59.91 mmol) , Pd 2 (dba) 3 (183 mg, 0.21 mmol) , 1-bromo-2- (trifluoromethyl) benzene (13.48 g, 59.91 mmol) and 2-fluoro-3-methyl-aniline A24-1 (6.00 g, 22.29 mmol) in 1, 4-dioxane (100 mL) was heated to 100 ℃ for 16 h. Then the reaction was filtered and the filtrate was concentrated in vacuo to give the crude product, which was purified by column chromatography on silica gel (eluting with PE; EA=100: 0 to 95: 5) to afford compound A24-2. MS (ESI) m/e (M+H +) : 270.1.
[1255]
Step B: N- (2-fluoro-3-methylphenyl) -3-methyl-N- (2- (trifluoromethyl) phenyl) but-2-enamide (A24-3) To a stirring solution of compound A24-2 (5.00 g, 18.57 mmol) in DMF (50 mL) was added 60%NaH (1.49 g, 37.11 mmol) dropwise at 0 ℃ under nitrogen atmosphere. After completion of the addition, the mixture was stirred at room temperature for 30 min. Then 3-methyl-but-2-enoyl chloride (2.64 g, 22.29 mmol) was added dropwise at 0 ℃. The resulting mixture was warmed to 30 ℃ and stirred 3 h. Then the reaction was washed with water and extracted with EtOAc twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by flash chromatography over silica gel (eluting with PE: EA=10: 1) to give compound A24-3. MS (ESI) m/e (M+H +) : 352.1.
[1256]
Step C: 8-fluoro-4, 4, 7-trimethyl-1- (2- (trifluoromethyl) phenyl) -3, 4-dihydroquinolin-2 (1H) -one (A24-4) A mixture of compound A24-3 (500 mg, 1.42 mmol) in trifluoromethanesulfonic acid (5.00 mL, 1.42 mmol) was heated at 30 ℃ for 16 h. Then the reaction mixture was quenched with saturated aqueous NaHCO 3 and was extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by flash chromatography over silica gel to provide compound A24-4. MS (ESI) m/e (M+H +) : 352.1.
[1257]
Step D: 8-fluoro-4, 4-dimethyl-2-oxo-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4-tetrahydroquinoline-7- carboxylic acid (A24-5) A mixture of compound A24-4 (600 mg, 1.71 mmol) and KMnO4 (1.35 g, 8.54 mmol) in water (15.00 mL) and t-BuOH (15.00 mL, 157.00 mmol) was heated to 80 ℃ for 20 h. The resulting mixture was basicified with NaOH to pH = 10, and washed with EtOAc twice. The water layer was acidified with HCl (2 N) to pH = 5, then extracted with EtOAc twice. The combined organic layers were dried over Na 2SO 4 and concentrated in vacuo to give crude compound A24-5, which was used directly in the next step. MS (ESI) m/e (M+H +) : 382.1.
[1258]
Step E: (8-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4-tetrahydroquinolin-7- yl) methanol (A24-6) To a solution of crude compound A24-5 (200 mg, 0.52 mmol) in THF (10 mL) at 0 ℃ was added BH 3·DMS (0.52 mL, 5.24 mmol) dropwise. The reaction mixture was stirred at 0 ℃ for one hour, then warmed to 20 ℃ and stirred for 16 h. Then the reaction was quenched with MeOH and concentrated in vacuo to afford a residue, which was purified by preparative TLC over silica gel to obtain compound A24-6. MS (ESI) m/e (M+H +) : 354.1.
[1259]
Step F: (5aR, 6S, 6aS) -tert-butyl 3- ( (8-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4- tetrahydroquinolin-7-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylate (A24-7) A mixture of Brett-Phos Palladacycle (27 mg, 0.034 mmol) , compound A24-6 (120 mg, 0.34 mmol) , intermediate 1-11 (108 mg, 0.41 mmol) and Cs 2CO 3 (277 mg, 0.85 mmol) in toluene (15 mL) was heated at 110 ℃ for 16 h. Then the reaction was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by preparative TLC over silica gel (PE: EA=4: 1) to afford compound A24-7. MS (ESI) m/e (M+H +) : 583.3.
[1260]
Step G: (5aR, 6S, 6aS) -3- ( (8-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4- tetrahydroquinolin-7-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylic acid (A24-8) To a mixture of compound A24-7 (90 mg, 0.15 mmol) in THF (5 mL) , MeOH (5mL) and H 2O (5 mL) was added NaOH (30 mg, 0.77 mmol) . The resulting mixture was stirred at room temperature for 2 h. Then the reaction was acidified with HCl (2 N) to pH=7, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to obtain a residue, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a Waters XSELECT C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 71-93%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to give compound A24-8. 1H NMR (400 MHz, MeOD-d 4) δ: 8.11 (s, 1 H) , 7.74 (d, J=7.83 Hz, 1 H) , 7.48-7.55 (m, 1 H) , 7.35 (t, J=7.63 Hz, 1 H) , 7.23 (d, J=7.83 Hz, 1 H) , 7.14 (d, J=8.22 Hz, 1 H) , 6.95-7.02 (m, 2 H) , 5.20 (s, 2 H) , 3.54-3.65 (m, 1 H) , 3.33-3.42 (m, 2 H) , 3.10-3.24 (m, 1 H) , 2.99 (d, J=5.48 Hz, 1 H) , 2.47-2.55 (m, 1 H) , 1.83-1.94 (m, 1 H) , 1.68-1.79 (m, 1 H) , 1.44 (s, 3 H), 1.37 (s, 3 H) , 1.25 (br. s., 1 H) . MS (ESI) m/e (M+H +) : 527.2.
[1261]
EXAMPLE 53
[1262]
(5aR, 6S, 6aS) -3- ( (6-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4-tetrahydroquinolin-7- yl)methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A25-10)
[1263]


[1264]
Step A: N- (3-bromo-4-fluorophenyl) -3-methylbut-2-enamide (A25-1) To a solution of 3-bromo-4-fluoroaniline (2.00 g, 10.53 mmol) and DMAP (0.129 g, 1.05 mmol) in pyridine (10 mL) at 0 ℃under N 2, was added 3-methylbut-2-enoyl chloride (2.50 g, 21.05 mmol) dropwise. The resulting solution was warmed to room temperature and stirred 2 h. The reaction was quenched with 1N HCl, extracted with EtOAc, washed with brine, dried over Na 2SO 4, and concentrated in vacuo to give a residue, which was purified by flash chromatography over silica gel (eluting with PE: EA=5: 1) to provide compound A25-1. MS (ESI) m/e (M+H +) : 272.0, 274.0.
[1265]
Step B: 7-bromo-6-fluoro-4, 4-dimethyl-3, 4-dihydroquinolin-2 (1H) -one (A25-2) To a solution of compound A25-1 (2.60 g, 9.55 mmol) in DCM (10 mL) under N 2 was added aluminum trichloride (1.91 g, 14.33 mmol) dropwise. The reaction was stirred at room temperature for 16 h, and then quenched with 1N NaHCO 3, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na 2SO 4, and concentrated in vacuo to give a residue, which was purified by flash chromatography over silica gel (eluting with PE: EA=5: 1) to provide 7-bromo-6-fluoro-4, 4-dimethyl-3, 4-dihydroquinolin-2 (1H) -one and compound A25-2. MS (ESI) m/e (M+H +) : 271.9, 273.9.
[1266]
Step C: ethyl 6-fluoro-4, 4-dimethyl-2-oxo-1, 2, 3, 4-tetrahydroquinoline-7-carboxylate (A25-3) A mixture of 7-bromo-6-fluoro-4, 4-dimethyl-3, 4-dihydroquinolin-2 (1H) -one A25-2 (200 mg, 0.74 mmol) , PdCl 2 (dppf) (54 mg, 0.073 mmol) and sodium acetate (121 mg, 1.47 mmol) in EtOH (100 mL) was heated to 80 ℃ for 16 h under a CO atmosphere (50 psi) . After cooling to room temperature, the reaction was filtered and the filtrate was concentrated in vacuo to afford a residue, which was diluted with EtOAc and water. The organic layer was separated and the aqueous layer was extracted with EtOAc twice. The combined organic layers were washed with water, dried over Na 2SO 4 and concentrated in vacuo to obtain a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=2: 1) to give compound A25-3. MS (ESI) m/e (M+H +) : 266.2.
[1267]
Step D: ethyl 6-fluoro-4, 4-dimethyl-1- (4-nitro-2- (trifluoromethyl) phenyl) -2-oxo-1, 2, 3, 4- tetrahydroquinoline-7-carboxylate (A25-4) To a solution of 1-fluoro-4-nitro-2- (trifluoromethyl) benzene (1.30 g, 6.22 mmol) and compound A25-3 (1.10 g, 4.15 mmol) in DMSO (5 ml) under N 2 was added t-BuOK (0.93 g, 8.29 mmol) . The mixture was stirred at room temperature until completion, and then quenched with H 2O and extracted with EtOAc. The combined organic extracts were washed brine, dried over Na 2SO 4 and concentrated in vacuo to obtain a residue, which was purified by column chromatography over silica gel (eluting with PE: EA=4: 1) to give compound A25-4. MS (ESI) m/e (M+H +) : 477.4.
[1268]
Step E: ethyl 1- (4-amino-2- (trifluoromethyl) phenyl) -6-fluoro-4, 4-dimethyl-2-oxo-1, 2, 3, 4- tetrahydroquinoline-7-carboxylate (A25-5) 10%Pd/C (995 mg, 9.35 mmol) was added to a solution of compound A25-4 (850 mg, 1.87 mmol) in MeOH (50 mL) . The resulting mixture was stirred at room temperature under H 2 (50 atm) for 6 h. The reaction mixture was filtered through Celite TM and the filtrate was concentrated in vacuo to give crude compound A25-5, which was used in the next step directly. MS (ESI) m/e (M+H +) : 411.1.
[1269]
Step F: methyl6-fluoro-4, 4-dimethyl-2-oxo-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4- tetrahydroquinoline-7-carboxylate (A25-6) Tert-Butyl nitrite (109 mg, 1.06 mmol) was added to a mixture of crude compound A25-5 (300 mg, 0.71 mmol) in DMF (10 ml) at room temperature. The reaction mixture was heated at 80 ℃ for 1 h. Then the reaction was cooled, water (50 mL) was added, and the mixture was extracted with ethyl acetate (60 mL) twice. The combined ethyl acetate layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to obtain crude compound A25-6, which was used in the next step directly. MS (ESI) m/e (M+H +) : 396.1.
[1270]
Step G: 6-fluoro-7- (hydroxymethyl) -4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -3, 4- dihydroquinolin-2 (1H) -one (A25-7)
[1271]


[1272]
To a solution of crude compound A25-6 (200 mg, 0.49 mmol) in dry THF (10 mL) , was added LiBH 4 (32 mg, 1.47 mmol) . The mixture was stirred for 12 h, then ice water was added to quench the reaction. The reaction mixture was extracted with DCM (50 mL) , then the combined organic layers were washed with H 2O (30 mL) , brine (30 mL) , dried with Na 2SO 4, and concentrated in vacuo to give a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=2: 1) to give compound A25-7 and compound A25-8. MS (ESI) m/e (M+H +) : 368.1.
[1273]
Step H: (5aR, 6S, 6aS) -tert-butyl 3- ( (6-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4- tetrahydroquinolin-7-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylate (A25-9) A mixture of compound A25-8 (60 mg, 0.17 mmol) , intermediate 1-11 (45 mg, 0.17 mmol) , Brett-Phos Palladacycle (13.6 mg, 0.017 mmol) , and cesium carbonate (138 mg, 0.43 mmol) in toluene (20 ml) was heated at 100 ℃ for 16 h. The reaction was then filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by preparative TLC over silica gel (eluting with PE: EA=3: 1) to give compound A25-9. MS (ESI) m/e (M+H +) : 583.2.
[1274]
Step I: (5aR, 6S, 6aS) -3- ( (6-fluoro-4, 4-dimethyl-1- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4- tetrahydroquinolin-7-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6- carboxylic acid (A25-10) To a mixture of compound A25-9 (40 mg, 0.069 mmol) in THF (1mL) , MeOH (1 mL) and H 2O (1mL) was added LiOH (49 mg, 2.06 mmol) . The reaction mixture was stirred at room temperature for 12 h, then acidified with HCl (1 N) to pH=6, and extracted with EtOAc (20 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by preparative. HPLC (on a GILSON 281 instrument fitted with a Phenomenex Synergi C18 100*21.2 mm*4um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 55-74%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to give compound A25-10. 1H NMR (400 MHz, MeOD-d 4) δ: 8.03-8.09 (m, 1 H) , 7.82 (d, J=7.43 Hz, 1 H), 7.72 (br. s., 1 H) , 7.54 (t, J=7.24 Hz, 1 H) , 7.35 (t, J=6.85 Hz, 1 H) , 7.08 (d, J=11.35 Hz, 1 H) , 6.91 (d, J=3.91 Hz, 1 H) , 5.92 (d, J=5.87 Hz, 1 H) , 5.21 (br. s., 2 H) , 3.49-3.58 (m, 1 H) , 3.40 (d, J=15.65 Hz, 2 H) , 3.12-3.20 (m, 1 H) , 3.01 (d, J=5.09 Hz, 1 H) , 2.54 (br. s., 1 H) , 1.94-2.05 (m, 1 H), 1.78-1.87 (m, 1 H) , 1.40 (d, J=9.78 Hz, 6 H) , 1.28 (br s., 1 H) . MS (ESI) m/e (M+H +) : 527.2.
[1275]
Table 10. Example 54 (compound A25-11) was prepared in a similar manner to Example 53 (Compound A25-10) using compound A25-7 and commercially available materials, and including procedures described across this application when necessary.
[1276]


[1277]
EXAMPLE 55
[1278]
(5aR, 6S, 6aS) -3- ( (3-fluoro-5, 5-dimethyl-8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8- tetrahydronaphthalen-2-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine- 6-carboxylic acid (Compound A26-16)
[1279]


[1280]
Step A: (4-bromo-3-fluorophenyl) methanol (A26-1) To a solution of 4-bromo-3-fluoro-benzaldehyde (20 g, 99.5 mmol) in MeOH (200 mL) at 0 ℃ was added NaBH 4 (5.7g, 150 mmol) portion wise, and the reaction was stirred for 3 h. Then the mixture was quenched with water, and extracted with EtOAc three times. The combined organic layers were concentrated to afford crude compound A26-1, which was used in the next step without purification.
[1281]
Step B: 1-bromo-4- (bromomethyl) -2-fluorobenzene (A26-2) To a solution of compound A26-1 (19 g, crude) in dry DCM (200 mL) at 0 ℃ was added PBr 3 (13.7 g, 50 mmol) dropwise. The reaction was stirred for 3 h, then warmed to 20 ℃ and stirred for 2 h. Then the reaction was quenched with water, neutralized with saturated aqueous NaHCO 3 to pH=7, and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, filtered and concentrated in vacuo to afford crude compound A26-2, which was used in the next step without purification.
[1282]
Step C: 2- (4-bromo-3-fluorophenyl) acetonitrile (A26-3) A mixture of compound A26-2 (20 g, 75 mmol) and KCN (8.6 g, 138 mmol) in ethanol (150 mL) and water (50 ml) was heated to 80 ℃ for 4 h. The cooled reaction mixture was concentrated in vacuo. The resulting residue was taken up in H 2O (50 mL) and extracted with EtOAc (80 mL) three times. The combined organic layers were washed with brine (50 mL) , dried over Na 2SO 4, and concentrated in vacuo to afford a residue, which was purified by chromatography over silica gel (eluting with PE: EA=5: 1) to give compound A26-3.
[1283]
Step D: 2- (4-bromo-3-fluorophenyl) -2-methylpropanenitrile (A26-4) To a solution of compound A26-3 (9.6 g, 45 mmol) in THF (100 ml) under N 2 at room temperature was added LDA (2M in THF, 56 ml) over 1h. Then the mixture was treated with iodomethane (22.3g, 157.5 mmol) . The mixture was then quenched by adding H 2O (50 mL) and extracted with EtOAc (100 mL) three times. The combined organic layers were washed with brine, dried over Na 2SO 4, and concentrated in vacuo to provide a residue, which was purified by chromatography over silica gel (eluting with PE: EA=10: 1) to give compound A26-4.
[1284]
Step E: 2- (4-bromo-3-fluorophenyl) -2-methylpropanal (A26-5) To a stirring solution of compound A26-4 (4 g, 16.5 mmol) in DCM (40 mL) at -78 ℃ under nitrogen was added a solution of DIBAl-H (1.0 M in toluene, 33 mL) dropwise. After completion of the addition, the mixture was stirred at this temperature for 1 hour. The reaction was then cooled to 0 ℃ and quenched by addition of 1.3 mL of H 2O, followed by 1.3 mL of 15%aqueous NaOH. After stirring at room temperature for 1 hour, the reaction was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by chromatography over silica gel (eluting with PE: EA=5: 1) to give compound A26-5.
[1285]
Step F: (E) -ethyl 4- (4-bromo-3-fluorophenyl) -4-methylpent-2-enoate (A26-6) To a stirring solution of ethyl 2- (diethoxyphosphoryl) acetate (3.8g, 17.1 mmol) in dry THF at 0 ℃ was added 60%NaH (912 mg, 22.8 mmol) portionwise. After stirring for 1 h at 0 ℃, a solution of compound A26-5 (2.8 g,17.1 mmol) in 10 ml of THF was added portion wise. The resulting mixture was stirred at 0 ℃ for 1h, then quenched with water, and acidified with HCl (1 N) to pH=7. The aqueous layer was separated and extracted with EtOAc twice. The combined organic layers were concentrated in vacuo to afford crude compound A26-6, which was used in the next step without purification. MS (ESI) m/e (M+H +) : 315.
[1286]
Step G: ethyl 4- (4-bromo-3-fluorophenyl) -4-methylpentanoate (A26-7) A mixture of crude compound A26-6 (2.6 g, 8 mmol) and bismuth (III) chloride (5.1 g, 16.4 mmol) ) in 80 ml of EtOH at 0 ℃ was treated with NaBH 4 portion wise. Then the reaction was filtered through Celite TM, and washed with EtOH. The filtrate was concentrated in vacuo and the resulting residue was taken up in water and EtOAc. The aqueous layer was separated and extracted with EtOAc three times. The combined organic layers were washed with brine, dried over Na 2SO 4, and concentrated in vacuo to afford a residue, which was purified by chromatography over silica gel (eluting with PE: EA=10: 1) to give compound A26-7. MS (ESI) m/e (M+H +) : 317.
[1287]
Step H: 7-bromo-6-fluoro-4, 4-dimethyl-3, 4-dihydronaphthalen-1 (2H) -one (A26-8) A mixture of compound A26-7 (2.0 g, 6.3 mmol) and triflic acid (10 ml) in 10 ml of TFA was heated to 80 ℃ for 2 h. Then the reaction was concentrated in vacuo to give a residue, which was purified by chromatography over silica gel (eluting with PE: EA=5: 1) to give product A26-8. MS (ESI) m/e (M+H +) : 271/273.
[1288]
Step I: methyl 3-fluoro-5, 5-dimethyl-8-oxo-5, 6, 7, 8-tetrahydronaphthalene-2-carboxylate (A26-9) A mixture of compound A26-8 (1.5 g, 5.5 mmol) , Et 3N (10 ml) and Pd (dppf) Cl 2 (150 mg, 10%) in DMF (10mL) and MeOH (50 mL) was heated to 80 ℃ for 16 h under a CO atmosphere (55 psi) . After cooling to room temperature, the reaction was filtered and the filtrate was concentrated in vacuo to afford a residue, which was partitioned with EtOAc and water. The aqueous layer was separated and extracted with EtOAc twice. The combined organic layers were washed with water, dried over Na 2SO 4, and concentrated in vacuo to afford a residue, which was purified by chromatography over silica gel (eluting with PE: EA=8: 1 to give compound A26-9. MS (ESI) m/e (M+H +-18) : 251.
[1289]
Step J: methyl 3-fluoro-5, 5-dimethyl-8- ( ( (trifluoromethyl) sulfonyl) oxy) -5, 6-dihydronaphthalene-2- carboxylate (A26-10) To a suspension of compound A26-9 (500 mg, 2 mmol) in dry THF (10 mL) at-78 ℃ under nitrogen was added LiHMDS (1 M in THF, 3 mL) dropwise. Then the reaction mixture was stirred for 30 min at -78 ℃ , followed by treatment with a solution of PhNTf 2 in 2 ml of THF. The reaction mixture was stirred for 3 hours, then quenched with water and neutralized with aqueous HCl (2N) to pH=7. The mixture was extracted with EtOAc and the combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by chromatography over silica gel to obtain A26-10. MS (ESI) m/e (M+H +) : 383.
[1290]
Step K: methyl 3-fluoro-5, 5-dimethyl-8- (2- (trifluoromethyl) phenyl) -5, 8-dihydronaphthalene-2- carboxylate (A26-11) A mixture of compound A26-10 (550 mg, 1.4 mmol) , 2-CF 3-phenylboronic acid (408 mg, 2.1 mmol) ) , K 3PO 4 (890 mg, 4.25 mmol) and Pd (dtbpf) Cl 2 (50 mg) in THF (10 mL) and H 2O (3 mL) was microwaved at 100 ℃ for 30 min under a nitrogen atmosphere. After cooling to room temperature, the reaction was filtered and the filtrate was extracted with EtOAc. The combined organic layers were washed with water, dried over Na 2SO 4 and concentrated in vacuo to obtain a residue, which was purified flash chromatography over silica gel to afford compound A26-11. MS (ESI) m/e (M+H +) : 380.
[1291]
Step L: methyl 3-fluoro-5, 5-dimethyl-8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalene- 2-carboxylate (A26-12) To a stirred solution of compound A26-11 (487 mg, 1.28 mmol) in MeOH was added 10%Pd/C (48 mg) and the reaction was stirred at 25 ℃ under H 2 (55 psi) for 16 h. The reaction mixture was then filtered and the filtrate was concentrated in vacuo to afford crude compound A26-12, which was used in the next step without purification. MS (ESI) m/e (M+H +) : 381.
[1292]
Step M: (3-fluoro-5, 5-dimethyl-8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8-tetrahydronaphthalen-2- yl) methanol (A26-13) To a solution of crude compound A26-12 (450 mg, crude) in dry THF (10 mL) at 0 ℃ was added LiAlH 4 (90 mg, 2.36 mmol) portion wise. After completion of the addition, the reaction mixture was stirred at 0 ℃ for 1h, then quenched with saturated aqueous NH 4Cl, and extracted with EtOAc twice. The combined organic layers were dried over Na 2SO 4 and concentrated in vacuo to obtain crude compound A26-13, which was used in the next step without purification. MS (ESI) m/e (M+H +-18) : 336.
[1293]
Step N: 6- (bromomethyl) -7-fluoro-1, 1-dimethyl-4- (2- (trifluoromethyl) phenyl) -1, 2, 3, 4- tetrahydronaphthalene (A26-14) To a solution of crude compound A26-13 (340 mg, crude) in dry DCM (5 mL) at 0 ℃ was added SOCl 2 (350 mg, 3 mmol) dropwise. The reaction was stirred at 0 ℃ for 1h, then warmed to 20 ℃ and stirred for 2 h. Then the reaction was quenched with water, neutralized with saturated aqueous NaHCO 3 to pH=7 and extracted with EtOAc. The combined organic layers were dried over Na 2SO 4 and concentrated in vacuo to obtain compound A26-14, which was used in the next step without purification. MS (ESI) m/e (M+H +) : 370, 372.
[1294]
Step O: (5aR, 6S, 6aS) -3- ( (3-fluoro-5, 5-dimethyl-8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8- tetrahydronaphthalen-2-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine- 6-carboxylic acid (A26-15) A mixture of compound A26-14 (170 mg, 0.46 mmol) , intermediate 1-9 (110 mg, 0.5 mmol) and Ag 2CO 3 (248 mg, 0.92 mmol) in toluene (5 mL) was heated at 100 ℃ for 2 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give a residue, which was purified by flash chromatography over silica gel to obtain compound A26-15. MS (ESI) m/e (M+H +) : 554
[1295]
Step P: (5aR, 6S, 6aS) -3- ( (3-fluoro-5, 5-dimethyl-8- (2- (trifluoromethyl) phenyl) -5, 6, 7, 8- tetrahydronaphthalen-2-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine- 6-carboxylic acid (A26-16) To a mixture of compound A26-15 (80 mg) in THF (3 mL ) , MeOH (3 mL) and H 2O (3 mL) was added LiOH (56 mg) . The resulting mixture was stirred at room temperature for 2 h. Then the reaction mixture was acidified with HCl (1 N) to pH=2, and extracted with EtOAc (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo to afford a residue, which was purified by preparative HPLC (on a GILSON 281 instrument fitted with a YMC-pack ODS-AQ YMC-Actus Triart C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water, mobile phase B: acetonitrile. Gradient: 56-76%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15 min) to obtain compound A26-16. 1H NMR (400 MHz, MeOD-d 4) δ: 1.17 (br. s., 1 H) 1.34 (s, 3 H) 1.39 (s, 3 H) 1.67-1.81 (m, 2 H) 1.88 (d, J=11.35 Hz, 1 H) 2.06 (br. s., 1 H) 2.45 (br. s., 1 H) 2.92 (d, J=5.09 Hz, 1 H) 3.04 (d, J=18.78 Hz, 1 H) 3.23 (d, J=7.43 Hz, 1 H) 4.38 (br. s., 1 H) 5.20 (s, 2 H) 6.62 (d, J=7.04 Hz, 1 H) 6.71 (d, J=10.17 Hz, 1 H) 6.92 (t, J=8.80 Hz, 1 H) 7.16 (dd, J=11.74, 2.74 Hz, 1 H) 7.31-7.42 (m, 2 H) 7.67 (d, J=7.43 Hz, 1 H) 7.93 (d, J=11.35 Hz, 1 H) . MS (ESI) m/e (M+H +) : 526.2.
[1296]
EXAMPLE 56
[1297]
(5aR, 6S, 6aS) -3- ( (5-fluoro-1- (2-fluoro-5-methoxyphenyl) -3, 3-dimethylindolin-6-yl) methoxy) - 5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A28-5)
[1298]


[1299]
Step A: 6-bromo-5-fluoro-1- (2-fluoro-5-methoxyphenyl) -3, 3-dimethylindoline (A28-1) A mixture of BINAP (255 mg, 0.41 mmol) , t-BuONa (787 mg, 8.2 mmol) , Pd 2 (dba) 3 (188 mg, 0.21 mmol) , 2-bromo-1-fluoro-4-methoxybenzene (1.26 g, 6.14 mmol) and 6-bromo-5-fluoro-3, 3-dimethylindoline A14-2 (1.0 g, 4.10 mmol) in toluene (30 mL) was heated under N 2 at 100 ℃ for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered. The filtrate was concentrated in vacuo and the resulting residue was purified by flash chromatography over silica gel (eluting with PE: EA=10: 1) to give compound A28-1. MS (ESI) m/e (M+H +) : 368.0, 370.0.
[1300]
Step B: 5-fluoro-1- (2-fluoro-5-methoxyphenyl) -3, 3-dimethylindoline-6-carbaldehyde (A28-2) To a stirring solution of compound A28-1 (900 mg, 2.44 mmol) in THF (15 mL) was added n-BuLi (2.5 M in hexane, 1.17 ml, 2.93 mmol) dropwise at -78 ℃ under a nitrogen atmosphere. After completion of the addition, the mixture was stirred at -78 ℃ for 15 min, then DMF (0.28 mL, 3.67 mmol) was added dropwise. The resulting mixture was stirred at -78 ℃ for 1 h, then quenched with saturated aqueous NH 4Cl and extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried over Na 2SO 4 and concentrated in vacuo to afford compound A28-2. MS (ESI) m/e (M+H +) : 318.1.
[1301]
Step C: (5-fluoro-1- (2-fluoro-5-methoxyphenyl) -3, 3-dimethylindolin-6-yl) methanol (A28-3) NaBH 4 (274 mg, 7.25 mmol) was added to a mixture of compound A28-2 (460 mg, 1.45 mmol) in MeOH (20 mL) at 0 ℃, and the mixture was stirred at 0 ℃ for 1 h. Then the reaction was quenched with water (20 mL) and extracted with ethyl acetate (20 mL) two times. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4, and concentrated in vacuo. The resulting residue was purified by flash chromatography over silica gel (eluting with PE: EA=5: 1) to give compound A28-3. MS (ESI) m/e (M+H +) : 319.1 (-17) .
[1302]
Step D: (5aR, 6S, 6aS) -tert-butyl 3- ( (5-fluoro-1- (2-fluoro-5-methoxyphenyl) -3, 3-dimethylindolin-6- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylate (A28-4) A mixture of Brett-Phos Palladacycle (8.75 mg, 11 μmol) , compound A28-3 (70 mg, 0.22 mmol) , intermediate 1-11 (64 mg, 0.24 mmol) and Cs 2CO 3 (179 mg, 0.548 mmol) in toluene (15 mL) was heated at 100 ℃ under an atmosphere of N 2 for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered. The filtrate was concentrated in vacuo and the resulting residue was purified by preparative TLC over silica gel (eluting with PE: EA=4: 1) to give compound A28-4. MS (ESI) m/e (M+H +) : 549.2.
[1303]
Step E: (5aR, 6S, 6aS) -3- ( (5-fluoro-1- (2-fluoro-5-methoxyphenyl) -3, 3-dimethylindolin-6- yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (A28- 5) To a mixture of compound A28-4 (58 mg, 0.11 mmol) in THF (1 mL) , MeOH (1 mL) and H 2O (1 mL) was added NaOH (42.3 mg, 1.1 mmol) , and the resulting mixture was stirred at 50 ℃ for 10 h. The reaction mixture was acidified with HCl (2 N) to pH=7, and extracted with ethyl acetate (10 mL) twice. The combined organic layers were washed with water, brine, dried over Na 2SO 4 and concentrated in vacuo, to provide a residue, which was purified by preparative HPLC (preparative HPLC on a GILSON 281 instrument fitted with a Waters XSELECT C18 150*30mm*5um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 60-80%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15 min) to give compound A28-5. 1H NMR (400 MHz, MeOD-d 4) δ: 8.36 (s, 1 H) , 7.02 (s, 1 H) , 6.75-6.87 (m, 3 H) , 6.59-6.67 (m, 1 H) , 6.51-6.59 (m, 1 H) , 5.30 (br. s., 2 H) , 3.73 (s, 3 H) , 3.66 (s, 2 H) , 3.27-3.40 (m, 1 H) , 3.02-3.19 (m, 2 H) , 2.51-2.62 (m, 1 H) , 1.34 (s, 6 H) , 1.28 (br. s., 1 H) . MS (ESI) m/e (M+H +) : 493.2.
[1304]
EXAMPLE 57
[1305]
(5aR, 6S, 6aS) -3- ( (6-fluoro-1- (1H-pyrazol-1-yl) -3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H- inden-5-yl) methoxy) -5, 5a, 6, 6a-tetrahydrocyclopropa [4, 5] cyclopenta [1, 2-c] pyridine-6-carboxylic acid (Compound A29-8A)
[1306]


[1307]
Step A: 5-bromo-6-fluoro-3- (2- (trifluoromethyl) phenyl) -1H-inden-1-one (A29-1) A mixture of compound A9-4 (0.5 g, 1.400 mmol) and selenium dioxide (0.777 g, 7.00 mmol) in 1, 4-dioxane (30 mL) was heated at 100 ℃ for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered. The filtrate was concentrated in vacuo and the resulting residue was purified by flash chromatography over silica gel (eluting with PE: EA=20: 1) to give compound A29-1. MS (ESI) m /e (M+H +) : 371.2, 373.1.
[1308]
Step B: ethyl 6-fluoro-1-oxo-3- (2- (trifluoromethyl) phenyl) -1H-indene-5-carboxylate (A29-2) A mixture of compound A29-1 (400 mg, 1.08 mmol) , PdCl 2 (dppf) (79 mg, 0.108 mmol) , and sodium acetate (177 mg, 2.156 mmol) in EtOH (10 mL) was heated at 80 ℃ for 16 h under a CO atmosphere (50 psi) . After cooling to room temperature, the mixture was diluted with EtOAc and filtered. The EtOAc layer was separated, washed with water and brine, dried over anhydrous Na 2SO 4 and concentrated in vacuo. The resulting residue was purified by flash chromatgraphy over silica gel (eluting with PE: EA=2: 1) to give compound A29-2. MS (ESI) m /e (M+H +) : 365.2.
[1309]
Step C: ethyl 6-fluoro-1-hydroxy-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5– carboxylate (A29-3) 10%Pd-C (35 mg) was added to a solution of compound A29-2 (350 mg, 0.96 mmol) in MeOH (30 ml) , and the resulting mixture was stirred at 50 ℃ under H 2 atmospheres (50 psi) for 12 h. The mixture was filtered over Celite TM and the filtrate was concentrated in vacuo. The resulting residue was purified by flash chromatography over silica gel (eluting with P: E=10: 1) to give compound A29-3. MS (ESI) m /e (M+H +) : 369.1.
[1310]
Step D: ethyl 1-chloro-6-fluoro-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5- carboxylate (A29-4) To a solution of compound A29-3 (180 mg, 0.489 mmol) and triethylamine (99 mg, 0.977 mmol) in dry DCM (3 mL) at 0 ℃ under N 2, was added MsCl (0.076 mL, 0.977 mmol) dropwise. The mixture was stirred for 12 h while warming to room temperature. Then saturated aqueous NaHCO 3 was added to quench the reaction. The reaction mixture was extracted with DCM (10 mL) three times. The combined organic layers were washed with brine, dried over anhydrous Na 2SO 4 and concentrated in vacuo to give crude compound A29-4, which was used for the next step without purification. MS (ESI) m /e (M+H +) : 387.2.
[1311]
Step E: ethyl 1-chloro-6-fluoro-3- (2- (trifluoromethyl) phenyl) -2, 3-dihydro-1H-indene-5-carboxylate (A29-5A and A29-5B)
[1312]


[1313]
A mixture of compound A29-4 (250 mg, 0.65 mmol) , 1H-pyrazole (440 mg, 6.46 mmol) and K 2CO 3 (268 mg, 1.94 mmol) in DMF (4 mL) was heated at 65 ℃ for 12 h. After cooling to room temperature, the mixture was diluted with EtOAc, filtered and concentrated in vacuo to give a residue. The residue was purified by reverse Preparative HPLC (on a GILSON 281 instrument fitted with a Phenomenex Synergi C18 100*21.2 mm*4um using water and acetonitrile as the eluents. Mobile phase A: water (containing 0.1%TFA, v/v) , mobile phase B: acetonitrile. Gradient: 56-71%B, 0-10min; 100%B, 10.5-12.5min; 5%B, 13-15min) to give compound A29-5A, followed by compound A29-5B. MS (ESI) m /e (M+H +) : 419.2 for both.
[1314]
Step F: ethyl 6-fluoro-1- (1H-pyrazol-1-yl) -3- (2- (trifluorometh